Mechanistic studies of the phenobarbital-type induction of cytochromes P450 : role of AMP-activated protein kinase by Blättler, Sharon
 Mechanistic Studies of the Phenobarbital-Type 
Induction of Cytochromes P450: Role of AMP-
Activated Protein Kinase 
 
 
 
Inauguraldissertation 
 
 
zur Erlangung der Würde eines  
Doktors der Philosophie  
 
 
 
 
vorgelegt der  
Philosophisch-Naturwissenschaftlichen Fakultät  
der Universität Basel 
 
 
von  
 
Sharon Blättler 
 
aus Hergiswil (NW) 
 
 
 
Basel, 2007 
 
  
Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät der Universität Basel auf Antrag 
von Herren Professoren Dr. Urs A. Meyer, Dr. Oliver Burk und Dr. Markus Affolter 
 
 
Basel, den 24. Oktober 2006 
 
 
 
                  Prof. Dr. Hans-Peter Hauri 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A mio nonno e a Markus 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
"The important thing in science is not so much to obtain new facts, 
 as to discover new ways of thinking about them." 
Sir William Bragg (1862 – 1942) 
 
 
"When I'm working on a problem, I never think about beauty.  
I think only how to solve the problem.  
But when I have finished, if the solution is not beautiful, I know it is wrong." 
R. Buckminster Fuller (1895 - 1983) 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table of Contents 
 
Abstract .............................................................................................................................................. 1 
 
 
 
Drug Metabolism in the Liver – The Role of Cytochromes P450 ........................................................... 5 
The Phenomenon of Drug-Mediated Induction of Cytochromes P450 .................................................. 5 
Nuclear Receptors............................................................................................................................... 7 
The Role of the Xenosensor Pregnane X Receptor and Constitutive Androstane Receptor in Drug 
Induction ............................................................................................................................................ 9 
Pregnane X Receptor ...................................................................................................................... 9 
Constitutive Androstane Receptor ..................................................................................................... 9 
Chicken X Receptor....................................................................................................................... 10 
Phosphorylation/Dephosphorylation Events in Phenobarbital-Mediated Induction of CYPs.................. 11 
Crosstalk Between Drug, Lipid and Bile Acid Metabolism ................................................................... 12 
Drug Induction – Lipid Homeostasis ................................................................................................ 12 
Drug Induction – Bile Acids ............................................................................................................ 13 
Drug Induction – Liver X Receptor .................................................................................................. 13 
Diverse Roles of the Constitutive Androstane Receptor ..................................................................... 14 
CAR in Xenobiotic Metabolism......................................................................................................... 14 
The Hepatotoxic Role of CAR - CAR as a Risk Factor .......................................................................... 14 
CAR as a Protective Factor - CAR and Hyperbilirubinemia ................................................................... 14 
CAR as a Protective Factor - CAR and Cholestasis .............................................................................. 14 
CAR in Endocrine Homeostasis and Disruption .................................................................................. 15 
CAR, Thyroid Hormone Homeostasis and Obesity .............................................................................. 15 
CAR and Tumorigenesis................................................................................................................. 16 
CAR in Glucose Metabolism ............................................................................................................ 16 
AMP-Activated Protein Kinase ........................................................................................................... 17 
LKB1, the AMPK Upstream Kinase in the Liver................................................................................... 19 
Conceptual Considerations ................................................................................................................ 20 
Aims of the Thesis ............................................................................................................................ 20 
 
 
 
Part I: The Evolution of Drug-Activated Nuclear Receptors: One Ancestral Gene Diverged into 
Two Xenosensor Genes in Mammals ..................................................................................... 23 
Abstract ...................................................................................................................................... 23 
Introduction................................................................................................................................. 24 
Results 
 
Introduction 
 
Table of Contents  ii 
    
Results and Discussion .................................................................................................................. 24 
Conclusions ................................................................................................................................. 31 
Materials and Methods .................................................................................................................. 32 
Acknowledgements .................................................................................................................... 33 
References .................................................................................................................................. 33 
Supplemental Data ....................................................................................................................... 36 
Part II: Chicken AMP-Activated Protein Kinase Alpha Characterization ............................................ 38 
In the Regulation of Cytochrome P450 Genes Phenobarbital Targets LKB1 for Necessary 
Activation of AMP-Activated Protein Kinase ....................................................................................... 41 
Abstract ...................................................................................................................................... 42 
Introduction................................................................................................................................. 43 
Results........................................................................................................................................ 45 
Discussion ................................................................................................................................... 51 
Materials and Methods .................................................................................................................. 55 
Acknowledgements ....................................................................................................................... 55 
References .................................................................................................................................. 55 
Figures ....................................................................................................................................... 59 
Supplemental Figures .................................................................................................................... 66 
Data not shown............................................................................................................................ 70 
Part III:  Additional Mechanistic Studies on the Phenobarbital-Mediated Induction of CYPs ............... 74 
Part IV:  Role of Protein Kinase C in the Phenobarbital-Mediated Induction of CYPs ......................... 78 
Part V:  Human Experiments........................................................................................................... 82 
Part VI:  Mouse Experiments............................................................................................................ 87 
Part VII:  Chicken X Receptor Immunoprecipitation and Phosphorylation ........................................... 89 
 
 
 
CXR is the Ancestral Gene of CAR and PXR ....................................................................................... 97 
The Molecular Mechanism of Drug Induction..................................................................................... 98 
AMPK Targets in the Mechanism of Drug Induction ......................................................................... 101 
AMPK-LKB1 Signaling...................................................................................................................... 103 
Phenobarbital and Mitochondria ...................................................................................................... 108 
The Phenobarbital “Receptor” ......................................................................................................... 109 
Cancer Cells.................................................................................................................................... 111 
Role of Mitochondria and/or AMPK in Drug Metabolism in the Elderly .............................................. 113 
The CXR and CAR Complexes ......................................................................................................... 114 
Protein Kinase C Zeta: Physiological Role ........................................................................................ 116 
Outlook........................................................................................................................................... 117 
Summary........................................................................................................................................ 121 
Discussion 
 
Table of Contents  iii 
    
 
 
Reagents ........................................................................................................................................ 125 
Cell Culture Methods....................................................................................................................... 125 
Assays ............................................................................................................................................ 126 
Animals .......................................................................................................................................... 130 
Statistics ......................................................................................................................................... 130 
 
 
 
References ..................................................................................................................................... 133 
 
 
 
APPENDIX 1: Primer Sequences...................................................................................................... 151 
APPENDIX 2: Abbreviations............................................................................................................. 152 
APPENDIX 3: Related Publication .................................................................................................... 154 
APPENDIX 4: Additional Publication ................................................................................................ 164 
APPENDIX 5: Acknowledgements.................................................................................................... 175 
APPENDIX 6: Curriculum Vitae ........................................................................................................ 177 
 
References 
 
Materials and Methods 
 
Appendices 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Abstract 
 
Inside the liver cells there are sophisticated mechanisms that have evolved over millions of years to 
metabolize toxic substances, many of which are fat-soluble compounds making them difficult for the 
body to excrete. Cytochromes P450 (CYPs) are drug-metabolizing enzymes predominantly expressed 
in the liver that catalyze the first step in the metabolism of lipophilic compounds into water-soluble 
and thus excretable compounds. Transcriptional activation of CYPs and other drug-metabolizing 
enzymes by drugs and xenobiotics in the liver is mediated by the mammalian constitutive androstane 
receptor (CAR) and pregnanes X receptor (PXR), whereas the chicken xenobiotic receptor (CXR) 
mediates drug responses in chicken hepatocytes. This phenomenon, which is called drug induction, is 
fully reversible and dose-dependent. By increasing the capability for metabolic detoxification and 
elimination, induction of CYPs is an integral part of the defense mechanism against xenochemical 
insult. However, it also has important negative clinical consequences, such as altered 
pharmacokinetics of drugs and carcinogens, drug-drug interactions, and changes in the metabolism of 
steroids, vitamin D, and other endogenous compounds. For these reasons, it is of great importance to 
understand the molecular mechanisms leading to drug induced gene expression of hepatic drug-
metabolizing enzymes.   
In this thesis the role of the AMP-activated protein kinase (AMPK) in the phenobarbital-mediated 
transcriptional regulation of CYPs was studied in hepatoma cells (chicken and human), and in 
hepatocytes (human and mouse). We show that AMPK activation by phenobarbital occurs via 
increased reactive oxygen species (ROS) formation in mitochondria and that increased AMPK activity 
is necessary for drug induction. Furthermore, we demonstrate that phenobarbital-type drugs affect 
the AMPK upstream kinase LKB1 and the protein kinase C zeta (PKCζ) activities. Importantly, these 
studies reveal that the signaling cascade involved in drug responses is conserved in evolution from 
birds to mice and humans. In addition, CXR interacting proteins were identified, which may also bind 
CAR in mammalian liver. 
In conclusion, these findings provide new insights into the so far poorly characterized molecular 
mechanism by which drugs lead to transcriptional regulation of CYP enzymes. 
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Drug Metabolism in the Liver – The Role of Cytochromes P450 
Although the cell membrane is a very efficient barrier against water-soluble toxic compounds, the 
human body is exposed every day to a huge number of exogenous or endogenous lipophilic toxic 
substances, which can cross this boundary and thus have to be excreted in order not to harm the 
organism. Over millions of years, sophisticated mechanisms have evolved in the liver to metabolize 
toxic substances, biotransformation and transport. One challenge in the detoxification pathway is the 
hydrophobicity of these compounds, which must be made more polar for an easy excretion from the 
organisms via body fluids. The liver is the primary detoxification site where fat-soluble substances are 
rendered water-soluble by several enzymes including cytochromes P450 (CYPs), which catalyze the 
so-called phase I in the detoxification pathway. In phase II, other enzymes further modify these 
compounds, which are subsequently transported in phase III for excretion by blood, urine, feces and 
bile [1]. 
CYPs are a huge family of heme proteins, which catalyze mono-oxygenase reactions from bacteria to 
animals. These proteins are located at the endoplasmic reticulum or at the inner mitochondrial 
membrane, whereas some bacteria have cytoplasmic CYPs forms. Comparison of amino acid 
sequences of prokaryotic and eukaryotic CYP genes indicates that they have diverged from a single 
common ancestor. These enzymes are essential to eukaryotic organisms because they are involved in 
a number of anabolic and catabolic biosynthetic pathways, such as metabolism of cholesterol, steroid 
hormones, bile acids, fatty acids, prostaglandins, leukotrienes, biogenic amines, and retinoic acids [2-
5].  
In addition to their role in endogenous metabolism, CYPs play an important role in the metabolism of 
foreign compounds, such as drugs, pollutants, pesticides and diet components [6]. CYPs involved in 
the xenobiotic metabolism show broad and overlapping substrate specificities, so that one particular 
CYP metabolizes a large number of different compounds, and a given compound may be metabolized 
by several CYPs. Nowadays, organisms have everything they need to deal with toxic compounds 
probably as result of an evolution started a long time ago when animals were challenged by 
chemicals, with which plants defended themselves from being eaten. 
 
The Phenomenon of Drug-Mediated Induction of CYPs 
Numerous xenobiotics and endobiotic substances induce the expression of drug- and steroid-
metabolizing enzymes such as cytochrome P450 in the liver, a phenomenon called induction [4, 6-8]. 
Altered expression of CYP genes has a major impact on drug effects including drug-drug interactions, 
drug toxicity, xenobiotic carcinogenicity, and therefore contributes to clinically important 
interindividual variability in drug responses and hormones disposal [9-13]. For these reasons, although 
xenobiotic metabolism by CYPs is necessary for organism detoxification, it represents a challenge from 
the clinical point of view and has to be considered in the treatment of patients. 
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In vertebrates, drug induction occurs predominantly in the liver, in the intestine and to a lesser extent 
in other extrahepatic tissues, such as skin, kidney, lung and brain. The phenomenon of drug induction 
was first observed more than 40 years ago in rats, which became progressively tolerant to treatment 
with phenobarbital (PB), a sedative and anticonvulsant drug, in long-term studies, due to enhanced 
metabolism and clearance. In these animals the smooth endoplasmic reticulum of hepatocytes was 
found to proliferate under PB treatment and the number of CYP enzymes, located on the membrane 
of smooth endoplasmic reticulum was also increased [14, 15].  
Induction most often occurs at the level of transcription and is a rapid, dose-dependent and reversible 
phenomenon. Many drugs have, similar to the prototypic substance PB, the ability to induce their own 
and others metabolism by transcriptional activation of CYPs. In addition, inducer compounds can 
drastically alter the panel of gene expression in hepatocytes giving raise to pleiotropic hepatic 
responses. For instance, PB was shown to regulate more than 50 genes in chicken embryos [16], and 
recent gene expression array data in mice indicate more than 100 affected genes after PB treatment 
[17]. The effects triggered by PB include beside the proliferation of smooth endoplasmic reticulum, 
also liver weight gain and liver tumor promotion (in rodents) [6].  
Drug-metabolizing enzymes mainly belong to the CYP1, CYP2, CYP3 and CYP4 families and their 
prototypical inducers are categorized in five classes: dioxin for the group of polyaromatic 
hydrocarbons inducing mainly CYP1As, PB-type inducers have a predominant effect on CYP2Bs, 
CYP3As and CYP2Cs subfamily genes, dexamethasone or rifampicin involved in CYP2Cs and CYP3As 
induction, clofibrate acting on CYP4As and ethanol that increases the activity of CYP2Es (reviewed in 
[18, 19]). PB induction has been reported in different species such as mammals, birds and bacteria, 
but not in yeast.  
The molecular mechanism of hydrocarbon induction of CYP1As by the polyaromatic hydrocarbon 
receptor (AhR) was elucidated already in the 1980s [20], whereas the scientific community had a hard 
time to figure out the mechanism of PB-type induction of CYPs due to several experimental 
limitations. Among them two contributed massively to the poor knowledge in this field; first, PB-type 
inducers bind with low affinity to their receptors, which made the discovery of the receptors very 
difficult; second, lack of cell lines, which maintain PB-type responses constrained the use of either 
whole organs or primary preparation of hepatocytes in these studies, which are both restricted 
systems in terms of mutagenesis and transfection studies. Continuously dividing cell systems lack this 
phenomenon due to the dedifferentiation process occurring in these systems. In fact, drug induction 
and metabolism are a hallmark of highly differentiated, nondividing hepatocytes [21]. 
To find a system to study the mechanisms underlying drug induction, our group developed the use of 
a chicken hepatoma cell line, the leghorn male hepatoma (LMH) cell line. Besides heme oxygenase-1 
regulation, triglycerides synthesis and lipogenesis comparable to chicken hepatocytes in primary 
cultures, these cells maintain the PB-type induction of CYPs [22] with all the advantages of 
continuously dividing cell lines in comparison to primary cultures: they are easy to handle and 
transfect, stably transfected subclones can be produced and there are no differences from preparation 
to preparation. When our group started using this system to study the molecular mechanism of drug 
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induction, several theories pointed to a receptor-dependent mechanism and experimental 
observations suggested the involvement of protein phosphorylation events (discussed below).  
The first insights in the transcriptional regulation of CYPs came from a negative regulated element in 
the proximal promoter of P450 BM-3 in Bacillus megaterium [23, 24]. Sequence homologous of this 
element, referred to as Barbie box, were also found in mammalian CYPs proximal promoters [25, 26]. 
Several proteins binding to the proximal promoter were identified and shown to regulate the basal 
levels of expression and the tissue-specific expression. However, accumulating body of evidence 
suggested an important role of distal enhancer elements in drug regulation of CYPs, first of all the 
identification of such a regulatory sequence in the CYP2H1 gene in chicken embryo hepatocytes [27] 
and later in rat CYP2B2 [28] and mouse Cyp2b10 [29] gene 5’-flanking regions. In the attempt to 
isolate small and well-defined distal elements in CYP genes that are necessary for drug-mediated 
induction, the regulatory sequences found in the chicken CYP2H1, rat CYP2B2 and mouse Cyp2b10 
were reduced to the minimal length still responsive to drugs. A 163-bp responsive element in the 
CYP2B2 [30, 31] as well as a 264-bp in CYP2H1 [22] and a 51-bp in the Cyp2b10 [29, 32] were 
shown to be sufficient to confer PB induction. Analysis of these sequences revealed the presence of 
putative hexamer half-sites suggesting for the first time that nuclear receptors are involved in drug-
regulated expression of CYPs (see next section). 
As mentioned earlier, since CYPs are heme-containing proteins, a dramatic increase in CYP proteins 
due to drug exposure enhances the demand of heme. As δ-aminolevulinic acid synthase 1 (ALAS1) is 
the rate limiting enzyme of heme biosynthesis and is highly inducible in the liver when heme demand 
increases, drug induction of CYPs affects the heme biosynthesis [33]. Therefore we characterized the 
regulatory elements in the ALAS1 gene that are both responsible for its drug-induced expression of 
and activated by xenosensing nuclear receptors. Binding sites for CAR, PXR and CXR were discovered 
in human, mouse and chicken 5’-flanking region of ALAS1 genes [34-36]. Thus, drug-mediated 
expression of ALAS1 is increased in parallel to the induction of CYPs as a response to an enhanced 
demand of heme in the liver. 
 
Nuclear Receptors  
Cell-cell communication within an organism is necessary in all phases from the embryogenesis to the 
coordination of all vital functions during the life span. Communication is assured by messenger 
molecules, which usually bind to membrane receptor or if they are lipophilic and small enough to 
cross the membrane they interact with members of the family of nuclear receptors, which act as 
transcription factors. This family is subdivided in three classes, the classical hormones receptors, the 
sensor receptors and the orphan nuclear receptors [37]. The endogenous ligands for the orphan 
nuclear receptors are not known, whereas the classical hormones receptors bind molecules such as 
glucocorticoids, thyroid hormone, estrogen and retinoic acids, and are thus key factors in the 
endocrine homeostasis maintenance. The third class of sensor receptors bind substances of the 
metabolic pathways such as fatty acids (peroxisome proliferators activated receptor, PPAR), oxysterols 
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(liver X receptor, LXR), bile acids (farnesoid X receptor, FXR), or sense drugs and toxic levels of 
endobiotics (constitutive androstane receptor, CAR and pregnanes X receptor, PXR). These receptors 
are sensors of the metabolic state and responsible for the metabolic adaptation by responding to 
incoming dietary signals and metabolites generated in the organism. The hepatocyte nuclear factor 4α 
(HNF-4α) is also considered a metabolic sensor receptor because of its effects on glucose, fatty acids 
and cholesterol metabolism; however the question about its endogenous ligands is not completely 
solved. 
The NR family is ancient in origin and was well diversified even before the arthropod/vertebrate split 
[38]. NRs control the activity of target genes directly by interacting as monomers, homodimers or 
heterodimers with the distal enhancer elements, located in the target gene flanking region. Response 
elements (RE) consist of two hexamer core half-sites, with consensus AGG/TTCA, which are arranged 
as direct repeats (DRs), inverted repeats (IRs) or everted repeats (ERs) spaced by different numbers 
of nucleotides. The NRs that bind as monomer, usually bind to an extended half-site, the extension 
being rich in A and T [39-41]. 
The mechanisms by which the nuclear receptors can regulate the transcription of the target gene are 
currently under intensive investigation. In addition to direct contact to the transcriptional machinery, 
NRs enhance or inhibit transcription by recruiting coactivator and corepressor proteins. The ligand 
binding causes a conformational change in the receptor, which leads to the release of corepressors 
and recruitment of coactivators. The role of the coactivators is to facilitate the communication 
between NRs, the basal transcriptional machinery and the chromatin environment in the presence of 
agonists. Because the NRs need to gain access to the DNA, which is wrapped around histones forming 
nucleosomes, they recruit proteins, which destabilize the chromatin structure by several mechanisms 
including histone acetylation. On the other hand, in the absence of ligands or in the presence of 
antagonists, the corepressors recruit the histone deacetylase, which stabilizes the chromatin and 
inhibits transcription [42-46]. 
Members of the nuclear receptor superfamily share structural and functional domains such as a highly 
conserved zinc finger DNA binding domain (DBD or C domain), which allows binding of the receptor to 
DNA, and a C-terminal ligand binding domain (LBD or E domain), which interacts with the ligand and 
allows dimerization. Other less conserved regions are the N-terminal region (A/B domain), a hinge 
region (D domain) between the DBD and the LBD, and a C-terminal region (F domain) in some 
receptors [47, 48].  
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The Role of the Xenosensors Pregnane X Receptor and 
Constitutive Androstane Receptor in Drug Induction  
In the last years, unique roles for nuclear receptors in the regulation of CYP enzymes emerged. In 
particular, two xenosensing receptors were discovered in mammals, CAR and PXR, which regulate the 
CYP2B and CYP3A genes expression, respectively [49, 50]. PXR and CAR are abundantly expressed in 
liver and intestine, the places where drug metabolism occurs. They bind to DNA as heterodimers with 
RXR, which is the heterodimerization partner of several sensor receptors (LXR, FXR, PPAR). In 
chicken, only one xenosensor is present, the chicken X receptor (CXR), which was characterized in our 
group. 
Pregnane X Receptor 
PXR, alternatively called steroid and xenobiotic receptor, was discovered in mice and human by three 
independent groups in 1998 [51-54]. This receptor is activated by a multitude of very different drugs 
due to its extraordinarily large and flexible ligand binding pocket. Amino acid sequence comparison of 
LBD of different PXR orthologs revealed an unusual high divergence [55]. This divergence explains the 
species differences observed in induction of CYPs by PXR. For example, changing four amino acids of 
mouse PXR into the corresponding amino acids of the human counterpart led to a typical human 
activation pattern [56]. Similarly, PXR knockout mice that express the human PXR exhibit a typical 
human response to different inducers [57]. The flexibility and relative lack of specific binding 
interactions is supported by the observation that even the potent inducer SR12813 can bind to PXR in 
three distinct orientations [56]. The analysis of the binding site in PXR target genes indicates that this 
receptor is rather flexible in its binding specificity. Among others, binding and activation of DR-3, DR-
4, ER-6, ER-8 and IR-0 were reported [52, 53, 58, 59]. PXR is found normally in the nucleus, where it 
is activated by ligand binding [60]. However, PXR was recently proposed to accumulate also in the 
cytoplasm in complex with Hsp90 and CCRP by overexpression of the latter [61]. The first identified 
targets of PXR were CYP3A1 and CYP3A4 in rat and human, respectively [53, 54, 57]. Later, other 
genes were shown to be regulated by PXR, such as CYP2Bs, MDR1, MRP2, OATP2 among others (for 
a recent review, see [62, 63]). 
In PXR knockout mice, induction of Cyp3a11 by PCN, which is a typical PXR inducer, is impaired. 
However, Cyp3a11 can still be activated by PB via CAR [57, 64], indicating that CAR may cross-
regulate Cyp3a11 as suggested by DNA binding and transfection experiments.  
Constitutive Androstane Receptor 
The PB-responsive unit (PBRU) in the CYP2B genes flanking region is composed of one DR-4 part of 
which was used in affinity purification for isolation of proteins binding to this sequence and mediating 
drug induction. This approach led to the observation that murine CAR binds to Cyp2b10 [65]. Like 
PXR, CAR shows high species-specific divergence in amino acid sequence in the LBD. Moreover, low-
affinity ligands are typical for CAR, although its ligand binding pocket is smaller in comparison to PXR. 
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CAR recognizes preferably DR-4 and DR-5 repeats [66, 67], but ER-6 and ER-8 can serve as CAR 
binding sites, too [68, 69]. Different activation mechanisms of CAR were reported, which do not 
require the binding of the inducer to the receptor. Although CAR can be directly activated by 
TCPOBOP binding, PB and other inducers were never shown to bind to the receptor. In contrast to 
PXR, CAR is usually located in the cytoplasm and is transferred to the nucleus by ligand binding or by 
an indirect mechanism, which does not require receptor binding. Initial reports described CAR as a 
constitutively active receptor [66, 67, 70] since transiently transfection of CAR in HepG2 cells elicited 
high basal activity of Cyp2b10 or CYP2B6 PBRU in reporter gene assays [69]. In these cells CAR is 
located already in the nucleus and can be inhibited by certain androstanols, which act as inverse 
agonists (mouse CAR). 
In primary cultures of hepatocytes and in liver, CAR is located in the cytoplasm. PB was shown to 
activate CAR by an indirect mechanism leading to its cytosolic-nuclear translocation [71]. This process 
is controlled by protein dephosphorylation events since the protein phosphatase inhibitor okadaic acid 
inhibits nuclear CAR transfer. In addition, translocation appears to be mediated by a leucine-rich 
xenobiotics response signal (XRS), which is located in the C-terminal region of CAR [72]. This 
xenosensor is retained in the cytoplasm under normal conditions in a complex of several proteins of 
which only a few are known. Heat shock protein 90 (Hsp90) and cytoplasmic CAR retention protein 
(CCRP) were recently described to interact with CAR in the cytoplasm, whereas protein phosphatase 
2A (PP2A) was shown to be recruited by PB treatment [73, 74]. If this cytosolic complex retains CAR 
in the cytoplasm and/or protects it from degradation is still not known. Experiments using 
calcium/calmodulin-dependent protein kinase (CaMK) inhibitors revealed that once CAR is in the 
nucleus, its activity is modulated by protein phosphorylation events [75]. 
In CAR knockout mice induction of Cyp2b10 by TCPOBOP and PB in the liver was absent establishing 
a fundamental role for CAR in this response. Furthermore, induction of other CAR target genes was 
impaired in the liver of knockout mice [17, 76-78]. As previously mentioned, pleiotropic effects in the 
liver were observed by treatment with PB, such as liver hypertrophy or liver tumor promotion by long-
term treatment, both of which are absent in CAR-null mice in comparison to wild-type mice [78-80]. 
Thus, CAR is not only responsible for the transcriptional upregulation of CYP genes caused by PB, but 
also for other hepatic responses. 
Despite much progress in understanding CAR-dependent hepatic responses, the molecular mechanism 
of CAR-mediated signal transduction remains enigmatic. 
Chicken X Receptor 
As mentioned above, the chicken hepatoma cell line LMH uniquely maintains a pleiotropic response to 
PB. This observation and the fact that the similarity between mammalian and chicken PBRUs was very 
high [22], prompt our group to clone the chicken orthologs of CAR and PXR. Surprisingly, only one 
xenosensor, the chicken xenobiotic receptor (CXR) was identified [81, 82], which is  equally related to 
both mammalian CARs and PXRs. 
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Chicken CXR and mammalian CAR and PXR as well as drug-inducible PBRUs could be freely 
interchanged in transactivation and electrophoretic mobility shift assay suggesting evolutionary 
conservation of the fundamental hepatic drug-induction mechanisms from birds to man. In addition, 
mouse Cyp2b10, rat CYP2B2 and human CYP2B6 PBRUs could be activated in LMH cells indicating that 
the proteins involved in the activation of the CYP2H1 PBRU are identical or similar to proteins binding 
to the mouse and rat PB-responsive enhancer sequences [83] despite the presence of only one 
xenosensor in chicken. Thus, LMH cells are the first PB-inducible cell line showing both qualitative and 
quantitative responses comparable to in vivo findings. Since our recent data show evolutionary 
conservation of hepatic PB responses, LMH cells are a valuable tool for the study of the regulatory 
mechanism of PB-type induction. In addition, with the release of the chicken genome in 2004 [84, 
85], studies in LMH cells will be facilitated in the future, especially experiments aimed to identify 
proteins or protein modification by mass spectrometry. From initial comparison with the mouse and 
human genome, it turned out that the overall pattern of gene order in the human genome is more 
similar to the chicken than to the mouse and that humans share about 60% of their genes with the 
chicken, with 75% identity on average. 
 
Phosphorylation/Dephosphorylation Events in Phenobarbital-
Mediated Induction of Cytochromes P450  
Several experimental observations pointed to a role of phosphorylation and dephosphorylation events 
in the indirect mechanism of PB induction of CYPs, but the literature in this field is chaotic and 
sometimes contradictory. 
For some years it was assumed that PB induction requires de novo protein synthesis. However, 
evidence accumulated indicated that de novo protein synthesis is not required for PB induction and 
that rather post-transcriptional processes are regulators of PB signaling in hepatocytes, i.e. protein 
kinase/phosphatase. 2-Aminopurine, a general inhibitor of serine/threonine protein kinases, blocked 
CYP2B1/2 induction in rat hepatocytes [86], and CYP2H1 and ALAS1 induction in chick embryo 
hepatocytes by PB [87]. Genistein, a tyrosine protein kinase inhibitor, also fully blocked Cyp2b10 
induction by PB in mouse hepatocytes [88]. However, other studies reported no effect of genistein on 
CYP2H or CYP2B induction by PB [87, 89, 90]. Elevated intracellular levels of cAMP resulted in a 
dramatic inhibition of PB-mediated induction of CYP2B1, CYP2B2 and CYP3A1 gene expression in 
primary cultures of rat hepatocytes [91] and of Cyp2b10 in mouse hepatocytes [71], suggesting an 
involvement of cAMP-dependent protein kinase A (PKA). In addition, elevation of intracellular cAMP by 
forskolin, an adenylate cyclase activator, led to a dose-dependent repression of PB-inducible gene 
expression. Consequently, PKA may exert a negative role on CYP2B induction by PB. However, a study 
by Honkakoski et al. in mouse hepatocytes did not find any effect of forskolin and dibutyryl cAMP on 
Cyp2b10 inducibility by PB [92]. Moreover, no direct effect of PB on cAMP levels or PKA activity could 
be detected in mouse and rat hepatocytes [92, 93] and in avian LMH cells [22]. However, data 
obtained by the use of forskolin have to be handled carefully, because this PKA modulator is a ligand 
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and activator of human and mouse PXR [94]. Other studies showed inhibition of Cyp2b10 and 
Cyp3a11 induction by PB in mouse hepatocytes treated with the Ca2+/calmodulin-dependent protein 
kinase inhibitor KN-62 or intracellular Ca2+ chelator BAPTA-AM [71]. In this regard, Yamamoto et al. 
blocked the TCPOBOB-mediated induction of Cyp2b10 in mouse hepatocytes by KN-62 [95]. 
Interestingly, this compound did not affect the nuclear translocation of CAR. Alternatively, okadaic 
acid, a potent inhibitor of serine/threonine phosphatases PP1 and PP2A, also fully prevented PB 
induction of CYP2B1/2B2 and Cyp2b10 in hepatocytes [96, 97]. These and other experimental 
observations strengthen the hypothesis that phosphorylation of yet unidentified proteins is involved in 
the molecular mechanism of PB-mediated regulation of CYPs, even though contradictory studies exist 
due probably to different experimental conditions, such as the systems employed or the concentration 
of inhibitors used. Functional studies approaching the role of phosphorylation in PB-mediated 
induction of CYPs without the use of pharmacological agents could shed more light on this very 
intricate field.  
 
Crosstalk Between Drug, Lipid and Bile Acid Metabolism 
The wide ligand specificity and overlapping DNA binding preferences of CAR and PXR lead to complex 
cross-regulation of drug-metabolizing enzymes. In addition, other nuclear receptors that are able to 
bind similar DNA motifs and are expressed in liver, such as VDR, LXR and FXR, may also modulate 
CAR and PXR target genes activation [98, 99]. Several data from our and other groups clearly show 
that a complex regulatory network involving crosstalk between nuclear receptors maintains lipid 
homeostasis, energy metabolism and drug detoxification.  
Drug Induction – Lipid Homeostasis 
A link between drug induction and lipid homeostasis has been established by several observations in 
cell culture, animals and patients. Squalestatin 1, an inhibitor of de novo cholesterol biosynthesis, was 
found to induce CYP2B1/2 in rat liver and primary cultures of hepatocytes [100-102]. Our studies in 
chicken hepatoma cells showed dose-dependent induction of CYP2H1 and CYP3A37 by squalestatin 1 
[103]. Rats fed with high cholesterol diet have a reduced basal and PB-induced CYP2B levels [104]. 
Furthermore, in obese fa/fa Zucker rats without functional leptin receptor PB induction of CYP2Bs is 
almost completely lost [105]. Long-term treatment with PB affects lipoprotein levels in rats [106, 107] 
and changes in plasma and hepatic lipid profiles in patients [108-110]. In fact, beneficial effects of 
this drug on cholestasis have been observed [111]. In our studies, we could demonstrate that PB 
lowers hepatic triglycerides by a direct effect of CAR and PXR on Insig-1 expression, a protein with 
antilipogenic properties (Roth A et al, submitted).  
These findings suggest that processes that influence hepatic cholesterol levels, such as defects in 
cholesterol biosynthesis pathways or hepatic accumulation of lipids, can ultimately alter drug 
metabolism, affecting the efficiency of drug treatment. 
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Drug Induction – Bile Acids 
Another example of crosstalk between drug metabolism and cholesterol homeostasis is regulation of 
bile acid levels. A significant part of hepatic cholesterol is metabolized into bile acids, which are then 
excreted. Bile acids have to be tightly regulated because they can reach toxic levels. FXR is the bile 
acid receptor and inhibits cholesterol 7α-hydroxylase (CYP7A), the enzyme of the rate limiting step of 
bile acid synthesis [112, 113]. In addition, it has been shown recently that PXR [114, 115], VDR [116] 
and even CAR [117, 118] and CXR [119] can sense toxic levels of primary bile acids. The CYP3A 
family is of particular importance for drug metabolism, because it is estimated that more than 50% of 
clinically used drugs are at least partly metabolized by the predominant human 3A isoform, CYP3A4, 
which is induced by several compounds and shows high interindividual expression variability. This has 
important clinical consequences, affecting the efficacy of drug treatment and causing drug-drug 
interactions [120-122]. For this reason understanding the regulation of this gene is of great interest. 
CYP3A can metabolize bile acids and indirect evidence shows that CYP3A induction occurs in response 
to cholestasis [123]. Since PXR was shown to respond to toxic bile acids levels and CYP3As are target 
genes of this receptor, it can be hypothesized that PXR regulates CYP3A under cholestasis condition. 
Interestingly, Cyp3a11 induction by bile acids was reported also in PXR-null mice [124]. Therefore, we 
studied the regulation of CYP3A4 via the xenobiotic responsive enhancer module (XREM) under 
cholestatic conditions. In this study we showed that primary bile acids modulate the expression of 
CYP3A via FXR, thus enhancing bile acids metabolism, in addition to inhibit their biosynthesis by 
inhibition of CYP7A genes (APPENDIX 4 [125]). The human CYP3A4 promoter is a good example for 
nuclear receptor interplay, because it responds to PXR, CAR and even FXR [125] and VDR [126].  
Drug Induction – Liver X Receptor 
Another example of regulated crosstalk is the oxysterols receptor LXR, which not only regulates 
CYP7A genes, but also affects drug-inducible CYPs by binding to the drug-responsive enhancer 
element in the 5’-flanking region of chicken CYP2H1, and the human CYP2B6 and CYP3A4 [119], 
respectively. Our studies showed that LXR competes with PXR, CAR and CXR for binding to the DR-4 
in the PB-responsive units, thus inhibiting PB-mediated induction of CYPs. We extended these results 
by in vivo experiments in LXR-null mice [127]. 
 
These three examples of crosstalk between drug induction and metabolic homeostasis clearly show 
that it is impossible to separate one from the other and that studies in this field have to consider the 
complicate network existing between them. In the next pages, the roles of CAR in the liver beside the 
regulation of drug metabolism are described. 
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Diverse Roles of the Constitutive Androstane Receptor 
CAR in Xenobiotic Metabolism 
CAR coordinates the regulation of multiple genes resulting in a higher metabolic capability of liver 
cells. As already mentioned, CYP genes were the first discovered targets of CAR. cDNA microarray 
analysis of wildtype and CAR-null mice revealed that CAR positively regulates not only CYPs (phase I 
enzymes) but also phase II drug-metabolizing enzymes and drug transporters.  By this mean, CAR 
increases both metabolism and excretion of drugs, and thus plays a central role in the defense against 
toxic compounds. 
The Hepatotoxic Role of CAR - CAR as a Risk Factor 
Although induction is advantageous in most instances, it is also associated with hepatotoxic effects, 
such as metabolic activation of procarcinogens. In fact, CAR may inadvertently activate some 
compounds to carcinogens or toxic metabolites by promoting their modification. One example of the 
role of CAR in hepatotoxicity is the metabolism of acetaminophen (APAP) [128]. High levels of APAP 
activate CAR resulting in activation of CYPs involved in generating the more toxic APAP metabolite, N-
acetyl parabenzoquinone imine (NAPQ1). This metabolite can react with cellular proteins causing 
toxicity. CAR-null mice are relatively resistant to APAP toxicity because no CAR-mediated increase in 
CYP production occurs, which would metabolize APAP to its toxic metabolite. The hepatotoxic role of 
CAR should thus not be underestimated. 
CAR as a Protective Factor - CAR and Hyperbilirubinemia 
Because the enzymes and transporters upregulated by CAR are also involved in the metabolism and 
secretion of endobiotics, the role of CAR as protective factor is extended to toxic endogenous 
substances. Bilirubin is the end product of the heme catabolism and is one of the most toxic 
breakdown product in the body. Hyperbilirubinemia is caused by increased accumulation of bilirubin, 
which can deposit in the central nervous system causing neurotoxicity and encephalopathy. The 
UGT1A1 gene encodes bilirubin UDP-glucuronosyltrasnferase that catalyzes conjugation of bilirubin 
with glucuronic acid. This conjugation reaction followed by transport by organic anion transporting 
polypeptide 2 (OATP2) and multidrug resistance-associated protein 2 (MRP2) constitutes the major 
bilirubin detoxification pathway. For a long time it has been known that PB can decrease elevated 
bilirubin levels [129]. This is now revealed to be due to the ability of CAR to activate the expression of 
several components involved in bilirubin clearance [130, 131].   
CAR as a Protective Factor - CAR and Cholestasis  
One of the most important functions of the liver is bile production. The major products of cholesterol 
catabolism are bile acids, which help intestinal absorption of lipophilic nutrients by acting as 
physiological detergents. The level of bile acids is regulated by the balance of synthesis and 
elimination; cytochrome P450 7A (CYP7A) is the rate-limiting enzyme of bile acid synthesis, while 
other enzymes and transporters play a major role in the elimination. Elevated bile acids level through 
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dysregulation of this process may lead to cholestasis and liver injury. 
For decades PB has been used to treat pruritis, a side effect of elevated serum bile acids associated 
with cholestasis. Recent studies showed that activation of CAR is necessary and sufficient to protect 
from the hepatotoxicity of lithocholic acid, a secondary bile acid [118, 132], thus explaining the 
beneficial effect of PB in the treatment of cholestasis. This finding implies that CAR agonist may be 
useful in the treatment of bile acids disorders.  
CAR in Endocrine Homeostasis and Disruption  
CAR affects endocrine homeostasis by altering hormone metabolism. Indeed, several CAR target 
genes are responsible for hormone metabolism, such as CYP2B or UGT1A1, which hydroxylate 
androgens and estrogens or glucuronidate estrogens to their inactive metabolites, respectively. Thus, 
CAR activation by xenobiotics or endobiotics increases steroid hormone catabolism affecting the 
endocrine homeostasis. Moreover, CAR activity was shown to be affected by steroids, such as 
androstanol and androstenol, which inhibit the receptor [133], or the active estrogen 17β-estradiol 
(E2), which activates CAR [134, 135]. Interestingly, CAR is not activated by inactive estrogens, 
suggesting a positive role of CAR-mediated estrogen metabolism against toxicity, because high doses 
of E2 often cause cholestasis in rodent as well as in humans [136]. 
The importance of CAR in endocrine homeostasis became even more prominent when CAR was found 
to be a primary glucocorticoid receptor (GR) target gene. A glucocorticoid response element (GRE) 
was identified in the human CAR gene and dexamethasone was shown to potentiate PB induction of 
CYP2B2 and Cyp2b10 via GR [137, 138]. 
CAR, Thyroid Hormone Homeostasis and Obesity 
Thyroid hormones act to increase the metabolic rate; high level of thyroxine (T4) and triiodothyronine 
(T3) in the serum is correlated to an increased metabolic rate. Chronic treatment with PB or PB-like 
inducers is known to promote thyroid hypertrophy in humans [139] and to decrease the level of total 
serum T4, thus decreasing the metabolic rate. Indeed, PB and similar drugs are known to increase 
enzymes involved in thyroid hormone metabolism, such as UDP-glucuronosyltransferase (UGT) and 
sulfotransferase (SULT), decreasing their serum levels in both animals and humans [140-143]. Obese 
individuals trying to lose weight have to face with the homeostatic resistance mechanisms that 
operate to resist weight loss. In fact, during periods of reduced caloric intake or fasting the level of 
thyroid hormones and consequently the basal metabolic rate are decreased, which results in low 
energy expenditure and low caloric loss. This major homeostatic barrier prevents weight loss under 
reduced caloric intake, making the life of obese individuals trying to diminish their weight very 
difficult. The importance of understanding the molecular basis of this homeostatic resistance pathway 
is huge: the opportunity to create pharmacological treatments for obesity. 
It is well documented that CAR targets genes, such as CYP2B, but more interestingly UGT and SULT, 
which can metabolize thyroid hormones, are upregulated during fasting [144]. It was thus reasonable 
to test if CAR plays a role in these events. Two recent studies reported that CAR is required for the 
increased expression of sulfo- and glucuronyl-transferases that accelerate the clearance of thyroid 
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hormones, in turn resulting in decreased serum T4 levels. Indeed, fasted CAR-null mice under calorie-
restricted diet for 12 weeks lost more than twice as much weight as the wildtype animals [144, 145].  
These studies indicate that CAR contributes to the homeostatic resistance to weight loss, and thus its 
inverse agonists might be useful in the treatment of obesity. 
CAR and Tumorigenesis 
Acute treatment with PB causes hepatomegaly apparently due to both hypertrophy and hyperplasia 
[78]. In the 1970s it was reported that chronic PB treatment promotes hepatocellular carcinoma 
(HCC) in rats [146]. This drug is the prototype of so-called nongenotoxic carcinogens that cause 
tumors without mutating DNA.  These tumor promoters increase the probability of cancer by 
accelerating the clonal expansion of cells transformed during tumor initiation. In humans, chronic PB 
treatment was never connected to liver tumor promotion probably due to the higher resistance of 
humans to tumorigenesis for a variety of reasons, including shorter telomeres. Indeed, telomerase-
deficient mice are resistant to chemically induced hepatocarcinoma [147]. However, the potential of 
human CAR as tumor promoter cannot be ruled out, because intriguing data in mice suggest that not 
all strains are susceptible to HCC promotion by PB. A locus on chromosome 1 was associated to the 
HCC formation susceptibility and the corresponding locus on the human chromosome 1 is amplified in 
more than half of human HCC samples. In two recent publications, CAR-null mice were used to 
investigate the role of CAR in the development of HCC. The data present experimental evidence that 
CAR has an essential role in the liver tumor promotion induced by TCPOBOP, another strong tumor 
promoter [79, 80].  
Thus, a short and transient hepatomegalic response promotes xenobiotic clearance, but chronic CAR 
activation can create a tumorigenic environment. For full understanding, further studies on the 
relationship of human CAR to HCC are necessary. 
CAR in Glucose Metabolism 
Several experimental observations point to a link between drug induction of CYPs and glucose 
homeostasis. Cyp2b10 expression is upregulated during fasting and in diabetes [144, 148]. Insulin 
was shown to repress drug induction in rat hepatocytes [144, 149], whereas glucagon was reported 
to increase CYP expression in chicken embryo hepatocytes [150]. In addition, treatment with PB 
decreases plasma glucose level in diabetic patients hence enhancing the insulin sensitivity [151] and 
inhibits gluconeogenic genes, such as phosphoenolpyruvate kinase (PEPCK) or glucose-6-phosphatase 
(G6P) in mice and rats [152, 153] via a CAR-mediated mechanism [17]. 
Kodama et al. recently showed that CAR and a forkhead transcription factor, FOXO1, interact 
coregulating reciprocally CAR and FOXO1 target genes, affecting both drug metabolism and 
gluconeogenesis [154]. These results shed light on the molecular mechanism of PB-induced 
repression of gluconeogenic enzymes and indicate a coordinate regulation of two major liver 
functions, the drug and the glucose metabolism.  
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AMP-Activated Protein Kinase 
The AMP-activated protein kinase (AMPK) is a metabolic-stress-sensing protein kinase that regulates 
metabolism in response to energy demand and supply by directly phosphorylating rate-limiting 
enzymes in metabolic pathways as well as controlling gene and protein expression. If the energy 
charge decreases, AMP/ATP ratio increases followed by activation of AMPK which subsequently turns 
off anabolic pathways such as fatty acid, triglycerides and cholesterol synthesis as well as protein 
synthesis and transcription, and switches on catabolic pathways such as glycolysis and fatty acid 
oxidation (FIGURE 1 and 2). Thus, all stresses that affect AMP/ATP ratio might activate AMPK and 
given that all physiological processes depend on energy, there are potentially many links with AMPK. 
In addition, hyperosmotic stress and the antidiabetic drug metformin were shown to increase AMPK 
activity without detectable changes in the AMP/ATP ratio, raising the possibility that other signals feed 
into this system, thus increasing the complexity of energy homeostasis regulation (reviewed in [155]). 
AMPK is a heterotrimeric enzyme that has been highly conserved throughout evolution as homologues 
of all three subunits have been identified in plants, yeast, nematodes, flies and mammals [156, 157]. 
AMPKα is the catalytic subunit, which has to be phosphorylated by upstream kinases to be activated. 
β and  γ are regulatory subunits, which are necessary for catalytic function and stability of the kinase. 
The β subunit acts as a targeting scaffold, whereas the γ subunit was shown to bind AMP. AMP seems 
to regulate AMPK activity by two different mechanisms, i.e. by making AMPK a better substrate for the 
upstream kinase or a worse substrate for protein phosphatases. 
 
 
From Hardie DG [158] 
FIGURE 1 
Physiological role of AMPK in the cell. Catabolism charges up the battery by converting ADP to ATP whereas ATP-
consuming processes convert ATP to ADP. AMPK acts to restore the energy homeostasis.  
 
Recent data showed that high cellular glycogen represses AMPK activation in muscle in vivo [159, 
160], suggesting that this kinase may be a sensor of glycogen content. Supporting this thesis, AMPKβ 
subunits contain glycogen binding domains that could associate AMPK to glycogen in overexpression 
studies [161]. 
Until today three AMPK upstream kinases were identified, LKB1, CaMKKα and CaMKKβ, which by 
phosphorylation of threonine172 of AMPKα activate the kinase in cells and in vivo [155]. LKB1 is 
ubiquitously expressed and was shown to be required for activation of AMPK in response to AMP/ATP 
ratio changes, both in cultured cells and in vivo [162, 163]. In contrast, increases in AMP do not 
stimulate phosphorylation of Thr172 by the CaMKKs, which is triggered instead by a rise in Ca2+ [164-
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166]. CaMKKs are mainly expressed in neural tissue, therefore their role in AMPK regulation in other 
tissue is not clear. 
In liver cells, activation of AMPK decreases the expression of gluconeogenic enzymes, PEPCK and G6P 
both in cell culture [167] and in vivo [168]. In type 2 diabetes the blood glucose level is elevated 
mainly due to increased gluconeogenesis. For this reason, AMPK-activating drugs are successful in the 
treatment of this condition.  
Much of the previous work on AMPK was focused on its effects on energy homeostasis within 
individual cells. However, recent results suggest that AMPK might affect whole-body energy 
metabolism by its activation by cytokines such as adiponectin and leptin, [168, 169], muscle 
contraction [170, 171] and its regulation of insulin secretion and expression in pancreatic β cells 
[172]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
From Hardie DG [158] 
 
FIGURE 2 
Targets of AMPK. Target proteins and processes activated by AMPK are shown on green, and those inhibited by AMPK 
activation are shown in red. 
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LKB1, the AMPK Upstream Kinase in the Liver 
LKB1, which was identified in humans as a tumor suppressor, is the gene mutated in the rare 
autosomal dominant human genetic disorder, Peutz-Jeghers syndrome (PJS) [173, 174]. PJS is an 
autosomal dominantly inherited disorder characterized by the occurence of intestinal polyps, which are 
benign tumors caused by disorganized growth of cells. LKB1 exists in a complex with two accessory 
proteins, Ste20-related adaptor protein (STRAD) and mouse protein 25 (MO25), which were shown to 
be important for LKB1 activity. STRAD, which is an inactive pseudokinase, anchors LKB1 in the 
cytoplasm, whereas MO25 appears to stabilize the LKB1:STRAD complex [175, 176]. 
LKB1 was shown to be necessary and sufficient for AMPK activation by most stimuli in HeLa cells, 
which do not express LKB1, and in immortalized fibroblast from LKB1-/- mouse embryos (MEFs) [162, 
177]. Recent evidence was presentated that LKB1 is the upstream kinase not only of AMPKα1 and α2 
subunits, but also of at least other twelve AMPK-related kinases, whose function is poorly understood. 
Apparently, LKB1 is a constitutive active kinase, which is not directly activated by stimuli. In fact, AMP 
binding to AMPK seems to make this kinase a better substrate for LKB1 [177, 178]. 
Furthermore, specific deletion of LKB1 in the liver resulted in a nearly complete loss of AMPK activity, 
providing evidence that LKB1 is the major AMPK upstream kinase in liver [179]. 
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Conceptual Considerations  
Hepatic cytochrome P450 enzyme activities and gene expression can be profoundly altered in disease 
states causing documented impairment of drug clearance and clinical drug toxicity. In order to make 
these effects more predictable, it will be important to gain a better understanding in the major 
physiological, cellular and molecular factors responsible for these changes. In the last years, the 
physiological role of CAR has expanded to include responses to metabolic and nutritional stresses. 
Particularly, two of the major liver functions, drug and glucose metabolism seem to be coordinately 
regulated by this receptor. The full elucidation of this interplay will help to understand the 
consequences of hepatic drug induction on the physiology and pathophysiology of the liver and the 
influence of metabolic and nutritional state on drug metabolism. Basal and drug-induced CYP 
expression is strongly affected by factors influencing the liver metabolic state, such as diabetes and 
energy starvation, and by phosphorylation/dephosphorylation events. Since AMP-activated protein 
kinase is an important energy sensor and regulates genes, which are affected by phenobarbital and 
CAR, too, its involvement in the molecular mechanism of cytochrome P450 enzyme induction was 
investigated in this thesis.  
Aims of the Thesis 
The initial goal of this thesis was to investigate the molecular mechanism of cytochromes P450 drug-
mediated induction, particularly by applying differential 2-dimensional electrophoresis to detect 
changes in the phosphoproteome of control versus phenobarbital samples. Since AMP-activated 
protein kinase was reported to be activated by phenobarbital in a human hepatoma cell line [180], we 
then focused on this protein kinase as possible mediator of the phenobarbital induction in liver. 
The chicken hepatoma cell line LMH was characterized and validated in previous studies showing that 
PB responses are preserved and evolutionary conserved in this system. For this reasons, this thesis 
firstly focused on this system to further unravel the pathway leading to the phenomenon of drug 
induction, particularly: 
 
1. Characterization of CXR in comparison to mammalian CAR and PXR (Results – Part I) 
 
2.  Investigation of the role of AMP-activated protein kinase in drug induction (Results – Part II) 
 
3.  Characterization of proteins involved in this drug response (Results – Part VII) 
 
4.  Confirmation and extension of the notion of evolutionary conservation of liver drug responses 
(Results – Part I to VII) 
 
5.  Confirmation of data from LMH cells in other systems, for instance human and mouse          
hepatocytes (Results – Part V and VI) 
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Supplemental data 
Human and mouse PXR and CAR genes contain 9 exons, 8 introns and highly conserved intron-exon 
junctions. Their amino acid sequences were aligned and compared with CXR highlighting conservation 
of the amino acids at the intron-exon boundaries (FIGURE 1.1, red amino acids). For identification and 
characterization of CXR introns, several primer pairs were designed at putative junctions (FIGURE 1.1, 
blue amino acids). A chicken genomic library was used as template in PCR reactions with different 
primer pairs. The PCR products were cloned, sequenced and examined on the existence of introns 
between the putative intron-exon junctions. After PCR condition improvements, all the primer pairs 
amplified pieces of CXR DNA sequences containing intron, only exception was the first intron because 
it is too large for amplification. Indeed, the position of the first intron-exon junction is not conserved 
among species and the intron length is very variable.  
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FIGURE 1.1 
Intron-exon junctions of CARs, PXRs and CXR. Amino acid sequences of human and mouse CAR or PXR, and CXR were aligned. 
The exon-intron boundaries are shown in red and the primers used for intron amplification in blue. 
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Part II 
Chicken AMP-Activated Protein Kinase Alpha Characterization 
 
To test if AMPK catalytic subunits are expressed in LMH cells, chicken cDNA was used as template in 
PCR reactions with primers specific for AMPKα1 or AMPKα2. In order to design the primers, human 
AMPKα1 or AMPKα2 DNA sequences were used in a Blast search in the partial sequenced chicken 
genome (at that time). Several Contig sequences highly similar to the human sequences used as baits 
were found. The putative AMPKα1 was found on the chicken chromosome Z, whereas AMPKα2 was on 
the chromosome 8. Luckily, the 5’ and the 3’ end containing the putative chicken start and stop 
codons of the two subunits were found in the Blast search, allowing specific primer design on the 
basis of the Blast retrieved sequences.  
Sequencing of the PCR fragments amplified with these primers revealed the identity of the amplified 
DNA sequences as chicken AMPKα1 and AMPKα2. The sequences of the newly characterized avian 
AMPK catalytic subunits were compared to the human and rat sequences on the amino acid level 
highlighting extremely high identity. The amino acid conservation is very high through the all 
sequence, but especially the kinase domain resulted almost completely conserved (FIGURE 2.0). 
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FIGURE 2.0A 
Chicken AMPKα  subunits are similar to the mammalian orthologs. AMPKα subunits were characterized in LMH cells. 
AMPKα1 and α2 were amplified from LMH cell cDNA. The amplified products were sequenced and the derived amino acid 
sequences compared to human and rat sequences. (A) Chicken AMPKα1 amino acid sequence is compared to the human 
AMPKα1 sequence. The kinase domain is evidenced by red amino acids.  
A 
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FIGURE 2.0B/C 
Chicken AMPKα  subunits are similar to the mammalian orthologs. (B) Chicken AMPKα2 amino acid sequence is 
compared to the human AMPKα2 sequence. The kinase domain is evidenced by red amino acids. (C) The amino acid identity 
between chicken, human or rat AMPKα sequences is shown in percentage.  
B 
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Abstract 
Transcriptional activation of cytochrome P450 (CYP) genes and various drug metabolizing enzymes by 
the prototypical inducer phenobarbital (PB) and many other drugs and chemicals is an adaptive 
response of the organism to exposure to xenobiotics. The response to PB is mediated by the nuclear 
receptor constitutive androstane receptor (CAR), whereas the chicken xenobiotic receptor (CXR) has 
been characterized as the PB mediator in chicken hepatocytes. Our previous results suggested an 
involvement of AMP-activated protein kinase (AMPK) in the molecular mechanism of PB induction. 
Here we show that the mechanism of AMPK activation is related to an effect of PB-type inducers on 
mitochondrial function with consequent formation of reactive oxygen species (ROS) and 
phosphorylation of AMPK by the upstream kinase LKB1. Gain- and loss-of-function experiments 
demonstrate that LKB1-activated AMPK is necessary in the mechanism of drug induction and that this 
is an evolutionary conserved pathway for detoxification of exogenous and endogenous chemicals. The 
activation of LKB1 adds a new proximal target to the so far elusive sequence of events by which PB 
and other drugs induce the transcription of multiple genes. 
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Introduction 
Evolution has provided organisms with an elaborate defense system against foreign compounds 
(xenobiotics). The liver of vertebrates contains numerous enzymes that can transform potentially toxic 
xenobiotics (e.g. nutrients or drugs) or endobiotics (e.g. bile acids) to inactive and extretable 
metabolites. The expression of these enzymes can be adapted to the needs for detoxification by a 
process called induction. Phenobarbital (PB) is the prototype of a number of drugs that induce their 
own and the metabolism of other xenobiotics. Induction of drug metabolism is part of a pleiotropic 
response of the liver to xenobiotic exposure, which includes liver hypertrophy, tumor promotion, and 
induction of numerous genes in addition to those encoding for drug-metabolizing enzymes and drug 
transporters [1, 2]. PB also was shown to decrease the transcription of gluconeogenic enzymes such 
as phosphoenolpyruvate carboxykinase 1 (PEPCK1) and glucose-6-phosphatase (G6P) [3], and of 
several hepatic genes responsible for fatty acid metabolism [4]. Moreover, PB increases the 
transcription of δ-aminolevulinic acid synthase 1 (ALAS1), the rate-limiting enzyme in the synthesis of 
heme, the prosthetic group of cytochromes P450 (CYPs) [5-8]. The molecular details of the 
mechanisms by which PB causes these effects are incompletely understood.  
The transcriptional activation by PB of genes encoding drug-metabolizing enzymes, such as Cyp2b10 
in mouse and CYP2B6 in human, is mediated by the nuclear receptor constitutive androstane receptor 
(CAR) [9, 10]. Another xenobiotic-sensing receptor, the pregnane X receptor (PXR) also responds to 
drugs like pregnenolone-16alpha-carbonitrile (PCN), dexamethasone or rifampicin by enhancing the 
expression of Cyp3a11 in mouse and CYP3A4 in human as well as many other genes [11-13]. The role 
of CAR and PXR was clearly established in transgenic mice, as PB-mediated induction of Cyp2b10 was 
completely abolished in CAR-/- mice [4], and PCN-mediated induction of Cyp3a11 was absent in PXR-/- 
mice [14]. However, the interaction of PB with CAR is complex. PB apparently does not bind directly to 
CAR, but rather triggers its translocation from cytoplasm to the nucleus by as yet unknown 
mechanisms [15-17]. In addition, phosphorylation and dephosphorylation events strongly affect PB 
induction of CYPs [18-20]. 
Interestingly, some of the effects of PB on energy metabolism in the liver were found to be CAR-
mediated. Cyp2b10 is upregulated during fasting and in diabetes [21, 22] and insulin has a repressive 
effect on induction of CYPs [23]. These and other observations point to an interaction between the 
energy state of liver cells and expression of CYPs and to a physiological role of CAR in the responses 
to metabolic and nutritional stress. 
An important energy sensor is AMP-activated protein kinase (AMPK). AMPK responds to any cellular 
stress that threatens to lower ATP levels by arresting non-essential ATP-utilizing functions and 
stimulating ATP-generating pathways [24]. Among the several genes regulated by AMPK is PEPCK1 
[25] an effect also exerted by PB. Because the effect of PB on CAR is influenced by phosphorylation 
and dephosphorylation events and the regulation of some CYPs can be affected by metabolic and 
nutritional stress, we investigated the role of AMPK in the induction response. AMPK indeed was 
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shown to be activated during PB-mediated induction of CYP2B6 in human hepatoma-derived cells [26] 
and in primary cultures of human and mouse hepatocytes [27]. However, the mechanism by which 
these drugs increase AMPK activity was unknown. 
The phenomenon of PB induction appears conserved in evolution and has been observed in bacteria, 
insects, fish and birds [2]. We have recently shown that in chicken hepatoma cells, the CAR- and PXR-
related chicken X receptor (CXR) confers PB-type induction by functionally identical or exchangeable 
signaling pathways triggered by the nuclear receptors CAR and PXR in mammals [28, 29]. In contrast 
to mammalian hepatoma cells, the chicken leghorn male hepatoma (LMH) cell line maintains a large 
spectrum of CYP gene induction by PB as well as by other drugs providing an accessible model for 
induction research [2]. Interestingly, PB responsiveness is a uniquely sensitive indicator of 
hepatocytes differentiation status [30]. 
In the present study, we have explored the mechanism by which AMPK is involved in the induction of 
three drug-inducible genes in chicken liver, namely CYP2H1, CYP3A37 and ALAS1. Our data confirm 
dose-dependent increase of AMPK activity after exposure of LMH cells to PB and extend this effect to 
metyrapone. The role of AMPK is further established through downregulation of AMPK expression by 
siRNA or decreasing AMPK activity by an inhibitor, which strongly reduce the drug-mediated induction 
of CYP2H1, CYP3A37 and ALAS1 genes. Most importantly, we observed that PB and metyrapone 
increase mitochondrial reactive oxygen species (ROS) generation and trigger the interaction of AMPK 
with one of its upstream kinases, LKB1, a protein kinase encoded by the Peutz-Jegher syndrome 
tumor suppressor gene. Our experiments confirm and extend the involvement of AMPK signaling in 
liver drug responses as an evolutionary conserved system from birds to mammals and suggest a 
mechanism by which inducer drugs activate AMPK. 
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Results 
AMPK activation by phenobarbital and metyrapone in LMH cells  
Because AMPK signaling pathways have not been characterized previously in LMH cells, AMPKα1 and 
AMPKα2 protein expression, localization and activation were analyzed in these cells. The endogenous 
expression of the two protein subunits in LMH cells was investigated through western blots using 
antibodies for the human, rat and mouse kinases (SUPPLEMENTAL FIGURE 2.1A). Expression of the 
avian α1 and α2 subunits was detected albeit at a relatively lower level than in primary human 
hepatocytes, which were used as control for the antibodies. A thick unspecific band, whose identity is 
unknown, was observed with the antibody against AMPKα2 in LMH cells, in contrast to human 
hepatocytes. Apparently, these antibodies recognize the chicken AMPK subunits, meaning that the 
AMPKα amino acid conservation between chicken and mammals is very high. In fact, the LKB1/AMPK 
cascade in chicken was recently characterized, showing a high degree of evolutionary conservation 
with values of 92% and 99% amino acids identity for LKB1 and AMPKα kinase domains, respectively 
(Results – Part II p.38 and [31]). 
The intracellular localization of the two proteins was studied by immunostaining using the same 
antibodies (SUPPLEMENTAL FIGURE 2.1B). Like in mammalian organisms [32], the protein recognized by 
α1 subunit antibodies was localized mostly in the cytoplasm, whereas the one recognized by α2 
subunit antibodies was also present in the nucleus.  
In order to test if a classical mammalian AMPK activator [33] would also increase chicken AMPK 
activity, LMH cells were exposed to AICAR. In mammalian cells, AICAR can usually double the kinase 
activity; the magnitude of activation in LMH cells is considerably lower with a 40-50% increase 
(FIGURE 2.1A). AICAR is a cell-permeable compound that is phosphorylated within cells by adenosine 
kinase to 5-aminoimidazole-4-carboxamide ribonucleoside (ZMP), an AMP analogue. This molecule 
mimics the effect of AMP and activates AMPK. Thus, AICAR conversion in LMH cells might not be as 
efficient or as fast as in other cells, explaining the lower AMPK activation. Another possible explanation 
is that LMH cells are not as sensitive as other cell lines to AMP increases. In fact, when we measured 
AMP/ATP ratio in these cells, the AMP level was considerably higher than in several mammalian cell 
lines. Western blots with antibodies against phosphorylated AMPK-Thr172 and ACC-Ser79, which is an 
indication of AMPK activation, confirmed the increased AMPK activity upon AICAR treatment (FIGURE 
2.1B).  
These results clearly show that AMPKα1 and α2 are expressed in LMH cells and that they are 
comparable to the mammalian counterparts both in subcellular localization and activation by AICAR. 
Recent studies have shown that PB activates AMPK in a human hepatoma-derived cell line [26]. To 
examine if this is also the case in our chicken cell line, two classical inducers of CYP2H1, CYP3A37 and 
ALAS1 [34], PB and metyrapone, were tested for their capacity to activate AMPK in LMH cells. Both 
compounds increased the AMPK activity after 1h treatment in a dose-dependent manner (FIGURE 
2.1A), PB showing a higher activation level than metyrapone. Increased activity was confirmed to be 
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due to higher AMPK-Thr172 phosphorylation by western blots (FIGURE 2.1B). Phosphorylation of the 
AMPK target ACC also was increased. In this experiment, we thus demonstrate that two different 
inducers of CYPs trigger dose-dependent AMPK activation. 
 
Activation or overexpression of AMPKα subunits affect CYP2H1, CYP3A37 and ALAS1 gene 
expression  
In order to test if modulation of AMPK activity alone affects CYP2H1, CYP3A37 and ALAS1 gene 
expression, compounds known to activate AMPK by different mechanisms were tested. AICAR is a 
compound which mimics AMP accumulation [33], metformin was shown to enhance ROS production 
[35], and NaN3 inhibits the complex IV of the respiratory chain provoking ATP depletion [36]. DNP 
uncouples the mitochondrial respiration leading to changes in the mitochondrial membrane potential 
[36], and rotenone is known to inhibit the complex I producing an initial increase in ROS production 
followed by ATP depletion [37]. After confirming that these compounds can effectively activate AMPK 
in LMH cells and lead to phosphorylation of AMPK-Thr172 and its target ACC-Ser79 (DATA NOT SHOWN 
2.1), their effects on expression of CYP genes were examined. CYP2H1, CYP3A37 and ALAS1 mRNA 
were indeed increased by all compounds, but to a lower extent than by PB and metyrapone (FIGURE 
2.2A + DATA NOT SHOWN FIGURE 2.6). By treating LMH cells with different AMPK activators, we could 
mimic the PB induction of CYP2H1, CYP3A37 and ALAS1, but since it cannot be excluded that these 
compounds are direct inducers, we decided to overexpress AMPKα1 and AMPKα2 subunits. 
When LMH cells were transiently transfected with rat AMPKα1 and AMPKα2 subunits, a strong 
increase of CYP2H1, CYP3A37 and ALAS1 induction by PB and metyrapone was observed (FIGURE 
2.2B). The latter showed a more pronounced effect most likely due to the difference in transfection 
efficiency of the two constructs. The basal expression level of the three genes was not altered. The 
increase in CYP induction obtained by AMPKα transfection was moderate probably as a result of the 
limited availability of AMPKβ and AMPKγ subunits, which were not co-transfected, but are known to be 
necessary for AMPK activation. These data show that induction of CYP2H1, CYP3A37 and ALAS1 is 
enhanced by increasing the expression of AMPKα. 
 
Downregulation of AMPKα activity by siRNA or Compound C decreases phenobarbital- and 
metyrapone-mediated induction of CYP2H1, CYP3A37 and ALAS1 
To establish if AMPK expression is necessary for drug-mediated induction of CYP2H1, CYP3A37 and 
ALAS1, AMPKα1 and AMPKα2 subunits were downregulated by gene-specific siRNA duplexes produced 
in vitro by recombinant Dicer enzyme [38-41]. mRNA levels of AMPKα1 and AMPKα2 were reduced to 
approximately 40% of the corresponding mRNAs of the control cells (SUPPLEMENTAL FIGURE 2.2A). 
None of the negative control genes (GAPDH and cyclophilin) were affected by AMPK-targeted siRNA 
duplexes (DATA NOT SHOWN FIGURE 2.2). The efficiency of AMPKα downregulation was tested also at 
the protein level by both activity assay and western blot. The AMPK activity was decreased to about 
50% of the control by α1 and α2 specific d-siRNA both separately as well as by the combination of the 
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two (SUPPLEMENTAL FIGURE 2.2A). In addition, the protein expression levels were clearly reduced as 
shown by western blot (FIGURE 2.3A). MAPK protein expression was used as negative control for the d-
siRNA specificity. Even if the downregulation of the two AMPKα subunits was not complete, it 
drastically reduced the effect of both PB and metyrapone on CYP2H1 and CYP3A37 mRNA (FIGURE 
2.3B). A complete inhibition of the drug induction was not expected, as there was residual AMPK 
activity. In the case of ALAS1, the effect of siRNA was weaker, suggesting that ALAS1 is subject to 
other regulatory mechanisms.  
Another way to modulate the AMPK activity is Compound C (cell-permeable pyrrazolopyrimidine 
compound), which is a specific and well-studied inhibitor of the kinase [42]. Preincubation of LMH 
cells with Compound C abolished the AMPK activation by DNP completely (SUPPLEMENTAL FIGURE 
2.2B), confirming the potency of this inhibitor. The increased phosphorylation of AMPK-Thr172 and 
ACC-Ser79 achieved by incubating LMH cells with PB or metyrapone could be prevented by 
preincubation of the cells with Compound C without affecting the AMPKα total protein expression 
(FIGURE 2.3C). Preincubation of LMH cells with Compound C drastically reduced the increase in mRNA 
expression of CYP2H1, CYP3A37 and ALAS1 genes without changing the basal activity (FIGURE 2.3D).  
All these studies firmly establish that an activation of AMPK is necessary for the effect of PB and 
metyrapone on the transcriptional activation of CYPs and also influences the regulation of ALAS1. 
Knowing that PB and metyrapone activate AMPK and that this kinase is essential to mediate their drug 
effects on CYP gene expression, we now focused on how these drugs can switch on AMPK activity.  
 
The AMPK upstream kinase LKB1 interacts with AMPKα upon phenobarbital and 
metyrapone treatment 
Several mechanisms of AMPK activation have been described, including ATP depletion, changes in 
mitochondrial membrane potential and formation of ROS. These mechanisms are not mutually 
exclusive and all involve the activation of AMPK by the upstream kinase LKB1. Since it is known that 
LKB1 is the upstream kinase of AMPK in the liver [43], we tested its function on the effects of PB and 
metyrapone on CYPs and ALAS1 mRNA. LKB1 and a LKB1 dominant negative (DN) form were 
transiently overexpressed in LMH cells. After treatment with PB or metyrapone, no statistically 
significant change in the CYP2H1, CYP3A37 and ALAS1 mRNA expression was detected with neither 
the wildtype nor the dominant negative form of LKB1 (SUPPLEMENTAL FIGURE 2.3A). The 
overexpression of the protein was confirmed by western blot with an antibody against the HA-tag and 
the AMPK activity was measured in LMH cells overexpressing LKB1 but no change in AMPK activity 
was detected by transfection of the LKB1 constructs (SUPPLEMENTAL FIGURE 2.3B). However, an LKB1 
involvement cannot be excluded by this experiment, because it is known that this kinase forms an 
active heterotrimeric complex with two accessory proteins, Ste20-related adaptor protein (STRAD) and 
the mouse protein 25 (MO25) in the cytosol, but if overexpressed on its own, it is localized mainly in 
the nucleus [44]. Thus, STRAD and MO25 could be the limiting factors in LMH cells preventing the 
activation of transfected LKB1.  
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In addition to overexpression experiments, we also measured LKB1 activity upon PB and metyrapone 
treatment, but we could not detect a clear and statistically significant increase in activity (DATA NOT 
SHOWN FIGURE 2.3), probably due to the fact that LKB1 is constitutively active. LKB1, although 
necessary for the activation of AMPK by several mechanisms, including AICAR, metformin, 
phenformin, muscle contraction, or H2O2, in all these cases does not influence directly the LKB1 
activity [45-48].  
Therefore, a direct interaction between AMPK and LKB1 was considered. Coimmunoprecipitation 
experiments were performed to find out if PB and metyrapone trigger an LKB1-AMPKα interaction. 
Western blots of lysates immunoprecipitated with anti-LKB1 antibodies revealed the appearance of a 
protein corresponding to AMPKα after 20min of PB and metyrapone treatment, which disappeared at 
40min of exposure (FIGURE 2.4A). Since AMPKα showed weak binding affinity to the protein G agarose 
beads in the preclearing step, we performed the vice versa experiment by immunoprecipitating 
AMPKα and assaying LKB1 by western blots. As a result a band after 20min appeared, which 
corresponds to LKB1 (FIGURE 2.4B). These experiments demonstrate that PB and metyrapone cause 
an interaction between LKB1 and AMPKα and establish LKB1 as a new target of these drugs. 
 
Phenobarbital and metyrapone affect mitochondrial membrane potential, ROS production 
and phosphorylation of LKB1-Ser428 
The involvement of LKB1 in the drug effects on CYPs led us to investigate by which mechanism PB 
and metyrapone prompt LKB1-AMPKα interaction and hence activate the latter by phosphorylation at 
Thr172. It was reported that some stimuli like AICAR provoke changes in the AMP/ATP ratio leading to 
AMPK activation by LKB1 [33]. Another recently described mechanism is the AMPK activation by 
metformin [35], which triggers mitochondrial ROS formation resulting in AMPK phosphorylation by 
LKB1. Troglitazone, an anti-diabetic drug, activates AMPK by a mechanism involving mitochondrial 
membrane depolarization, but in this case, LKB1 involvement was not investigated [49].  
In our experiments, we could not detect changes in the AMP/ATP ratio caused by treatment with PB 
and metyrapone (DATA NOT SHOWN FIGURE 2.4), suggesting an AMP/ATP ratio-independent 
mechanism in this system. We then tested for effects of PB and metyrapone on the mitochondrial 
membrane potential applying the JC-1 dye, which can enter the mitochondrial membrane and form 
aggregates. If the potential drops, the dye is released into the cytoplasm as monomers. Aggregates 
and monomers emit fluorescence at two different wavelengths that can be monitored. 
DNP, an uncoupler that leads to a membrane potential drop, was used as positive control. Exposure of 
LMH cells to 500µM PB or metyrapone, 1mM AICAR or 0.4mM DNP, caused changes in mitochondrial 
membrane potential (FIGURE 2.5A), whereas AICAR as expected had no effect. 
Because an increase in ROS production can lead to AMPK activation [50], PB and metyrapone were 
then tested for their capacity to enhance intracellular ROS production. The DCFH-DA dye, a 
nonfluorescent and cell-permeable compound that is oxidized by intracellular ROS to yield the highly 
fluorescent product DCF, was employed for the measurements, the effects of rotenone served as 
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positive control. Both PB and metyrapone increased ROS production to a similar extent as did 
rotenone (FIGURE 2.5B). As expected, AICAR did not affect ROS levels, because of its different AMPK 
activating mechanism. ROS were recently shown to activate AMPK by promoting the phosphorylation 
of LKB1 at Ser428 [51]. PB and metyrapone also caused an increase in LKB1-Ser428 phosphorylation 
(FIGURE 2.5C). These data clearly show that PB and metyrapone affect mitochondrial functions. 
 
Interference with ROS production affects phenobarbital- and metyrapone-mediated 
CYP2H1, CYP3A37 and ALAS1 gene expression and AMPK activation 
To assess if PB- and metyrapone-stimulated ROS increase plays an important role in CYP induction, 
we decided to modulate the cellular ROS production by either overexpression of uncoupling protein 1 
(UCP-1) or ROS scavenging by N-acetyl L-cysteine (NAC). UCP-1 is known to block the electron 
transfer of the respiratory chain and prevent O2 • formation [52]. For this reason, its effect on the 
drug-mediated CYP2H1, CYP3A37 and ALAS1 gene expression was tested. Transfection of UCP-1 in 
LMH cells provoked a considerable decrease of the effect of PB and metyrapone on mRNA levels of 
both CYP2H1 and CYP3A37 (FIGURE 2.6A), whereas the effect on ALAS1 was smaller. As expected, the 
AICAR effect on CYP induction was not altered. To establish if ROS production is indeed critical for 
AMPK activation by PB and metyrapone, the phosphorylation of AMPK-Thr172 and ACC-Ser79 was 
assessed in LMH cells overexpressing UCP-1 (FIGURE 2.6A). The AMPK and ACC phosphorylation 
normally triggered by PB and metyrapone was diminished by UCP-1, indicating that the increase of 
ROS produced by these drugs is linked to their ability to activate AMPK. In addition, ROS scavenging 
by NAC [53] strongly diminished the PB and metyrapone induction of CYP2H1, CYP3A37 and ALAS1 
(FIGURE 2.6B) without altering the AICAR effect on these genes. Cotreatment of PB- or metyrapone-
induced cells with NAC decreased AMPK-Thr172 and ACC-Ser79 phosphorylation (FIGURE 2.6B). These 
experiments show that ROS generation is necessary for activation of AMPK by PB and metyrapone. 
Since the mitochondrial respiration chain is the major site of ROS production, we investigated the role 
of mitochondria in drug induction. 
 
Phenobarbital and metyrapone-mediated induction of CYP2H1, CYP3A37 and ALAS1 is 
mediated by effects on mitochondria 
Variation of mitochondrial membrane potential and ROS production could be detected in response to 
PB and metyrapone. To provide evidence that mitochondria act as mediators of PB and metyrapone in 
the cascade, which leads to increased ROS production and subsequently to AMPK activation, 
mitochondrial DNA (mtDNA) was destroyed and consequently the number of functional mitochondria 
was lowered. Ethidium bromide is an inhibitor of DNA/RNA synthesis, which at low concentration more 
affects transcription and replication of extrachromosomal genetic components by intercalating into 
circular DNA without any detectable effect on nuclear DNA division. Treatment of cells with this 
reagent prevents mitochondrial DNA synthesis, leading to a smaller number of functional 
mitochondria. These cells are dependent on glycolysis to produce ATP and have to be supplied with 
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uridine and pyruvate to survive [54, 55]. In order to produce LMH cells with a decreased number of 
functional mitochondria, these cells were incubated for 12 weeks with ethidium bromide giving rise to 
the modified cell line LMHρ°. At the beginning of the treatment LMH cells grew at a slower rate, 
presumably because the cells have to switch first to glycolysis for ATP production as a consequence of 
their deficient mitochondrial respiration. After a short adaptation period, the cells were perfectly viable 
and normally dividing. Mitochondrial markers were monitored and NADH dehydrogenase 1 (ND1), 
cytochrome c oxidase 1 (COX1) and cytochrome b (Cytb) mRNA levels decreased to approximately 
40% of the level of wildtype LMH cells (DATA NOT SHOWN 2.5), in contrast to GAPDH, which is 
expressed by the nuclear genome that was not affected by ethidium bromide treatment. After PB or 
metyrapone treatment, LMHρ° cells showed a drastically decreased induction of CYP2H1, CYP3A37 
and ALAS1 gene expression (FIGURE 2.7) without a change of the basal level of the three genes in the 
LMHρ° cells. A complete inhibition of drug induction was not observed presumably due to still 
functional mitochondria present in the cells. 
The effect of the mitochondrial poison rotenone and of AICAR was also tested in these cells. As 
expected, the AICAR induction of CYP2H1, CYP3A37 and ALAS1 was not affected in the LMHρ° cells 
indicating that the AICAR effect is not mediated by mitochondria. On the other hand, the rotenone 
effect on induction decreased, which was expected since this compound targets mitochondria 
(SUPPLEMENTAL FIGURE 2.4). These data imply an important role for mitochondria in the mechanism of 
drug induction and identify these organelles as targets of inducer drugs. 
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Discussion 
In the present study we demonstrate that PB induces drug-metabolizing enzymes such as CYPs by a 
cascade of events that involves an initial interaction with mitochondrial function and leads to 
phosphorylation of LKB1, the upstream kinase of AMPK. LKB1 then phosphorylates the AMPKα subunit 
at Thr172 and activates AMPK. This activation of AMPK is a necessary step in the induction of these 
genes by PB, as recently shown in human hepatoma cells, primary mouse and human hepatocytes 
[27] and here in LMH cells. 
The direct interaction of the two kinases LKB1 and AMPK was evidenced by coimmunoprecipitation 
experiments and was associated with the drug-induced phosphorylation of LKB1 at Ser428. The 
activation of LKB1 adds a new proximal target to the so-far elusive sequence of events by which PB 
induces the transcription of multiple genes. 
Our findings also raise numerous new questions. For instance, do all PB-type inducers work by 
affecting LKB1 and thereby AMPK? Is activation of AMPK a necessary step of all inducers of CYPs? Is 
activation of AMPK sufficient to explain the pleiotropic effect of PB on gene transcription? Which 
kinase(s) activate LKB1 and how are these mechanisms related to mitochondrial functions? 
The fact that metyrapone, another inducer drug, in all our experiments mimicked the dose-dependent 
response of PB, suggests an identical mechanism for this and possibly other inducers. An interesting 
drug is metformin, used in the treatment of diabetes, which increases AMPK activity by a similar or 
identical mechanism [35]. Recently, some studies proposed that this drug increases mitochondrial 
ROS production leading to AMPK activation. Clearly, if a compound like PB activates AMPK in a similar 
way than metformin, the question arises if PB can be used to treat diabetes. Indeed, PB has been 
used beneficially to improve glycemic control in patients with non-insulin-dependent diabetes mellitus 
by enhancing glucose utilization in the liver and glucose storage in muscle [56]. However, even if 
these two drugs activate AMPK by ROS increase, they do not share all their effects. Probably, 
metformin also has antidiabetic effects, which are not AMPK-mediated. In our experiments in cell 
culture metformin activated expression of CYPs as did PB and metyrapone, supporting the role of 
AMPK activation in the induction process. However, metformin apparently is not an inducer in animal 
or human liver in vivo. This is most probably due to its rapid renal excretion, which prevents sustained 
accumulation in the liver required for induction. 
 
LKB1-AMPK activation is necessary for induction of CYP genes 
The experiments reported here confirm and extend previous studies, which suggest that induction of 
CYPs by PB requires increased AMPK activity. This interpretation is derived from the following results: 
(a) AMPK activity is dose-dependently increased upon PB or metyrapone treatment; (b) AMPK 
overexpression enhances induction of CYPs by PB and metyrapone; (c) downregulation of AMPK 
expression by siRNA drastically reduced induction. These experiments in avian cells establish that 
Results – Part II  52   
   
AMPK is necessary for the PB induction of CYPs and reveal evolutionary conservation of the 
mechanism of drug-mediated induction of CYPs. 
 
Phenobarbital interacts with mitochondria 
An important observation in explaining the effect of PB and metyrapone on LKB1 was that these drugs 
lead to increased production of ROS. This is suggested by the observation that overexpression of UCP-
1 inhibits drug induction of CYPs and that ROS scavenging by NAC decreases this effect on drug 
induction. In addition, we prepared LMH cells with a decreased number of functional mitochondria and 
the PB and metyrapone effect on expression of CYPs was strongly decreased, indicating the role of 
these organelles in the drug-elicited effect. ROS are commonly thought to be toxic, resulting in 
oxidation of various cell constituents such as DNA, lipids and proteins and consequently these 
oxidations may cause damage to the cellular machinery leading to cell death as the ultimate 
consequence. ROS have been implicated in the etiology of a wide array of human diseases, including 
cancer. But evidence is now also accumulating that ROS might play a role as signaling molecules if 
tightly regulated. In particular, ROS affect stress-activated pathways like NF-κB signaling, which 
interestingly also is upregulated by PB [57]. Our experiments therefore strongly suggest a role for 
ROS in drug induction but the precise mechanism remains unknown and further studies are needed to 
unravel the direct downstream targets of these molecules. 
Cell lines are tumour-derived cells and for this reason they may be less dependent than primary cells 
on the respiratory chain to generate ATP (aerobic metabolism). It is well known that cell lines usually 
have predominant anaerobic metabolism (glucose uptake and glycolysis) and low mitochondrial 
respiration. Our results show that mitochondrial functions are required by PB and metyrapone to exert 
their inducing effects on CYPs. Since in most cell lines the phenomenon of drug induction is not 
maintained, we speculate that this may be due to reduced mitochondrial function. If this is the case, 
LMH cells, which are highly inducible, should have higher aerobic metabolism in comparison to other 
cell lines. This hypothesis is currently under investigation. Our speculation could also explain why cell 
lines need higher drug doses to respond and induce CYPs in comparison to primary cells, which are 
more dependent on mitochondrial respiration. A correlation between mitochondrial 
dysfunctions/oxidative stress and diabetes has been repeatedly reported [58] and knowing that 
transcriptional regulation of CYPs is affected in diabetes suggests that these two effects may be 
somehow related. Moreover, the mechanism of PB and metyrapone-mediated induction of CYPs via 
effects of these drugs on mitochondria may also be considered in regard to the recent findings that 
mitochondrial dysfunction is involved in aging [59] and to the observation that in elderly there is a 
decline in drug metabolism capacity [60-62]. Mitochondria also are the site where ALAS1 is located 
and this enzyme is quickly upregulated upon drugs not only at the mRNA level but also at the activity 
level (Peyer AK, unpublished results). An interaction between drugs and mitochondria could allow a 
rapid ALAS1 activity regulation. All these observations strongly support a role of mitochondria in the 
response to inducer drugs. 
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How is AMPK activated? 
AMPK is activated by several stimuli, which are sensed as stress for the cells/organism. Previous 
studies in a hepatoma cell line [26] and experiments done in our laboratory in primary cultures of 
human hepatocytes [27] detected AMP/ATP ratio changes in response to PB treatment. In LMH cells 
we could not detect changes in AMP/ATP ratio in response to PB and metyrapone but when we 
measured AMP, ADP and ATP levels by HPLC in these cells, we noticed that AMP is much higher in 
LMH cells as compared to other cell lines. This could mask the presence of an effect on the AMP/ATP 
ratio or make the cells less sensitive to AMP/ATP changes. We therefore cannot exclude that inducer 
drugs change the AMP/ATP ratio under specific conditions.  
In this study we demonstrate changes in mitochondrial membrane potential and ROS generation 
caused by PB and metyrapone. These effects as well as AMP/ATP ratio changes are not mutually 
exclusive, suggesting that if inducer drugs target the mitochondria, several changes may occur at the 
same time. In fact, an inhibition of the mitochondrial respiration chain could explain all of these 
effects. 
As a novel concept, our results propose mitochondria as a target for inducer drugs.  Obviously, further 
studies are required to understand how exactly drugs affect these organelles. 
 
AMPK targets in the mechanism of drug induction 
Our results implicate LKB1/AMPK in the drug induction mechanism and also raise new questions about 
the target/s of this cascade. Which proteins does AMPK phosphorylate and how does this lead to 
drug-mediated increased expression of CYPs? Major efforts in our lab are directed to answer this 
question. Preliminary results show that the xenobiotic-sensing nuclear receptor CAR is not a direct 
target of AMPK (Matis M. et al, unpublished observation). However, dephosphorylation of CAR by the 
protein phosphatase 2A (PP2A) was recently shown to be necessary for nuclear translocation triggered 
by PB [63]. Is this dephosphorylation related to the AMPK activation caused by drugs? If CAR has to 
be dephosphorylated to translocate, which kinase does phosphorylate CAR? 
AMPK activation by inducers could play a role in different ways. An interesting hypothesis is that AMPK 
affects transcriptional coactivators or corepressors important for nuclear receptor-mediated 
transcriptional regulation. Does AMPK phosphorylate cofactors interacting with CAR? This may be 
possible since AMPK was already shown to affect p300 [64] and peroxisome proliferators-activated 
receptor γ coactivator 1α (PGC-1α) [65], two transcriptional coactivators. Otherwise, AMPK may affect 
the CAR cytosolic complex and change the localization of the nuclear receptor. Does AMPK 
phosphorylate a component of this complex thus releasing CAR? Is AMPK activation affecting the 
nuclear export of CAR? In this regard, it was previously reported that importin alpha1, an adaptor 
protein involved in nuclear import, is a downstream target of AMPK [66]. Importin alpha1 interacts 
with the nuclear localization signal (NLS) of proteins and translocates them through the nuclear pore 
complex. It may be interesting to test if this protein also mediates CAR nuclear translocation, since 
two NLS were recently identified in the amino acid sequence of this nuclear receptor [67]. 
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If we consider that AMPK is usually activated in stress situations, it is not unreasonable that this 
kinase is activated by compounds which upregulate CYPs. Drugs are probably sensed by organisms as 
a stress, because switch to drug metabolism for detoxification purposes is an energy consuming 
process. For this reason rapid initial AMPK activation by drugs could switch off unnecessary pathways 
allowing the organism to concentrate on the disposal of these compounds. 
 
Transcriptional regulation of ALAS1 
ALAS1 is the rate-limiting enzyme in heme synthesis and more than 80% of the heme synthesized in 
the liver is incorporated into CYPs. This enzyme is upregulated by drugs when the demand for 
reconstitution of CYPs increases. ALAS1 is transcriptionally regulated by the same nuclear receptors 
that drive drug-mediated induction of CYPs [6]. Thus it was reasonable to test if AMPK is also involved 
in ALAS1 drug upregulation. In our experiments, both by overexpression of AMPKα subunits or by 
siRNA dowregulation or by ROS scavenging, the effect on ALAS1 was present but not as strong as 
that on CYPs. This suggests that other mechanisms act on ALAS1 transcriptional regulation. This is 
likely, since the PB effect on ALAS1 was detected also in CAR-/- mice, indicating a CAR-independent 
mechanism. Since ALAS1 has a central role in heme production, it is reasonable to assume that this 
enzyme is tightly regulated by several pathways. In support of these data, we recently observed that 
the transcription coactivator PGC-1α, which is a target of AMPK, is responsible for the nutritional 
regulation of ALAS1 [68].  
 
In conclusion, we demonstrate that PB- and metyrapone-mediated transcriptional regulation of three 
chicken hepatic drug-inducible genes, CYP2H1, CYP3A37 and ALAS1, is achieved by a signaling 
cascade involving mitochondrial functions leading to ROS generation, LKB1 phosphorylation and 
consequent interaction with AMPK, which is in turn phosphorylated and activated. These findings add 
new knowledge regarding the mechanism by which PB and metyrapone lead to transcriptional 
regulation of CYPs via AMPK. To our knowledge this is the first time that inducers of CYPs have been 
revealed to affect the AMPK upstream kinase LKB1.  
Future studies are needed to understand how ROS production leads to activation of AMPK, which 
is/are the downstream target/s of AMPK and which is the LKB1 upstream kinase in this pathway. The 
biotransformation and detoxification of xenobiotics and endobiotics metabolism evolved over millions 
of years. Understanding the molecular mechanism of drug-mediated induction of CYPs is of 
importance for the molecular links between expression of CYPs and the metabolic state of the liver, 
for the problems caused by drug-drug interactions and adverse drug reactions, and for the crosstalk 
between disposal of endogenous and exogenous molecules.  
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Materials and Methods 
For methods used in these studies see the Material and Methods section at page 123. 
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Figures 
 
 
 
FIGURE 2.1 
Chicken AMPKα  subunits are activated by the classical activator AICAR and by phenobarbital-type inducers. (A) 
LMH cells were treated with increasing doses of AICAR, PB or metyrapone for 1h. AMPK activity was measured by SAMS peptide 
assay and shown as percentage of the control. *p<0.01, **p<0.05 (control versus treatment). (B) Phosphorylation of AMPK-
Thr172 and ACC-Ser79 is shown by western blot using 500µM for all three compounds and the same conditions as for the 
activity measurements. M, metyrapone. 
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FIGURE 2.2 
Activation or overexpression of AMPKα  subunits affect CYP2H1, CYP3A37 and ALAS1 gene expression. (A) LMH 
cells were treated with 1mM AICAR (AIC) or metformin (Met), 0.2mM DNP, 1mM NaN3, or 1µM rotenone (Rot) for 16h. Gene 
expression of CYP2H1, CYP3A37 and ALAS1 was analyzed by RT-PCR. p<0.01. (B) LMH cells transiently transfected with 
AMPKα subunits were treated with 500µM PB or metyrapone (Mety) for 16h. Gene expression of CYP2H1, CYP3A37 and ALAS1 
was analyzed by RT-PCR. *p<0.01, **p<0.05.  
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FIGURE 2.3 
Downregulation of AMPKα  activity by d-siRNA or Compound C decreases phenobarbital- and metyrapone-
mediated induction of CYP2H1, CYP3A37 and ALAS1. (A) LMH cells were transiently transfected with AMPKα1 and 
AMPKα2 specific d-siRNA. AMPKα protein expression was detected by western blots with antibodies against mammalian 
AMPKα1 or AMPKα2. MAPK protein expression was detected as negative control for d-siRNA unspecific downregulation. (B) 
LMH cells transiently transfected with d-siRNA were treated with 500µM PB or metyrapone for 16h. Expression of CYP2H1, 
CYP3A37 and ALAS1 was measured by RT-PCR. p<0.01 (mock d-siRNA versus α1+α2 d-siRNA). (C) Activation of AMPK by 
500µM PB or metyrapone with or without 30min pretreatment with 20µM Compound C is shown by western blot evidencing the 
phosphorylation of AMPK-Thr172 and ACC-Ser79. (D) LMH cells were incubated 16h with 500µM PB or metyrapone with or 
without  pretreatment for 30min by 20µM Compound C. mRNA level of CYP2H1, CYP3A37 and ALAS1 was measured by RT-PCR. 
*p<0.01, **p<0.05. M, metyrapone. 
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FIGURE 2.4 
Phenobarbital and metyrapone trigger the interaction of AMPKα  with its upstream kinase LKB1. (A) 
Immunoprecipitation of overexpressed HA-LKB1 by anti-HA antibody upon 500µM PB or metyrapone treatment at three 
different time points. Immunoprecipitation of HA-LKB1 was checked by western blot with anti-HA antibody. The western blot 
with anti-AMPKα antibody shows co-immunoprecipitation of AMPKα subunits with LKB1. (B) Immunoprecipitation of 
overexpressed Myc-AMPKα upon 500µM PB or metyrapone treatment. Immunoprecipitation of Myc-AMPKα was checked by 
western blot with anti-Myc antibody. The western blot with anti-LKB1 antibody shows co-immunoprecipitation of LKB1 with 
AMPKα. M, metyrapone; wb, western blot. 
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FIGURE 2.5 
Phenobarbital and metyrapone affect mitochondrial membrane potential, ROS production and LKB1 
phosphorylation. (A) LMH cells were incubated with the JC-1 fluorescent dye. Fluorescence was detected after 1h treatment 
with 500µM PB or metyrapone, 0.4mM DNP, or 1mM AICAR. The mitochondrial membrane potential is expressed as the 
590nm/540nm fluorescence ratio in comparison to the control sample. p<0.05. (B) Intracellular ROS was detected by the 
DCFDA fluorescence dye. LMH cells were treated with 500µM PB or metyrapone, 5µM rotenone and 1mM AICAR for 1h and 
fluorescence was detected. The result is shown as fold increase in comparison to the control sample. p<0.01. (C) 
Phosphorylation of LKB1-Ser428 upon PB and metyrapone is proven by western blot with antibodies specific for the LKB1 
phosphorylated form. M, metyrapone; Rot, rotenone; AIC, AICAR. 
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FIGURE 2.6 
Decrease in intracellular ROS production by UCP-1 overexpression or by NAC-mediated scavenging attenuates 
drug-mediated increase of CYP2H1, CYP3A37 and ALAS1 gene expression and AMPK activity. (A) LMH cells were 
transiently transfected with UCP-1 and then incubated with 500µM PB, metyrapone or 1mM AICAR for 16h. CYP2H1, CYP3A37 
and ALAS1 gene expression was detected by RT-PCR. *p<0.01. Activation of AMPK after 1h treatment with 500µM PB or 
metyrapone and 1mM AICAR is shown by western blot evidencing the phosphorylation of AMPK-Thr172 and ACC-Ser79. (B) 
LMH cells were incubated with 500µM PB or metyrapone, or 1mM AICAR, with or without 10mM NAC for 16h. CYP2H1, 
CYP3A37 and ALAS1 mRNA level was measured by RT-PCR. *p<0.01. Activation of AMPK after 1h treatment with 500µM PB or 
metyrapone, or 1mM AICAR with or without NAC is shown by phosphorylation of AMPK-Thr172 and ACC-Ser79. M, metyrapone; 
AIC, AICAR.
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FIGURE 2.7 
Mitochondrial functions are necessary for phenobarbital- and metyrapone-mediated induction of CYP2H1, 
CYP3A37 and ALAS1 gene expression. LMH wildtype () or LMHρ0 cells () were incubated with 500µM PB or metyrapone 
for 16h. CYP2H1, CYP3A37 and ALAS1 mRNA level was detected by RT-PCR. *p<0.01. M, metyrapone. 
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SUPPLEMENTAL FIGURE 2.1 
Chicken AMPKα  subunits are similar to the mammalian orthologs. AMPKα subunits were characterized in LMH cells. 
(A) Endogenous protein expression of the two chicken subunits was assessed by western blot with antibodies against human 
AMPKα1 and AMPKα2. Human hepatocytes were used as positive control for the antibodies. (B) The subcellular localization of 
the chicken AMPKα subunits was determined by immunofluorescence (IF) staining. The left panels show the immunostaining of 
AMPKα1 and AMPKα2 using the same antibodies as for the western blots. DAPI staining of the nuclei is shown in the right 
panels. 
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SUPPLEMENTAL FIGURE 2.2 
Downregulation of AMPKα  subunits expression or activity by d-siRNA and Compound C. (A) Gene expression of 
AMPKα subunits was measured by RT-PCR. The results are shown as fold expression relative to the control sample (upper 
panels). In the lower panel AMPK activity of d-siRNA transfected cells was measured and is shown as percentage of the control 
activity. p<0.01. (B) LMH cells were pretreated with 20µM Compound C for 30min. The potency of Compound C was tested by 
measuring the AMPK activity upon 0.4mM DNP with or without Compound C preincubation and is shown as percentage of the 
control. 
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SUPPLEMENTAL FIGURE 2.3 
LKB1 overexpression does not affect phenobarbital- and metyrapone-mediated CYP induction and AMPK 
activity. (A) LMH cells transiently transfected with LKB1 wildtype or LKB1 dominant-negative (DN) form were treated with 
500µM PB or metyrapone (M) for 16h. CYP2H1, CYP3A37 and ALAS1 mRNA level was analyzed by RT-PCR. (B) Expression of 
LKB1 protein was checked by western blot with antibodies against the HA-tag of the constructs (upper panel). AMPK activity 
was measured in LKB1-overexpressing cells (lower panel). 
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SUPPLEMENTAL FIGURE 2.4 
Rotenone and AICAR induction in LMHρ0 cells. LMH wildtype () or LMHρ0 cells () were incubated with 1mM AICAR or 
2µM rotenone for 16h. CYP2H1, CYP3A37 and ALAS1 mRNA level was detected by RT- PCR. *p<0.05. Rote, rotenone; AIC, 
AICAR. 
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Data not shown 
 
DATA NOT SHOWN FIGURE 2.1 
AMPK activation by different compounds. LMH cells were treated with 1mM NaN3, 0.2mM DNP or 1µM rotenone for 1h. 
AMPK activity was measured by SAMS peptide assay and shown as percentage of the control. p<0.01 (control versus 
treatment). Phosphorylation of AMPK-Thr172 and ACC-Ser79 is shown by western blot using the same compound concentration 
and conditions as for the activity measurement. 
 
 
 
 
 
 
 
 
 
 
 
 
DATA NOT SHOWN FIGURE 2.2 
Downregulation of AMPKα  subunits expression by d-siRNA is specific. Transfection of siRNA specific against AMPKα 
subunits does not affect the expression of other genes. Gene expression of GAPDH and cyclophilin was measured by RT-PCR. 
The results are shown as fold expression relative to the control sample. 
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DATA NOT SHOWN FIGURE 2.3 
LKB1 is not activated by phenobarbital, metformin or AICAR. (A) LMH cells were treated with 1mM PB, 1mM metformin 
(Metf) or 1mM AICAR (AIC) for different times. LKB1 activity was measured by LKB1 peptide assay and shown as fold in 
comparison to the control. (B) LMH cells were treated with 1mM PB in a time-course. LKB1 activity was measured by LKB1 
peptide assay and shown as fold in comparison to the control. 
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DATA NOT SHOWN FIGURE 2.4 
Phenobarbital and metyrapone do not affect AMP/ATP ratio. (A) LMH cells were treated with 500µM PB, 500µM 
metyrapone (M) or 0.2mM DNP for 1h. AMP and ATP level were measured by HPLC as described in material and methods. 
AMP/ATP ratio is shown. (B) LMH cells were treated with 500µM PB, 500µM metyrapone or 0.2mM DNP for different times. ATP 
level was measured by ATP Bioluminescence Assay Kit as described in material and methods.  
 
 
 
 
 
 
 
 
 
 
 
DATA NOT SHOWN FIGURE 2.5 
Expression level of mitochondrial markers in LMHρ0 cells. Mitochondrial DNA markers (ND1, COX1, Cytb) and one 
nuclear DNA marker (GAPDH) were measured in LMH wildtype and LMHρ0 cells. The expression level in LMHρ0 cells is shown as 
percentage in comparison to wildtype cells. 
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DATA NOT SHOWN 2.6 
AMPK activators dose-dependently enhance CYP2H1 and CYP3A37 gene expression. LMH cells were treated with 
increasing doses of AICAR (A), metformin (B), NaN3, DNP and rotenone (C) for 16h. Gene expression of CYP2H1 and CYP3A37 
was measured by RT-PCR. The results are shown as fold expression relative to the control sample. 
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Part III 
Additional Mechanistic Studies of the Phenobarbital-Mediated 
Induction of Cytochromes P450 
We demonstrated that AMPK activation is necessary for the drug-mediated increase of CYP expression 
(Results – Part II and [181]). In the next section, experiments to elucidate the mechanism by which 
AMPK affects the transcriptional regulation of CYPs are described.  
 
AMPK positive effect on CYP transcriptional regulation is mediated by distal PB-
responsive units in LMH reporter gene assay 
By reporter gene assay it is possible to link effects on transcription to a definite regulatory region in 
the 5’ flanking region of the gene of interest. The CYP2H1 264-bp and the CYP3A37 159-bp PB-
responsive units (PBRUs) were transfected along with increasing quantity of AMPKα1 (FIGURE 3.1A) or 
α2 (FIGURE 3.1B) followed by measurement of the luciferase expression after 16h of treatment with 
500µM PB or 500µM metyrapone. Drug-mediated induction of both reporter genes was increased by 
overexpression of AMPKα subunits without affecting the basal level. 
 
 
 
 
FIGURE 3.1 
Phenobarbital- and metyrapone-mediated activation of CYP2H1 264-bp and CYP3A37 159-bp PBRU reporter 
gene constructs is increased by AMPKα  overexpression. LMH reporter gene assays. LMH cells co-transfected with either 
tk-luc CYP2H1 264-bp or tk-luc CYP3A37 159-bp PBRU along with or without increasing concentrations of AMPKα1 (A) or 
AMPKα2 (B) were treated with 500µM PB or metyrapone (M) for 16h. Luciferase expression level is shown as relative 
expression to the control *p<0.01. 
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These experiments are evidence for an AMPK transcriptional regulation of CYPs via the short distal 
PBRUs, meaning that CYP2H1 264-bp and CYP3A37 159-bp PBRU are sufficient to mediate a direct or 
indirect effect of AMPK on gene expression. These findings suggest that AMPK may affect proteins 
directly involved in the transcriptional machinery binding to PBRUs, such as transcription factors, 
corepressors or coactivators. 
As already observed on mRNA level, the overexpression of LKB1 wildtype or the dominant negative 
form did not affect the reporter gene expression under any condition (FIGURE 3.2). 
 
 
FIGURE 3.2 
Phenobarbital- and metyrapone-mediated activation of CYP2H1 264-bp and CYP3A37 159-bp PBRU reporter 
gene constructs is not affected by LKB1 overexpression. LMH reporter gene assays. LMH cells co-transfected with either 
tk-luc CYP2H1 264-bp or tk-luc CYP3A37 159-bp PBRU along with or without LKB1 wildtype or LKB1 dominant-negative (DN) 
form were treated with 500µM PB or metyrapone for 16h. Luciferase expression level is shown as relative expression to the 
control. *p<0.01. 
 
 
AMPK positive effect on CYP transcriptional regulation is mediated by distal PB-
responsive elements in mammalian cells  
In order to assess if distal drug responsive elements are sufficient to mediate the AMPK effect on CYP 
gene regulation also in mammalian systems, Cyp2b10 51-bp and CYP2B6 51-bp PBREM reporter gene 
constructs were transfected into CV-1 cells with mouse or human CAR and increasing quantity of 
AMPKα1 or α2. After 16h of treatment cells were lysed and luciferase measurement was carried out. 
Both mouse (FIGURE 3.3A) and human (FIGURE 3.3B) PB-induced reporter gene expression were 
increased by AMPKα overexpression, which did however not affect the basal levels. Furthermore, an 
increase was also observed with the Cyp2b10 51-bp PB responsive enhancer module (PBREM) upon 
TCPOBOP (FIGURE 3.3A). In contrast, CITCO induction of CYP2B6 PBRU was not affected by increased 
AMPKα expression (FIGURE 3.3B). As already discussed in the manuscript (Results – Part II), the 
availability of AMPKβ and γ subunits may be the explanation for the limited effect of AMPKα 
overexpression on the transcription of CYPs. The distal drug responsive elements of mammalian CYP 
genes are thus the mediator of the AMPK effect on CYP gene upregulation by PB, like in avian cells, 
but not all inducers (for instance CITCO) seem to signal through this kinase. 
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FIGURE 3.3 
Phenobarbital-mediated transactivation of mouse Cyp2b10 51-bp and human CYP2B6 51-bp PBREM by CAR is 
increased by AMPKα  overexpression. CV-1 cells transactivation assays. (A) CV-1 cells co-transfected with mouse tk-luc 
Cyp2b10 51-bp PBREM along with mouse CAR were treated with 500µM PB or 10µM TCPOBOP for 16h in the presence of 
increasing concentration of AMPKα1 or α2. Luciferase expression level is shown as relative expression to the control. (B) CV-1 
cells co-transfected with human tk-luc CYP2B6 51-bp PBREM along with human CAR were treated with 500µM PB or 50nM 
CITCO for 16h in the presence of increasing concentration of AMPKα1 or α2. Luciferase expression level is shown as relative 
expression to the control. *p<0.01. 
   
Since AICAR and metformin increased expression of CYP2H1, CYP3A37 and ALAS1 in LMH cells, their 
effects in transactivation assays on Cyp2b10 51-bp PBREM were tested. Both compounds enhanced 
the reporter gene expression considerably as did the mouse inducer TCPOBOP (FIGURE 3.4). 
Interestingly, in contrast to TCPOBOP, AICAR and metformin could not reverse the inverse agonistic 
effect of androstanol suggesting that their effect on CYP expression is not via binding to CAR but via 
an indirect mechanism that cannot compete with the repression of CAR by androstanol. 
 
 
 
 
 
 
 
 
 
 
FIGURE 3.4 
Transactivation of mouse Cyp2b10 51-bp PBREM by CAR is increased by AICAR and metformin. CV-1 cells 
transactivation assays. (A) CV-1 cells co-transfected with the reporter gene vector tk-luc Cyp2b10 51-bp PBREM along with 
mouse CAR were treated with 500µM AICAR, 500µM metformin or 10µM TCPOBOP (as positive control) for 16h. Luciferase 
expression level is shown as relative expression to the control. p<0.01. (B) CV-1 cells co-transfected with tk-luc Cyp2b10 51-bp 
PBREM along with mouse CAR were treated with 500µM AICAR (AIC), 500µM metformin or 10µM TCPOBOP for 16h in the 
presence of the inverse agonist androstanol. Luciferase expression level is shown as relative expression to the control. AICAR, 
AIC; metformin, Metf; TCPOBOP, TCP. p<0.01. 
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Phenobarbital and metformin effects on CYP2H1, CYP3A37 and ALAS1 expression are not 
additive 
Our data demonstrate that PB shares a part of the mechanism of AMPK activation with metformin, for 
instance ROS formation and LKB1 recruitment to AMPKα. Cotreatment with both compounds should 
thus result in no additive effect if they use the same mechanism, in contrast an additive effect may 
appear if the compounds use two different mechanisms. 
Cotreatment of LMH cells with PB and metformin did not cause an increase in the PB induction of 
CYP2H1, CYP3A37 and ALAS1, whereas addition of NaN3, which is an inhibitor of mitochondrial 
complex IV and thus of ATP synthesis, strongly increased their expression upon PB (FIGURE 3.5). 
These results suggest that PB and metformin share the signaling pathway leading to AMPK activation 
and CYP induction, whereas NaN3 activates AMPK by a different mechanism resulting in a additive 
effect. Knowing that metformin targets the mitochondrial complex I, we can speculate that PB may 
have the same mitochondrial target.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3.5 
Phenobarbital and metformin effect on CYP expression are not additive. LMH cells were treated with 500µM 
metformin (Metf), 1mM NaN3 with or without 500µM PB for 16h. Gene expression of CYP2H1, CYP3A37 and ALAS1 was 
measured by RT-PCR. *p<0.01. 
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Part IV 
Role of Protein Kinase C in the Phenobarbital-Mediated 
Induction of CYPs 
The findings presented in the manuscript (Results - Part II) demonstrate that LKB1 is involved in 
AMPK activation by PB-type drugs. In order to find a player further upstream in this cascade, the 
identity of the LKB1 upstream kinase was investigated.  
So far, eight LKB1 phosphorylation sites (four of which are autophosphorylated) were identified. The 
kinases that phosphorylate LKB1-Ser31 and Ser325 (numbers referred to the human sequence) are 
not known, whereas LKB1-Thr366 was shown to be phosphorylated by checkpoint ataxia 
telangiectasia mutated (ATM) kinases and Ser428 by protein kinase A (PKA) or by the 90kDa 
ribosomal S6 kinases (p90RSK) [182-184]. ATM kinases are key players in the cell cycle regulation, 
whereas PKA and p90RSK are activated by extracellular signal-regulated protein kinases in response 
to many stimuli [185]. Since these last two kinases phosphorylating LKB1-Ser428 are rather 
responding to extracellular stress stimuli (such as drugs), the next experiments focused on Ser428. In 
accordance with these considerations, a ROS-dependent phosphorylation of LKB1-Ser428 was recently 
shown to lead to an interaction between LKB1 and AMPKα, which is in turn activated [186]. Because 
that study identified protein kinase C zeta (PKCζ) as the LKB1 upstream kinase in endothelial cells, we 
focused our experiments on this kinase. 
 
 
From Alessi DR et al. [187] 
FIGURE 4.0 
Posttranslational modification sites of the mouse LKB1 protein. Autophosphorylation sites are depicted in red, and the 
sites phosphorylated by other kinases are in black. The Cys433 farnesylation site is depicted in green. Residues Thr366, Ser404, 
Ser431, and Cys433 in the mouse sequence correspond to human LKB1 residues Thr363, Thr402, Ser428, and Cys430, 
respectively. The noncatalytic domains are in white, and the kinase domain is light blue.  
 
 
 
Results – Part IV  79 
    
Downregulation of PKCζ  activity by its pseudosubstrate decreases phenobarbital- and 
metyrapone-mediated induction of CYP2H1, CYP3A37 and ALAS1 
To assess if PKCζ may be a player in the signaling cascade leading to increased expression of CYPs by 
drugs, LMH cells were treated with 500µM PB or 500µM metyrapone in combination with increasing 
doses of PKCζ pseudosubstrate, a peptide whose effect is to decrease the kinase activity. The inhibitor 
alone did not affect the basal expression of CYP2H1, CYP3A37 and ALAS1, but it dose-dependently 
reduced their PB- and metyrapone-mediated increase in mRNA expression (FIGURE 4.1A). 
The decrease in CYP induction by PB and metyrapone caused by PKCζ pseudosubstrate was 
associated with less phosphorylated AMPK-Thr172 as shown by western blot suggesting an 
involvement of PKCζ in AMPK activation upon drugs (FIGURE 4.1B).  
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 4.1 
PKCζ activity is necessary for phenobarbital- and metyrapone-mediated induction of CYP2H1, CYP3A37 and 
ALAS1 gene expression. (A) LMH cells were treated with 500µM PB or metyrapone (Mety) for 16h in the presence of 
increasing concentration of PKCζ inhibitor (PKCζ Inh.). Gene expression of CYP2H1, CYP3A37 and ALAS1 was analyzed by RT-
PCR. (B) Phosphorylation of AMPK-Thr172 by treatment with PB or metyrapone (M) with or without PKCζ inhibitor is shown by 
western blot. 
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Overexpression of PKCζ  increases phenobarbital- and metyrapone-mediated induction of 
CYP2H1, CYP3A37 and ALAS1 
When LMH cells were transiently transfected with PKCζ, a strong increase in CYP2H1, CYP3A37 and 
ALAS1 induction by PB and metyrapone was observed (FIGURE 4.2). The basal expression level of the 
three genes was not altered. These data show that induction of CYP2H1, CYP3A37 and ALAS1 is 
enhanced by increasing the expression of PKCζ. 
 
 
 
FIGURE 4.2 
PKCζ overexpression increases phenobarbital- and metyrapone-mediated induction of CYP2H1, CYP3A37 and 
ALAS1. LMH cells transiently transfected with mock or PKCζ DNA were treated with 500µM PB, 500µM metyrapone (Mety) or 
1mM AICAR for 16h. Gene expression of CYP2H1, CYP3A37 and ALAS1 was analyzed by RT-PCR. *p<0.01, **p<0.05. 
 
 
Phosphorylation of PKCζ  occurs prior to LKB1 and AMPK phosphorylation 
To test if PKCζ is upstream of LKB1 and AMPK, LMH cells were treated with 500µM PB and activation 
of PKCζ, LKB1 and AMPK was assessed by detection of their increased phosphorylation state at 
different time points. In the PB time-course, phosphorylation and thus activation of PKCζ occurred at 
early time points, already after 15min of PB treatment, whereas LKB1 and AMPKα phosphorylation 
were increased later at 30min and 45min, respectively (FIGURE 4.3), indicating that PKCζ is upstream 
of LKB1/AMPK. 
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FIGURE 4.3 
PKCζ phosphorylation caused by phenobarbital occurs before LKB1 and AMPKα  phosphorylation. LMH cells were 
treated with 500µM PB for different times. Phosphorylation of PKCζ, LKB1-Ser428 and AMPK-Thr172 upon treatment with PB is 
shown by western blot. 
 
 
Phenobarbital treatment triggers PKCζ  translocation to the plasma membrane  
PKCζ is known to translocate to the plasma membrane upon activation by several stimuli [188]. To 
test if PB is able to trigger PKCζ translocation, western blot of cytoplasmic and membrane proteins 
were performed, which showed increased PKCζ-Thr410 membrane localization upon exposure of LMH 
cells to 500µM PB for 10min (FIGURE 4.4A). Immunofluorescence studies also detected increased 
amount of PKCζ localized at the plasma membrane (FIGURE 4.4B).  
 
 
 
 
 
 
 
 
 
 
FIGURE 4.4 
Phenobarbital causes PKCζ translocation to the plasma membrane. (A) Western blot of LMH cytosolic and membrane 
fractions after exposure to 500µM PB for different times. (B) Immunofluorescence staining of PKCζ in LMH cells treated with 
500µM PB for 10min. 
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Part V 
Human Experiments 
Phenobarbital dose-dependently activates AMPK in primary cultures of human 
hepatocytes 
In the attempt to test if the molecular mechanism of PB-mediated CYP induction via PKCζ-LKB1-AMPK 
derived from the studies in chicken hepatoma cells is conserved through evolution, primary culture of 
human hepatocytes were exposed to AICAR or metformin. Thereafter, AMPK activity was increased by 
PB treatment in a dose-dependent manner, as well as CYP2B6 and CYP3A4 expression [181]. Since 
these data demonstrate that the AMPK signaling pathway is triggered by PB in human hepatocytes, 
too, the involvement of mitochondrial functions in the mechanism of PB induction of CYPs was tested 
in human hepatocytes and hepatoma cells. 
 
Phenobarbital affects mitochondrial membrane potential and ROS formation in primary 
cultures of human hepatocytes and in human hepatoma cells 
The results in LMH cells clearly showed that mitochondrial membrane potential and ROS formation are 
affected by treatment with drugs. Since this is a fundamental finding for the proposed mechanism of 
drug-mediated CYP induction, the corresponding experiments were also carried out in human primary 
cultures of hepatocytes and in human G2F hepatoma cells (G2F cells were described in [180]). The 
effect of PB on the mitochondrial membrane potential was measured by applying the JC-1 dye. 
Exposure of human hepatocytes to 500µM PB and 0.4mM DNP, or of G2F cells to 2mM PB and 0.4mM 
DNP caused changes in the mitochondrial membrane potential (FIGURE 5.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 5.1 
Phenobarbital affects mitochondrial membrane potential in primary cultures of human hepatocytes and in G2F 
hepatoma cells. Cells were incubated with the JC-1 fluorescent dye. Fluorescence was detected after 1h treatment (A) with 
500µM PB or 0.4mM DNP in human hepatocytes and (B) with 2mM PB and 0.4mM DNP in G2F cells. The mitochondrial 
membrane potential is expressed as the 590nm/540nm fluorescence ratio in comparison to the control sample. p<0.01. 
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PB was then tested for its capacity to enhance intracellular ROS production by the DCFH-DA dye. PB 
at 500µM increased ROS production to a similar extent as the positive control rotenone in human 
hepatocytes (FIGURE 5.2), whereas ROS could not be measured in G2F cells. These experiments 
clearly show that mitochondrial functions are affected by PB in human hepatocytes and at least in part 
in G2F cells, too. 
 
 
 
 
 
 
 
 
 
 
  
 
 
FIGURE 5.2 
Phenobarbital affects ROS formation in primary cultures of human hepatocytes. Human hepatocytes were incubated 
with the DCFH-DA dye. Fluorescence was detected after 1h treatment with 500µM PB, 500µM AICAR (AIC) or 2µM rotenone 
(Rot). The mitochondrial membrane potential is expressed as the 590nm/540nm fluorescence ratio in comparison to the control 
sample. p<0.01.  
 
 
Activation of AMPK increases CYP2B6, CYP3A4 and ALAS1 gene expression in primary 
cultures of human hepatocytes and in human hepatoma cells 
In order to investigate if modulation of AMPK activity alone affects CYP gene expression in human 
cells, like in LMH cells, compounds known to activate AMPK were tested for their effects on CYP2B6, 
CYP3A4 and ALAS1 mRNA levels. The expression of all three genes was increased by DNP, NaN3 and 
rotenone in primary cultures of primary hepatocytes (FIGURE 5.3A), in addition to AICAR and 
metformin [181]. Furthermore, the same effect was observed in G2F cells (FIGURE 5.3B) 
 
 
Inhibition of AMPK decreases CYP2B6, CYP3A4 and ALAS1 gene expression in primary 
cultures of human hepatocytes  
Inhibition of AMPK activity by Compound C completely blocked PB-mediated induction of CYP2B6, 
CYP3A4 and ALAS1 in human hepatocytes (FIGURE 5.4). In addition, transfection of a dominant 
negative form of AMPKα decreased the PB induction of CYP2B6 and CYP3A4 [181]. These data 
showed that AMPK activity is necessary for PB-mediated induction of CYP2B6, CYP3A4 and ALAS1 in 
human hepatocytes. 
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FIGURE 5.3 
Activation of AMPK increases CYP2B6, CYP3A4 and ALAS1 gene expression in primary cultures of human 
hepatocytes and in human hepatoma cells. (A) Human hepatocytes were treated with 500µM PB, 1mM NaN3, 0.2mM DNP 
or 2µM rotenone (Rote) for 16h. CYP2B6, CYP3A4 and ALAS1 mRNA expression was analyzed by RT-PCR. p<0.01. (B) G2F cells 
were treated with 2mM PB, 2mM NaN3, 0.4mM DNP, 4µM rotenone (Rot) or 2mM AICAR (AIC) for 16h. CYP2B6, CYP3A4 and 
ALAS1 mRNA expression was analyzed by RT-PCR. p<0.01.  
 
 
 
FIGURE 5.4 
Inhibition of AMPK decreases phenobarbital-mediated induction of CYP2B6, CYP3A4 and ALAS1 gene expression 
in primary cultures of human hepatocytes. Human hepatocytes were incubated with 500µM PB with or without 
pretreatment for 30min by 20µM Compound C. After 16h treatment, mRNA level of CYP2B6, CYP3A4 and ALAS1 was measured 
by RT-PCR. *p<0.01. 
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Downregulation of PKCζ  activity by its pseudosubstrate decreased phenobarbital-
mediated induction of CYP2B6, CYP3A4 and ALAS1 in primary cultures of human 
hepatocytes 
Human hepatocytes were treated with 500µM PB or AICAR in combination with increasing doses of 
the PKCζ pseudosubstrate for 16h. The basal expression of CYP2B6, CYP3A4 and ALAS1 was not 
affected by the inhibitor, which could however dose-dependently reduce the PB-mediated induction 
but not the AICAR effect on mRNA expression of CYP2B6, CYP3A4 and ALAS1 (FIGURE 5.5A). This 
experiment demonstrates the involvement of PKCζ in the PB induction of CYPs in human hepatocytes 
and the xenobiotic-specificity of this effect, since AICAR-induced upregulation of CYP2B6, CYP3A4 and 
ALAS1 was not affected. 
 
 
FIGURE 5.5 
PKCζ activity modulation affects phenobarbital-mediated induction of CYP2B6, CYP3A4 and ALAS1 gene 
expression. (A) Human hepatocytes were treated with 500µM PB or AICAR for 16h in the presence of increasing 
concentration of PKCζ inhibitor (PKCζ Inh.). Gene expression of CYP2B6, CYP3A4 and ALAS1 was analyzed by RT-PCR. (B) 
PKCζ transiently transfected G2F cells were treated with 2mM PB or AICAR for 16h. Gene expression of CYP2B6, CYP3A4 and 
ALAS1 was analyzed by RT-PCR. *p<0.01. 
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PKCζ  overexpression increases phenobarbital-mediated induction of CYP2B6, CYP3A4 and 
ALAS1 in human hepatoma cells 
G2F cells were transfected with PKCζ and then treated with 2mM PB or 2mM AICAR for 16h. The 
basal expression of CYP2B6, CYP3A4 and ALAS1 was not affected by PKCζ overexpression, whereas 
the PB-mediated induction of CYP2B6, CYP3A4 and ALAS1 was increased. As expected, the AICAR 
effect on these genes was not affected (FIGURE 5.5B). This experiment shows that PB induction of 
CYPs and ALAS1 in G2F cells is potentiated by increasing the availability PKCζ. 
 
Phenobarbital and metformin effects on CYP2B6, CYP3A4 and ALAS1 expression are not 
additive in primary cultures of human hepatocytes 
Our data demonstrate that PB shares a part of the mechanism of AMPK activation with metformin and 
since the effect of metformin and PB were not additive in LMH cells, human hepatocytes were treated 
with 500µM PB, 500µM metformin or the combination of the two. Cotreatment did not cause an 
increase in the PB induction of CYP2B6, CYP3A4 and ALAS1, whereas addition of NaN3 strongly 
increased their expression upon PB treatment (FIGURE 5.6). These results suggest that PB and 
metformin share the signaling pathway leading to AMPK activation and CYP induction, whereas NaN3 
shows a strong additive effect in combination with PB in primary cultures of human hepatocytes, like 
in LMH cells. 
 
 
 
 
FIGURE 5.6 
Phenobarbital and metformin effect on CYP expression are not additive. Human hepatocytes were treated with 500µM 
metformin (Metf), 1mM NaN3 with or without 500µM PB for 16h. Gene expression of CYP2B6, CYP3A4 and ALAS1 was measured 
by RT-PCR. *p<0.01. 
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Part VI 
Mouse Experiments 
AICAR increases Cyp2b10, Cyp3a11, ALAS1 and CAR mRNA level in primary cultures of 
mouse hepatocytes 
The data presented in this thesis were achieved in LMH cells and confirmed in primary cultures of 
human hepatocytes. To further emphasize that the proposed molecular mechanism of PB induction is 
conserved among species, some experiments were also carried out in mouse hepatocytes or mouse 
liver. Exposure of primary cultures of mouse hepatocytes to AICAR increased the gene expression of 
Cyp2b10, Cyp3a11 and ALAS1 (FIGURE 6.1A and [181] in APPENDIX 3). In addition, CAR expression 
was also strongly enhanced, in contrast to the expression of two other nuclear receptors, PXR and 
HNF4α, which was not affected by AICAR (FIGURE 6.1B).  
 
 
 
 
FIGURE 6.1 
AICAR increases Cyp2b10, Cyp3a11, ALAS1 and CAR expression in primary cultures of mouse hepatocytes. Mouse 
hepatocytes were treated with 500µM AICAR or PB for 16h. Gene expression of (A) Cyp2b10, Cyp3a11 and ALAS1 and (B) 
CAR, PXR and HNF4α was measured by RT-PCR. p<0.01. 
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Phenobarbital induction of Cyp2b10 is abolished in AMPK knockout mice 
To prove that AMPK is indeed necessary for the in vivo PB induction of CYPs, AMPK knockout mice 
were treated with 100mg/kg for 16h and Cyp2b10 mRNA expression was measured. PB induction of 
Cyp2b10 was completely abolished in AMPK knockout mice (FIGURE 6.2), but the basal level of this 
gene was dramatically increased (FIGURE 6.2, insert graph). To reduce the effect of potential 
circulating factors on CYP basal expression in AMPK knockout, liver-specific AMPKα1 or AMPKα2 
knockout mice were used for further experiments, which are described in [181] (APPENDIX 3) and will 
be reviewed in the Discussion. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 6.2 
Phenobarbital induction of Cyp2b10 is abolished in AMPKα  knockout mice. Mice were treated with 100mg/kg PB for 
16h. Gene expression of Cyp2b10 was measured by RT-PCR. The results are expressed as fold induction (big graph) or as 
relative expression (small graph). p<0.01. 
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Part VII 
Chicken X Receptor Immunoprecipitation and Phosphorylation 
Several proteins interact with CXR: studies by immunoprecipitation and mass 
spectrometry 
It was shown that CAR forms a complex with heat-shock protein 90 (Hsp90), protein phosphatase 2A 
(PP2A) and a cytosolic CAR retention protein (CCRP) in the cytoplasm of uninduced cells [73, 74]. 
Though size of this complex could be approximately 500kDa, many proteins in this complex remain 
unknown. Since the signaling pathway triggered by PB is conserved from birds to mammals, in order 
to identify new potential CAR interacting proteins, we tried to isolate the chicken X receptor (CXR) 
complex from LMH cells and to characterize it by mass spectrometry. To this purpose, HA-CXR was 
transfected for 24h into LMH cells, which were subsequently treated with 500µM PB for 3h. CXR was 
immunoprecipitated by anti-HA antibodies. Under these conditions several proteins were 
coimmunoprecipitated together with CXR (FIGURE 7.1), among which Hsp90 (band 4) and PP2A (band 
6), were clearly identified in complex with CXR (band 8), too (TABLE 7.1). In addition, Hsp70 (band 5) 
and Hsp40 (band 8) were shown to coimmunoprecipitate with CXR, which was never shown for CAR. 
These heat shock proteins were previously identified in the estrogen receptor and glucocorticoid 
receptor complexes as essential chaperone. Interestingly, several proteins involved in miRNA-
mediated gene expression regulation were identified, such as trinucleotide repeat-containing 6B 
protein (TNRC6B, band 1), translation initiation factor 2C1 and 2C2 (band 3), which are necessary for 
rapid decay of mRNAs by miRNA. Furthermore, tubulin (band 6), several DEAD box proteins (band 4 
and 5), pyruvate carboxylase (band 2), aldehyde dehydrogenase (band 7) and alpha enolase (band 8) 
were shown to precipitate with CXR. No difference between control and PB treatment could be 
established because of the difference in total protein level between control and PB. 
 
 
 
 
 
 
 
 
 
FIGURE 7.1 
CXR immunoprecipitation from LMH cells. LMH cells transiently transfected with HA-CXR were treated with 500µM PB for 
3h. Immunoprecipitated proteins were loaded on a 10% SDS gel, which was stained by cosmassie. Bands 1-8 were cut and 
analyzed by mass spectrometry. 
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TABLE 7.1 Mass spectrometry identification of SDS gel bands 
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Phenobarbital treatment affects the phosphorylation of several proteins 
immunoprecipitating with CXR 
Preliminary studies performed in our group suggested that AMPK does not phosphorylate CAR 
peptides in vitro (Matis M, unpublished observation). Nevertheless, dephosphorylation of CAR upon PB 
treatment was shown to be necessary for CYP induction. To test if CXR/CAR are phosphorylated or 
dephosphorylated upon PB treatment, immunoprecipitated CXR was checked for phosphorylation by 
anti-phosphoThr/Ser/Tyr antibodies. LMH cells transiently transfected with HA-CXR were exposed to 
PB for 1h, 2h, 3h, 6h and 10h. After immunoprecipitation, CXR was immunoblotted and 
phosphorylation was visualized. In the control western blot immunoprecipitated lysates were assayed 
by anti-HA antibodies to ascertain that the same amount of CXR was transferred to the nitrocellulose 
membrane (FIGURE 7.2). Both threonine and serine phosphorylation of CXR were detected, without 
observing a significant change upon PB treatment (FIGURES 7.3 and 7.4). In contrast, only a weak 
tyrosine phosphorylation was observed (FIGURE 7.5). Other proteins coimmunoprecipitated with CXR 
were also found to be phosphorylated at threonine and serine residues (FIGURES 7.3 and 7.4, entire 
blot), whereas no significant band was detected with the anti-pTyr antibody (FIGURE 7.5, entire blot). 
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FIGURE 7.2 
CXR immunoprecipitation from LMH cells. LMH cells transiently transfected with HA-CXR were treated with 500µM PB for 
different times. Immunoprecipitated proteins were loaded on a 10% SDS gel and blotted into nitrocellulose membrane. The blot 
was incubated with anti-HA antibodies. 
 
 
Western blot: pThr 
1. In the first magnification no significant change in the band intensity was detected.  
2. Interestingly, in the second magnification an increase in threonine phosphorylation of an 
approximately 100kDa protein is detected after PB treatment for 6h.  
3. CXR phosphorylation at threonine residue is detected.  
4. Threonine phosphorylation of an approximately 35kDa protein was also increased after 6h of 
PB (third band), whereas the other bands showed a slightly time-dependent increase 
beginning at 2h until 6h PB, which disappeared after 10h PB. 
 
FIGURE 7.3 
CXR immunoprecipitation from LMH cells. LMH cells transiently transfected with HA-CXR were treated with 500µM PB for 
different times. Immunoprecipitated proteins were loaded on a 10% SDS gel and blotted into nitrocellulose membrane. The blot 
was incubated with anti-pThr antibodies. 
 
Western blot: pSer 
1. Serine phosphorylation of an approximately 200kDa protein was slightly enhanced at 6h and 
10h PB. 
2. Serine phosphorylation of an approximately 100kDa protein was slightly increased beginning 
at 2h PB. 
3. CXR serine phosphorylation 
4. The first two and the fourth bands did not change significantly, whereas the serine 
phosphorylation of the third band was increased after 2h until 10h PB. Note: these four bands 
may correspond to the bands in the fourth magnification of the pThr western blot. 
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FIGURE 7.4 
CXR immunoprecipitation from LMH cells. LMH cells transiently transfected with HA-CXR were treated with 500µM PB for 
different times. Immunoprecipitated proteins were loaded on a 10% SDS gel and blotted into nitrocellulose membrane. The blot 
was incubated with anti-pSer antibodies. 
 
 
 
 
 
FIGURE 7.5 
CXR immunoprecipitation from LMH cells. LMH cells transiently transfected with HA-CXR were treated with 500µM PB for 
different times. Immunoprecipitated proteins were loaded on a 10% SDS gel and blotted into nitrocellulose membrane. The blot 
was incubated with anti-pTyr antibodies. 
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CXR is the Ancestral Gene of CAR and PXR 
CXR represents the ancestral gene that diverged into CAR and PXR in the course of evolution as an 
adaptive response to different environmental and nutritional pressures (Results – Part I). Consistent 
with this view, CXR is one of the most promiscuous receptors with regard to the spectrum of drugs 
and endobiotics that activate or inhibit it compared with the mammalian xenosensors [189-190]. In 
contrast to the two xenobiotic-sensing receptors in mammals, only one xenosensor has been found in 
non-mammalian species, e.g. chicken, fish (fugu and zebrafish) or nematodes (FIGURE 1). The 
majority of these non-mammalian receptors resemble PXR more closely than CAR, suggesting that 
CAR may be a mammalian receptor that diverged from PXR later in the evolution.  
A recent phylogenetic study by Krasowski et al. aimed to find evidence of a positive selection 
(molecular adaptation) in the CAR and PXR genes among vertebrates [191]. Nuclear receptor (NR) 
genes generally show strong sequence conservation and little positive selection, especially in the DNA 
binding domain (DBD), characterized by ω<1 (usually less than 0.01), the ratio between non-
synonymous (changes in amino acid sequence encoded by the codon) versus synonymous nucleotide 
variation (no change in amino acid sequence). ω<1 reflects a negative or purifying selection to 
maintain a conserved amino acid sequence (applying for most gene comparisons). ω=1 means neutral 
selection (usually for pseudogenes), whereas ω>1 suggests positive selection. Among the NR 
superfamily, CAR and PXR are an exception and show relatively high ω values, probably due to the 
adaptation to cross-species differences in toxic compound exposure of the ligand binding domain 
(LBD) for functional advantage. For these two genes the positive selection may be directed at fine-
tuning the ligand specificity towards the most important toxic compounds for a given species. One 
example of positive selection is the PXR activation by bile acids, which has expanded from narrow 
specificity for C27 bile alcohol sulfates (early fish) to a broader specificity for recent bile acids (birds, 
mammals). PXR specificity for bile acids has thus paralleled the increasing complexity of the bile acids 
synthetic pathway during vertebrate evolution, an unusual example of ligand-receptor coevolution in 
the nuclear hormone receptor superfamily [192]. 
The ω ratio for CAR DBD is also on the higher end for the NR superfamily. According to the authors, 
this may reflect the recent divergence of the CAR gene following duplication of a pre-mammalian PXR 
gene, which supports our findings that CXR is the ancestral gene of PXR and CAR (Results – Part I). 
In fact, functional diversification with higher rates of non-synonymous to synonymous substitutions is 
common in a recently duplicated gene [193, 194].  Once two copies of a gene exist, one of the two 
genes can diversify its function to evolutionary advantage although the two genes still may share 
overlapping functions (like in the case of CAR and PXR). The high ω ratio of the CAR DBD suggests 
that it is diversifying to recognize other binding elements, in accordance with the recently new 
proposed roles of CAR, such as in glucose and energy homeostasis, which are not exerted by PXR. 
Our previous findings and the results presented in this thesis show that LMH cells are an excellent 
system to study the molecular mechanism of PB induction. 
 
Discussion  98 
    
 
 
  
Handschin and Meyer, Pharmacological Reviews (2003) [62] 
 
FIGURE 1 
Phylogeny of the nuclear receptor subfamilies NRI2 and NRI3. Full-length amino acid sequences of the NR1I2 (CAR) 
and NR1I3 (PXR) subfamily members were compared, and an unrooted phylogenetic tree was derived. The scale bar represents 
0.1 substitutions per site.  
 
 
The Molecular Mechanism of Drug Induction 
In the present thesis, we demonstrated that PB transcriptionally induces CYP enzymes by a cascade of 
events that involves an initial impact on mitochondrial functions and triggers drug-induced 
phosphorylation of PKCζ-Thr410 and LKB1-Ser428. LKB1 subsequently interacts with AMPKα and 
phosphorylates AMPK-Thr172 increasing its activity and thus CYP gene expression (FIGURE 2). The 
results are based on experiments carried out in chicken and human hepatoma cells (LMH and G2F), in 
human and mouse primary cultures of hepatocytes and in mouse liver (this thesis and [181] in 
APPENDIX 3). 
The assumption of mitochondria involvement in the PB induction is based on the following results: (a) 
mitochondrial functions were affected by PB treatment leading to changes in the membrane potential, 
ROS generation and ATP level (in human hepatocytes); (b) genetic and pharmacological ROS 
scavenging reduced AMPK activation and CYP induction by PB; (c) PB induction was strongly inhibited 
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in cells with decreased number of functional mitochondria. These data strongly suggest a role of ROS 
and mitochondria in drug induction, however further studies are required to unravel the direct 
downstream targets of ROS and if mitochondria are the primary target of drugs. 
PKCζ activity also seems to affect PB induction based on the following observations: (a) PKCζ was 
phosphorylated and translocated to the plasma membrane upon PB treatment; (b) pharmacological 
inhibition of PKCζ decreased PB activation of AMPK and CYP induction; (c) overexpression of PKCζ 
enhanced CYP induction by PB treatment. Though all these results point to a role of PKCζ activity in 
PB induction, genetic ablation is necessary to clearly show whether or not it is essential. 
The role of LKB1 in the mechanism of drug induction was difficult to establish due to the constitutive 
activity of this kinase. Nevertheless, immunoprecipitation studies demonstrated that LKB1 is 
phosphorylated and interactes with AMPKα in a PB-induced manner. 
Additionally, we prove that AMPKα activity is necessary in the induction of CYP genes by PB in LMH 
cells, in mouse liver and primary cultures of hepatocytes, and in primary cultures of human 
hepatocytes (this thesis and [181] in APPENDIX 3). This interpretation is derived from the following 
results: (a) AMPK activity is dose-dependently increased upon PB treatment; (b) AMPK overexpression 
enhances induction of CYPs by PB; (c) downregulation of AMPK expression by siRNA or by transfection 
of an AMPKα dominant negative form drastically reduced induction in LMH cells and human 
hepatocytes; (d) pharmacological inhibition of AMPK activity blocks PB induction; (e) PB induction is 
abolished in AMPKα knockout mice. All these data establish that AMPK is essential for the PB induction 
of CYPs and reveal evolutionary conservation of this mechanism from birds to mice and humans. 
From mechanistic studies, some suggestions about the molecular mechanism by which AMPK affects 
transcriptional regulation of CYPs could be derived. Our data suggest that AMPK positively regulates 
PB induction of CYP2H1, CYP3A37, CYP2B6 and Cyp2b10 expression in chicken, human and mouse, 
respectively, through an effect on the PB-responsive enhancer element (PBREM) in the promoter 
showing that these short elements are sufficient to mediate AMPK effect on CYP expression. This 
interpretation is derived from the results of reporter gene and transactivation assays. Furthermore, 
the mitochondrial complex I may be the PB target on these organelles, since the effects of metformin, 
which was shown to affect complex I activity, and PB on CYP gene expression are not additive, 
whereas NaN3, which inhibits complex IV, and PB show additive effects. Further studies need to be 
done to confirm this assumption.  
Immunoprecipitation of the CXR complex from LMH cells with subsequently identification of the 
interacting proteins led to the identification of two proteins Hsp90 and PP2A known to bind to CAR, for 
instance, and of several other proteins, which are potentially CAR interacting partners, too. Among 
them, many are involved in mRNA posttranscriptional regulation, which may be an additional way for 
nuclear receptors to affect gene expression. Additional experiments aimed to detect CXR 
phosphorylation changes upon PB, showed that many proteins immunoprecipitating with CXR are 
phosphorylated in a PB-induced manner. The identification of these proteins will be the focus of future 
experiments. 
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FIGURE 2 
The molecular mechanism of drug induction. Model for PB-type induction of CYP genes. 
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AMPK Targets in the Mechanism of Drug Induction 
The data presented in this thesis demonstrate that AMPK is necessary for the PB-mediated induction 
of CYPs, but the targets of AMPK in this mechanism are unknown (see also manuscript discussion in 
Results – Part II). Recent studies demonstrated okadaic acid-sensitive PP2A recruitment to the CAR 
complex upon PB treatment in mice [74] and involvement of  dephosphorylation of CAR at Ser202 in 
its nuclear translocation. However, these observations are not sufficient to explain the translocation, 
which needs probably other factors, like CCRP or the xenobiotic responsive signal (XRS) [195]. 
Preliminary experiments in our group showed that CAR peptides containing putative AMPK target 
sequences incubated with AMPK in vitro were not phosphorylated, however the experimental 
conditions are far from the in vivo situation. Though we cannot yet exclude definitely that CAR is not 
phosphorylated by AMPK, other potential AMPK targets have to be considered, starting from proteins 
known to be phosphorylated by AMPK. One potential candidate is p300, a transcriptional coactivator 
with acetyltransferase activity, which acts not only as an adaptor between basal transcription 
machinery and transcription factors, but also plays a role in acetylation of histones to increase DNA 
accessibility or other proteins for their activation, nuclear retention or modulation of half-life [196]. 
AMPK was shown to phosphorylate p300 [197] inhibiting thus its interaction with several nuclear 
receptors, such as PPARγ, RAR, RXR and TR, but not with proteins, like p53 or GATA4. However, in 
this study it was not demonstrated that abrogation of this interaction has an effect on the 
transcriptional activation by these nuclear receptors, thus leaving unknown whether or not 
phosphorylation of p300 by AMPK may affect transcriptional regulation. But, even if this assumption 
would be true, it is impossible to predict if this effect would also hit CAR-p300 interaction, because 
apparently this effect seems to be selective. Nevertheless, it is worth noticing that p300 activation is 
responsible for histone hyperacetylation, which generally increases transcription. In this regard, 
CBP/p300 activity is related to the extent of PB-induced CYP2H1 gene expression in chick embryo 
primary hepatocytes [198]. 
Recent experiments performed in cell culture demonstrated that AMPK triggers the nuclear import of a 
member of the Hu family, which plays a very important role in mRNA stability, via increased p300-
mediated acetylation and phosphorylation of importinα [199]. The importinα-importinβ pathway 
transports cargo proteins containing nuclear localization signals (NLS) through the nuclear pore 
complex. The authors proposed that under stress conditions activation of AMPK occurs leading to 
phosphorylation/acetylation of importinα and thus to an increase in the efficiency of the nuclear 
transport of cargo proteins. Until now this has been demonstrated only for one member of the Hu 
family, but because the nuclear translocation of CAR is necessary in the mechanism of drug induction, 
in which AMPK is clearly involved, the possibility that CAR may be a cargo protein for importinα is very 
fascinating. Consistent with this hypothesis, two nuclear localization signals were identified in the 
mouse CAR [200]. Activation of importinα-mediated nuclear import by AMPK/p300 upon xenobiotics or 
other stresses would be a means for AMPK to alter gene expression patterns. 
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Another candidate protein is the PPARγ coactivators 1α (PGC1α), which plays a role in mitochondria 
biogenesis and oxidative metabolism, keeping thus an energy homeostasis, for example by promoting 
responses to fasting. PGC1α mRNA expression was shown to increase upon AMPK activation in mice 
skeletal muscle and to be necessary for the AMPK-stimulated fatty acid oxidation [201]. In addition, 
AMPK-mediated enhancement of PGC1α mRNA and protein is important in mitochondria biogenesis 
[202-205]. Hence, drug treatment may increase the coactivator PGC1α protein expression via AMPK 
activation leading to potentially higher transcriptional power. However, there is no evidence that 
PGC1α is important for CAR target gene expression besides the observation that PGC1α coactivates a 
chimerical GAL4-CAR fusion protein on the artificial luciferase reporter gene UAS-LUC under basal 
conditions in a ligand-independent manner [206]. Nevertheless, a role for PGC1α as transcriptional 
regulator of CAR in fasting was shown. The group of Jeff Staudinger in collaboration with Frank 
Gonzalez identified an interaction between PGC1α and hepatic nuclear factor 4α (HNF4α) that directly 
regulates CAR gene expression. Expression of PGC1α in cells increases CAR expression and ligand-
independent activity, whereas fasting-induced CAR and CAR target gene expression is abolished and 
basal expression of CAR was severely diminished in HNF4α knockout mice [207].  
In the light of these results, it is plausible that PB-mediated activation of AMPK enhances PGC1α 
expression, increasing thus CAR gene expression and consequently the expression of CYPs. However, 
in experiments done in collaboration with the Bruce Spiegelman group we could show that PGC1α 
knockout mice retain Cyp2b10, Cyp3a11 and ALAS1 PB-mediated induction [208] suggesting against 
an essential role for this coactivator in the drug induction mechanism. If the role of PGC1α in the 
coactivation of HNF4α on the CAR promoter can be replaced by another cofactor is not known yet, but 
it is clear that cofactors are very redundant in their function. 
Despite a double role for CAR in metabolic and in xenobiotic stress, it is still not clear if this two 
responses are mediated by the same factors. It is possible that CAR xenobiotic response is different 
from its metabolic response and is initiated through interaction with other cofactors. Nevertheless, 
CAR is activated in response to metabolic or nutritional stress in a ligand-independent manner acting 
as an energy sensor, which is exactly the role of AMPK. 
While PGC1α is apparently not necessary for drug-mediated CYP induction, HNF4α was demonstrated 
to be important.  In HNF4α knockout mice CAR expression is drastically reduced and Cyp2b10 
induction by CAR activators is abolished [209, 210]. Additionally, HNF4α response elements present in 
several CYP genes are essential for maximal CAR-mediated drug induction [211-213]. So, HNF4α 
would be a perfect AMPK target since both are essential for induction. However, Leclerc et al. showed 
in 2001 that treatment of rat hepatocytes by AICAR decreases HNF4α protein expression (but not its 
mRNA level) and some HNF4α target genes, which is not compatible with the possibility of AMPK 
regulating drug induction by increasing the HNF4α expression or activity. Despite of this, it is worth 
noticing that AICAR is not a specific AMPK activator and also that those experiments showed 
transiently HNF4α protein decrease without long-term transcriptional regulation upon AICAR. 
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Many other potential targets for drug-activated AMPK could be considered, from proteins binding to 
CAR in the cytosol, such as the chaperone Hsp90 or the cochaperone CCRP, to unidentified proteins in 
the complex, which is thought to be in the 500kDa range implying the existence of other proteins in 
this complex (see Discussion on the CXR complex).  
 
AMPK-LKB1 Signaling  
Our data are consistent with a model, in which PB-type drugs affect mitochondrial functions leading to 
LKB1-AMPK activation necessary for the transcriptional regulation of CYPs by drugs. These findings 
prompt to consider why PB-type drugs activate AMPK and if this activation favors drug induction and 
can explain the pleiotropic effects of PB in the liver. 
 
AMPK-LKB1-mediated inhibition of mTOR-regulated protein synthesis  
Protein synthesis accounts for approximately 20% of energy turnover in growing cells and is 
particularly sensitive to decreases in ATP level, wherefore AMPK could link translation and energy 
metabolism. Recently, it was demonstrated that AMPK inhibits the mammalian target of rapamycin 
(mTOR) pathway by phosphorylating the tuberous sclerosis complex 2 (TSC2 or tuberin), which 
regulates mTOR activity [214]. Furthermore, LKB1 was shown to be necessary for AMPK-mediated 
inhibition of mTOR [215], which can also be directly phosphorylated by AMPK [216]. All these data 
indicate that in case of low energy AMPK inhibits protein synthesis by decreasing mTOR activity 
(FIGURE 3).  
The distinction between short- and long-term PB effects could explain the apparent incongruence that 
PB activation of AMPK may inhibit translation, knowing that PB treatment in rodents causes liver size 
increase, wherefore protein synthesis is needed. In fact, our studies indicate that PB activates AMPK 
within 1h, but even if AMPK activation can still be detected after 3h (data not shown), long-term 
effects of PB on AMPK were not studied. Thus, a short-term AMPK activation by PB would not 
preclude a long-term liver size increase.  
Another consideration is that in response to many types of stimuli or stress, global changes in protein 
synthesis are relatively modest (up to twofold), but the translation rates of a small population of 
mRNAs is dramatically modulated. In fact, the general translation apparatus can discriminate between 
different mRNA, giving raise to the so-called "translational discrimination". mRNA species can be 
divided into two categories, the 5’ TOP mRNA and the 5’ cap mRNA. On one hand the 5’ TOP 
(terminal oligopyrimidine tracts) mRNAs code for ribosomal proteins, translation factors involved in 
mRNA translation, such as elongation factors eEF1A and eEF2, and poly A binding proteins amongst 
others. The abundance of 5’ TOP mRNAs varies, but can account for up to 15–20% of total cell mRNA. 
On the other hand, the nuclear encoded mRNAs are capped with a 7-methyl guanosine residue at the 
5’ end, which necessarily binds to initiation factors in order to start translation (cap-dependent 
translation). Within 5’ cap mRNAs huge differences exist in the cap-proximal 5' UTR secondary 
structure. Because 40S ribosomal subunit binding appears to require a region of single-stranded 
Discussion  104 
    
mRNA, mRNAs with structured and complicated secondary structures in the cap-proximal 5' UTR need 
high helicase activity to unwind RNA. Therefore, their translational efficiency is reduced by rendering 
the mRNA less accessible to a ribosome, and by impeding the scanning process. In fact, while eIF4F 
helicase activity is low, translation of mRNAs with low 5' UTR secondary structure is affected to a 
lesser degree than mRNAs possessing extensive 5' UTR secondary structure, and eIF4E 
overexpression preferentially enhances the translation of mRNAs with structured 5' UTRs [217, 218]. 
 
FIGURE 3 
AMPK inhibition of protein synthesis. mTOR pathways controlling protein synthesis are shown.  
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Recent data demonstrate that the synthesis of all proteins is not repressed equally. Fibronectin, for 
example, was shown to stimulate cap-dependent translation but not 5’ TOP mRNA translation [219]. 
In conditions of nutrient deprivation, lack of growth factors or after initiation of a differentiation 
program, the translation of 5' TOP mRNAs is potently repressed, whereas other proteins are not 
affected, suggesting that the 5' TOP tract confers very stringent translation regulation of 5’ TOP 
mRNAs [220, 221]. This is because the production of ribosomes is an energetically very costly process 
that requires the action of all three RNA polymerases and involves more than hundred gene products 
[222].  
In the view of this "translational discrimination" occurring in cells, it may be possible that short-term 
PB inhibits (via AMPK-mTOR pathway) translation of 5’ TOP mRNAs in order to enhance the 
translation efficiency of 5’ cap mRNAs coding for proteins involved in drug metabolism. Only later, the 
5’ TOP mRNAs are translated to increase ribosome content and protein synthesis capacity, explaining 
the long-term PB effect on the liver size. Consistent with this, exposure of LMH and G2F cells to PB in 
combination with rapamycin, which is a mTOR inhibitor and consequently also an inhibitor of protein 
synthesis, strongly increases the PB effect on CYP gene expression (FIGURE 4). Interestingly, 
rapamycin was shown to possess a particular inhibitory effect on 5’ TOP mRNA translation, whereas 
its effect on non-5’ TOP mRNA was weaker [223]. By addition of the protein synthesis inhibitor 
cycloheximide (data not shown) PB induction of CYP2H1, CYP3A37 and ALAS1 expression in LMH cells 
is potentiated in chick embryo hepatocytes and liver [224, 225]. Discriminatory inhibition of translation 
by AMPK activation may then be compatible with the need of protein synthesis for drug-metabolism 
and immediate-early gene induction does not require protein synthesis since it is activated by 
transcription factors that preexist in a latent form. 
 
AMPK-LKB1-mediated inhibition of mTOR-regulated cell growth and proliferation  
Several results show that mTOR plays a role in protein synthesis and cell growth and responds to 
several different types of stresses to ensure that growth occurs only when overall conditions are 
favorable. Stress conditions other than nutrient limitation may be heat shock, H2O2, osmotic stress, 
oxidative stress, pH changes and DNA damage.  
The LKB1-AMPK-TSC2 pathway negatively regulates mTOR during cellular stress leading to protection 
against apoptosis and decreased protein synthesis and cell growth. These recent findings open 
intriguing opportunities for the AMPK signaling to act as an energy checkpoint that determines if 
cellular energy status is sufficient before the cell starts growth triggered by the mTOR pathway. 
Studies by Jones et al. [226] demonstrated that AMPK couples glucose availability to the cell-cycle 
machinery by promoting cell cycle arrest in the G1 phase under low glucose. AMPK activation in 
HepG2 cells causes a cell cycle arrest in the G1 phase through stabilization of p53 [227] and 
treatment of cells with AICAR protects cells from cell death in response to different stimuli. 
Furthermore, reduction of AMPK levels was recently shown to decrease cellular viability after glucose 
deprivation in a number of human tumor cell lines [214], whereas LKB1-deficient cells are 
hypersensitive to apoptosis induced by energy stress [177, 228, 229]. In a proposed mechanism, 
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stress induces the LKB1-AMPK system, which leads to direct or indirect p53 phosphorylation and to 
overexpression of p21CIP and p27KIP, two cyclin-dependent kinase inhibitors (CDKIs), followed by cell 
cycle arrest and inhibition of apoptosis. This pathway allows the cells to gain time to attempt 
restoration of cellular homeostasis caused by metabolic stress.  
 
 
FIGURE 4 
The mTOR inhibitor rapamycin potentiates the phenobarbital induction of CYP genes in chicken and human 
hepatoma cells. LMH and G2F cells were treated for 16h with 500µM and 2mM PB, respectively, with or without 100nM 
rapamycin. Gene expression of CYP2H1, CYP3A37, CYP2B6, CYP3A4 or ALAS1 was measured by RT-PCR. *p<0.01, **p<0.05. 
 
 
Taken that AMPK exerts anti-proliferative and anti-apoptotic effects, the question raises if this is 
compatible with the pleiotropic responses triggered by PB. Effects caused by PB and TCPOBOP (two 
non-genotoxic carcinogens) include decreased apoptosis, increased DNA replication and tumor 
promotion, which are all CAR-mediated effects, too. The anti-apoptotic effect of these drugs correlates 
nicely with the cell survival promotion by AMPK activation, giving a speculative explanation for this 
effect.  
In regard to the effect of PB on DNA replication, no reports exist that link AMPK activation to DNA 
replication, but in low energy conditions AMPK may repress this energy-demanding task. The majority 
of hepatocytes are tetraploid (4N) under normal conditions with small numbers of diploid (2N) and 
octoploid (8N) cells. PB and TCPOBOP were shown to increase the 8N/4N ratio (thus DNA replication) 
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in wildtype mice but not in CAR knockout mice [79]. Furthermore, in recent studies exposure of mice 
to PB effectively promoted liver growth, which was however mainly due to cell enlargement 
(hypertrophy) accompanied by hepatocytes polyploidization, and not to cell proliferation (hyperplasia) 
[230]. In contrast, PB-mediated liver growth in long-term experiments was due to cell proliferation 
and led to tumor promotion. This fast response to PB stress leading to hypertrophy is not incongruent 
with its AMPK activation. Indeed, when AMPK was activated by putting cells in low-glucose medium 
for 24h, surprisingly the cells exhibited a larger size, although AMPK-dependent cell-cycle arrest was 
detected [226]. Cell cycle arrest was also caused by low quantity of the AMPK activation AICAR, while 
rapamycin-sensitive cell growth was maintained, whereas high AICAR concentration was associated 
with both cell cycle and cell growth arrest. The data presented in this study demonstrate that low 
glucose can induce an AMPK-dependent cell cycle arrest under conditions where mTOR remains active 
and stimulates cell growth, indicating that cell cycle and cell growth can be differentially regulated by 
nutrients availability. The tempting speculative proposal that this could also happen upon PB 
treatment may explain some PB effects. In conclusion, short-term PB stress leads to transient 
increased liver size due to cell enlargement (and not to cell division), which should promote drug 
clearance, particularly because an increase in hepatocyte ploidy has been associated with higher 
metabolic activity [231]. Importantly, these effects of PB are not incompatible with its AMPK 
activation, on the contrary they can be explained by increased AMPK activity. 
In contrast with this conclusion, it is apparently paradoxal that PB, which activates AMPK, promotes 
tumorigenesis (as mentioned in the Introduction) since AMPK is correlated with tumor suppressor 
genes, such as LKB1 and TSC2 that tightly control mTOR signaling to protein synthesis and cell 
growth. 
Recent results show that PB or TCPOBOB treatment enhances murine double minute-2 (Mdm2) 
expression by CAR binding to a DR4 element, implicating that Mdm2 is a primary target gene [79]. 
Mdm2 is an E3 ubiquitin ligase, which keeps p53 level low by targeting it for proteasome degradation, 
thus inhibiting the p53-induced apoptosis under normal conditions. Upon stress, p53 is 
phosphorylated and released from Mdm2, leading to apoptosis. If xenobiotics induce overexpression 
of Mdm2, p53 level is constantly kept low hampering its response in case of necessary apoptosis. 
Therefore, putative transiently activation of AMPK by PB with following p53-mediated antiapoptotic 
effect helps cells going through a threat (drug exposure) and allows them to recover, whereas drug-
mediated transcriptional upregulation of Mdm2 by CAR creates a tumorigenic environment by 
inhibition of p53-dependent cell cycle surveillance and apoptosis in the long-term. As discussed in the 
Introduction, tumor promoter effects of PB in humans were never found, but interestingly, CAR 
knockout mice expressing hCAR exposed to PB showed all the acute responses observed with mCAR, 
for instance, liver size and hepatocytes octoploidy increase, Mdm2 upregulation and antiapoptotic 
effects. In addition, preliminary results from the David Moore’s group indicate that chronic xenobiotic 
stress promotes tumorigenesis in the hCAR mice suggesting that the human receptor is able to create 
a tumorigenic environment in a mouse background. Furthermore, not all mice strains are susceptible 
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to non-genotoxic carcinogens at the same extent, pointing again to the importance of the 
background. For all these reasons, the role of hCAR in tumorigenesis must not be underestimated.  
In addition, the phenomenon of hormesis should also be considered. Hormesis is a biphasic dose-
response relationship, in which a chemical exerts opposite dose-dependent effects [232]. Even if PB is 
a well-known non-genotoxic carcinogen and tumor promoter in rodents, in many studies, beneficial 
effects were shown from low-level exposure of rats to PB, whereas high doses turned out to promote 
tumor, a phenomenon being known as hormesis (FIGURE 5) [233, 234]. This hormetic effect of PB in 
the liver indicates the existence of a threshold for its carcinogenicity and possibly also for other 
effects. Interestingly, a dose of 10µM PB was recently shown to inhibit cell growth in human breast 
cancer cells [235], which fits perfectly in a hormetic effect of PB. 
In summary, chronic PB treatment leads to liver size increase both by hyperplasia and hypertrophy, 
inhibition of apoptosis, DNA replication and tumorigenesis. Even if some of these effects are 
apparently incompatible with the AMPK-mediated inhibition of protein synthesis, speculative but 
strongly supported explanations were presented in the last pages. 
 
 
 
 
 
 
 
 
 
FIGURE 5 
Hormesis and dose-response-mediated mechanisms in carcinogenesis. (A) Induction of GST-P positive foci in the liver 
of rats treated with phenobarbital. (B) Potential mechanisms mediating hormesis in carcinogenesis. Figure adapted from 
Fukushima, S. et al. Carcinogenesis 2005 26:1835-1845 [233]. 
 
Phenobarbital and Mitochondria 
Many years ago, barbiturates were shown to depolarize neuronal mitochondria [236] and depress 
mitochondrial respiration [237, 238]. In isolated mitochondria, compounds of the oxybarbiturate class 
(including secobarbital, amobarbital, and amytal) inhibit respiration by interfering with complex 1 of 
the electron transport chain, whereas thiobarbiturates (including thiamylal and thiopental) may 
additionally have an uncoupling effect on the oxidative phosphorylation. 
In consideration of our studies, we propose that PB and metyrapone affect mitochondrial functions 
leading to changes in the mitochondrial membrane potential, ROS generation (in LMH cells and 
human hepatocytes) and in the AMP/ATP ratio that increased in G2F cells and human hepatocytes. 
However, it is still unknown if drugs influence the mitochondria by direct binding to these organelles  
A B 
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or by an indirect effect via unknown signaling pathways. Considering that mitochondria isolation is a 
challenging step and that the drug doses used in induction experiments are quite high for a possible 
detection of specific binding, this questions could remain unanswered for a long time. Interestingly, 
metformin was shown to inhibit mitochondrial complex I, but its binding to mitochondria was found to 
be very weak [239]. 
It is also worth noticing that androstanol, which is an inverse agonist of CAR, inhibits iNOS expression 
via binding of CAR to a DR4 response element in its flanking region [240], thus keeping ROS 
formation low. However, PB does not seem to affect iNOS mRNA expression, but an effect on the 
protein level cannot be excluded. In this regard, estradiol was recently shown to induce a Hsp90-
eNOS interaction, thus activating eNOS-mediated generation of NO in an AMPK-dependent and 
estrogen receptor-independent manner [241]. 
Since PB increases ROS formation, the inhibition of apoptosis caused by PB could allow the cell to 
evade from the p53-mediated apoptotic pathway triggered by transient ROS overproduction. ROS in 
low quantity was also shown to promote proliferation via the mitogen-activated protein kinase (MAPK) 
pathways [242, 243], which may be related with the PB-mediated increase in proliferation since recent 
evidence showed that PB activates p38 MAPK in rat hepatocytes [244]. 
 
The Phenobarbital “Receptor” 
Despite many efforts to characterize the phenobarbital receptor, the primary target of this drug still 
remains unidentified. The search for a cytosolic receptor has failed, at least in part because of the 
apparent low potency of PB-type inducers. Interestingly, after exposure of cells to radioactively 
labeled PB, only a minor amount of radioactivity was detected inside the cells (earlier unpublished 
experiments). This finding would suggest a membrane receptor for PB, which triggers a signaling 
cascade ending in the nucleus. Years ago, our group started an effort to test if PB binds to the 
peripheral benzodiazepine receptor (PBR), which was shown to be involved among others in porphyrin 
and cholesterol transport and heme biosynthesis. PBR is a multiprotein complex located at the contact 
site between inner and outer mitochondrial membranes but it is also found at the plasma membrane. 
Unfortunately, PBR increased expression upon PB treatment could never be detected and 
stereobenzodiazepines, which do not bind to the receptor, induced CYP expression (unpublished 
observations). The plasma membrane GABAA receptor complex contains benzodiazepine binding sites, 
which bind among others barbiturates. Recently, different GABAA and PBR ligands were tested for CYP 
induction, but no correlation between binding affinity to the receptor and potency to induce CYPs was 
observed [245]. 
Metformin is an antihyperglycemic agent widely used in the treatment of type 2 diabetes. This drug 
stimulates glucose transport and utilization by peripheral tissue sensitive to insulin and inhibits hepatic 
gluconeogenesis. In studies by the Leverve’s group, metformin was shown to inhibit mitochondrial 
complex I in intact cells but not in isolated mitochondria of rat hepatocytes, oocytes and in a human 
carcinoma-derived cell line (KG cells) [239, 246, 247]. Metformin treatment of permeabilized cells or 
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direct injection inside the cells had no effect on complex I activity and in addition, the direct binding 
to mitochondria is very weak. Leverve also demonstrated that a prolonged incubation was necessary 
to detect the radioactive-labeled metformin in the cytosol. Though less than 0.1% of radioactive 
metformin was associated to whole cells after 60 minutes, metformin potentiation of insulin effects 
was observed even before [248]. All these findings indicate that metformin has probably a 
mitochondrial target, which can be reached only in living cells via plasma membrane related events, 
suggesting the cell membrane itself as primary site for metformin action. This phenomenon was 
suppressed at low temperatures (21°C) and completely insensitive to any inhibitors of signaling 
pathways supporting the role of the plasma membrane in the metformin transport [246]. 
Interestingly, estrogen uptake by clathrin-coated pits was detected in rat liver and HepG2 cells [249, 
250], indicating membrane-mediated endocytosis. It is in fact established that estrogen has also 
estrogen receptor-independent non-genomic effects. 
Some observations indicate that the plasma membrane is involved in PB signaling, too. In older 
studies, PB was shown to interact with the outer layer of the plasma membrane changing thereby its 
fluidity [251, 252]. In addition, in overexpression experiments performed by the AMAXA device, which 
is based on electroporation, the PB induction was strongly decreased possibly due to damages in the 
plasma membrane destroying some microdomains important for the PB effect. In contrast, when 
using Lipofectamine, which is a cationic lipid transfection reagent, no difference in the induction range 
was detected (FIGURE 6). Furthermore, barbiturates suppress glucose transport across the blood-brain 
barrier (BBB) in rats [253-255] and in cultured mammalian cells and human erythrocytes by 
interacting directly with purified GLUT-1 [256], suggesting that they interact with proteins at the 
plasma membrane. 
These three experimental observations support the speculative role of the plasma membrane in PB 
signaling, although, in the light of the PB and metyrapone effects on mitochondria presented in this 
thesis, mitochondrial targets must also be considered. 
 
 
 
FIGURE 6 
Effect of plasma membrane disturbance on phenobarbital-mediated CYP induction. The effect of transfection by 
lipofectamine2000 or electroporation (AMAXA) on PB induction of CYP2H1, CYP3A37 and ALAS1 is shown as fold induction. 
Transfection by electroporation drastically decreases PB induction. 
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Cancer Cells 
Tumor-derived cell lines usually loose the ability to induce CYP gene expression upon drugs, which is 
a huge problem for mechanistical studies on the molecular level of this transcriptional regulation. It is 
thought that the rapid cell division and dedifferentiation of hepatoma cells are the basis of the loss of 
PB responses in cell lines. Cell lines differ from hepatocytes in various points. Firstly, cell lines usually 
express lower levels of CAR and PXR, but since G2F cells, which express more CAR than HepG2 cells 
(that have no PB responses), are not particularly inducible, this can not completely explain the loss of 
drug-mediated induction in cell lines. 
Secondly, as already mentioned in the discussion of the manuscript (Results – Part II), cell lines are 
less dependent on mitochondrial respiration for ATP production since the glycolysis is strongly 
increased. Reduced mitochondrial functions may attenuate the effect of PB on these organelles and 
thus leading to lower or abolished drug induction. 
Thirdly, the most common and profound phenotype of cancer cells is their propensity to utilize and 
catabolize glucose at high rates. Cancer cells have higher glucose uptake, glycolytic rate and lactic 
acid production because of higher hexokinase and glucose transporter 1 (GLUT1) expression, a 
glucose transporter that is quickly saturated at low plasma glucose concentrations. Hepatocytes, in 
contrast, express only GLUT2, which transports glucose much better that GLUT1 because it is a low-
affinity transporter that is not easily saturated at even high plasma glucose levels. Hepatoma derived 
cell lines loose GLUT2 expression and overexpress GLUT1, which was also observed in G2F cells in 
comparison to human hepatocytes (Rencurel F, unpublished observation). Knowing that PB can bind 
glucose transporter and block the glucose uptake, and that CAR was recently shown to be involved in 
glucose homeostasis, interplay between PB and glucose may occur. If PB blocks GLUT2 in human 
hepatocytes, which express only this transporter, the level of glucose uptake is drastically decreased, 
thus the cells sense glucose starvation. In cell lines, which express also GLUT1, the effect is probably 
not as strong. It is therefore possible that PB leads to AMPK activation by causing glucose deprivation, 
which is sensed by the kinase as low energy state. 
Interestingly, exposure of cells to cytochalasin B, which is a GLUT inhibitor, increases the expression 
of CYP2B6 and CYP3A4 (Rencurel F, unpublished observation). 
LMH cells, which are hepatoma cells, should be somehow different from other cell lines because they 
retain drug responses very well. In preliminary experiments, GLUT1 and GLUT2 turned out to be 
similarly expressed on mRNA level in LMH cells (Blättler S, unpublished observation) in contrast to 
G2F, which express low level of GLUT2 and are maybe therefore not strongly inducible. The reason for 
this higher GLUT2 expression could be the fact that LMH cells are cultured in medium with higher 
glucose concentration, which keeps the GLUT2 expression higher.  
To verify the hypothesis that PB causes ATP depletion leading to AMPK induction, several ATP-
depleting agents were tested for their capacity of inducing CYP gene expression (Results – Part II, 
NaN3 effect). Among them, glucosamine and 2-deoxyglucose, which are rapidly phosphorylated by 
hexokinase without being further metabolized by glycolysis to produce ATP, were used to deplete 
ATP. Indeed, both compounds increased the CYP2H1, CYP3A37 and ALAS1 expression, but an 
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attenuation of PB induction of these genes was observed by glucosamine or 2-deoxyglucose addition, 
the last having a stronger effect possibly due to the higher affinity binding to GLUT  (FIGURE 7) [257].  
Considering that both of them are transported by GLUT, we can speculate that competition with PB 
for binding to the transporter occurs dampening thus the PB effect. This would support a role for 
glucose transporters in PB signaling, but obviously further experiments are needed to prove this 
possibility. However, the experimental observation that glucose attenuates CYP gene inducibility in 
hepatocytes, the so-called glucose effect, is in good correlation with a competition between PB and 
glucose for binding to GLUT and with a decreased AMPK activity in high glucose state. 
 
 
 
 
 
FIGURE 7 
Glucosamine and 2-deoxyglucose decrease PB induction in LMH cells. Exposure of LMH cells to 500µM PB in 
combination with glucosamine or 2-deoxyglucose (2-DG) decreases PB induction of CYP2H1, CYP3A37 and ALAS1. 
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Role of Mitochondria and/or AMPK in Drug Metabolism in the 
Elderly 
It has been reported that aging diminishes hepatic capacity, particularly the clearance of drugs. Liver 
drug metabolism decreases with age in animals [258-261]. In human, the rate of drug elimination of 
several substances was shown to decline with age in vivo [262, 263], whereas in vitro data showed 
unaltered CYP content. For long time there was a discrepancy on the effect of age on CYP activity 
probably due to interindividual variation in restricted numbers of liver samples and the difficulty of 
getting representative liver samples from healthy subjects. In 1997, Sotaniemi could show a reduction 
of in vitro and in vivo drug metabolism with age in humans in a study with 226 patient samples. The 
reduction of drug metabolism (-30%) after 70 years of age indicates that the prescription of drugs for 
elderly people is very delicate [264]. In addition, aging causes a significant reduction in liver volume 
and blood flow [265-267], where drug clearance appears to be reduced parallel with diminished liver 
volume in healthy aging man [268, 269]. Moreover, some data suggest a loss of inducibility [270, 
271] and a loss of hepatic smooth endoplasmic reticulum associated with aging in animals [272-274]. 
Generally, lower drug doses are required to achieve the same effect with advancing age. 
Studies in male Fischer 344 rats with PB showed a significant decline in the non-induced and induced 
activities of liver drug-metabolizing enzymes and in the amount of CYPs between maturity (16 
months) and senescence (27 months), whereas essentially no differences exist between very young (1 
month) and mature animals. The livers of young and mature animals treated with PB exhibit greater 
hepatomegaly, faster rates of induction and post-induction recovery of normal enzyme activities and 
higher maximally induced levels of CYPs in comparison to senescent rats [275]. 
In the last years, researchers have speculated that mitochondria might contribute to aging, either by 
releasing tissue-damaging reactive oxygen molecules or by deteriorating and depriving the cell of its 
needed energy. Attardi et al. reported some of the first hard evidence that mitochondria deteriorate 
during aging. His team found that mutations in the 16,500-base mitochondrial genome accumulate 
with time in a particularly important 1000-base segment that controls the genome's replication [276]. 
Acquired mitochondrial dysfunction and age-associated accumulation of mutations in mitochondrial 
DNA may play a role in aging, as well as in age-related metabolic and degenerative diseases (such as 
diabetes, Parkinson’s disease, Alzheimer disease, cancer) [276-278]. For example, mice with a 
defective mitochondrial DNA polymerase have been shown to age prematurely [279] and a 
mitochondrial DNA (mtDNA) polymorphism, eventually related to a low production of ROS, is often 
found among centenarians [280]. 
Our data show an important role of mitochondria in the mechanism of drug induction, especially 
changes in the mitochondrial potential and in ROS formation are triggered by PB and metyrapone in 
LMH cells and by PB in human primary cultures of hepatocytes and in human hepatoma cells. In the 
light of recent observations, mitochondria dysfunction may be related to aging and to the decrease of 
drug metabolism in elderly. The observation that in aged cells mitochondrial potential is reduced by 
decreased respiration and that endogenous ROS production rises with aging [281, 282] support this 
Discussion  114 
    
speculation, meaning that the sensitivity to PB-mediated changes in potential or ROS level may be 
attenuated in aged cells leading to reduced drug induction and metabolism. 
In this regard, new findings showed that changes in expression or regulation of AMPK are related to 
aging. Hyperphosphorylated AMPK was found only in old but not in young muscles and the reduced 
muscle hypertrophy typically found in aged-muscles was correlated to high phosphorylation extent of 
AMPK [283, 284]. Also increases in aortic superoxide anion with aging were significantly correlated 
with changes in AMPK expression and regulation [285]. Another study in old mice demonstrated that 
the diminished stress tolerance characteristic for aging is associated to age-related changes in hepatic 
AMPKα1 basal activity, which was increased, and to reduced capacity of hypoxia to activate the kinase 
[286]. All these data suggest that old mice were generally less tolerant to stress with a clear 
correlation to AMPK expression and activity. So, an age-related elevation in AMPK phosphorylation 
may partly contribute to the attenuated drug responsiveness in elderly. 
 
The CXR and CAR Complexes 
By immunoprecipitation several proteins were found in the complex with CXR. Among them, two were 
also coimmunoprecipitated with mouse CAR, Hsp90 and PP2A, supporting evolutionary conservation 
also in this aspect. However, two new cochaperones, Hsp70 and Hsp40, were identified in the CXR 
complex. The Hsp90/Hsp70 chaperone machinery is a multiprotein complex, which assists the 
assembly of receptors or of other signal transduction proteins into heterocomplexes. The minimal 
system to assemble stable receptor heterocomplex is composed of five proteins, for instance Hsp90, 
Hsp70, Hsp40, Hop and p23 [287]. Three out of these five proteins were identified in complex with 
CXR. It was shown that J domain-containing proteins play important regulatory roles as cochaperones, 
recruiting Hsp70 and Hsp40 [288].  CCRP, which was shown to interact with CAR, contains a J domain 
[73] supporting our findings. Hsp90 was shown to regulate the nuclear retention of the glucocorticoid 
receptor (GR) because Hps90 inhibitors, such as geldanamycin and radicicol that bind to the ATP/ADP 
binding site of the chaperone interrupting its function, accelerate GR nuclear export [289]. 
Furthermore, geldanamycin inhibits TCPOBOP-mediated Cyp2b10 induction by decreased CAR nuclear 
accumulation [74]. In addition to their role as chaperones, heat shock proteins (Hsp) are activated by 
cellular stress, and likely help to maintain viability under stress conditions. Barrett et al. showed that 
treatment of a human cell line with micromolar concentration of a mitochondrial poison resulted in 
inhibition of cytochrome oxidase with subsequent ROS formation. Increase in ROS caused Hsp70 
nuclear translocation and activation [290]. The authors concluded that mitochondrial electron 
transport chain dysfunction activates an Hsp response, which is mediated by oxidative stress. The 
purpose of this nuclear translocation is unknown but most likely the presence of Hsp in the nucleus 
affects gene expression, maybe by transporting transcription factors, such as CXR/CAR into the 
nucleus. It was also shown that Hsp70 binds histone deacetylase complex (HDAC), one way how 
mitochondria may affect gene expression via ROS. 
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Another identified CXR interacting protein is tubulin, which is quite interesting in consideration of the 
observation that colchicine, which destroys the tubulin network, decreases basal and PB-induced 
CYP2B6 and CYP3A4 expression in human hepatocytes [291]. In addition, CAR was suggested to 
colocalize with tubulin in mouse liver [73], wherefore CXR/CAR nuclear translocation mediated by the 
tubulin network is plausible 
Two bands (1 and 3) were related to three proteins involved in microRNA (miRNA)-mediated gene 
downregulation, eukaryotic translation initiation factor 2C1 (or Ago1), eukaryotic translation initiation 
factor 2C2 (or Ago2) and trinucleotide repeat-containing 6B protein (TNRC6B). miRNAs are small 
noncoding RNAs that repress gene expression by recruiting effector complexes (miRNPs) to miRNA 
complementary sites on mRNAs and thus blocking translation initiation. In animals, nearly all miRNAs 
investigated to date appear to regulate gene expression by imperfect base-pairing at the 3’ UTR of 
target mRNAs. miRNAs assemble into the RNA-induced silencing complex (RISC), which is the effector 
of RNAi. The key component of the RISC complex is an argonaute protein. Repressed mRNAs, Ago 
proteins, and miRNAs accumulate in so-called cytoplasmic processing bodies (p-bodies), which are 
stress granules that bear sites for mRNA degradation or mRNA storage of translationally repressed 
mRNA. Interestingly, it was recently shown that this miRNA-mediated repression can be relieved 
suggesting that this is a rather dynamic regulation [292]. It is estimated that 20-30% of all genes are 
miRNA targets (for reviews on miRNA [293, 294]). In support to an interaction between CXR and 
these three proteins, the identified TNRC6B was shown to bind to Ago1 and Ago2. These data suggest 
that CXR interacts with proteins involved in miRNA repression of translation extending the CXR 
potential regulation to post-transcriptional events. Consistently, in band 4 and 5 several proteins 
associated to RNA were identified, for instance, DEAD box proteins (RNA helicases), heterogeneous 
nuclear ribonucleoproteins and the poly A binding protein, which was also linked to mRNA translation 
inhibition. If this data will be confirmed by coimmunoprecipitation studies followed by western blot, 
new players in the complicated xenosensor-mediated gene expression regulation will be added. 
Band 2 was identified as pyruvate carboxylase, an enzyme of the gluconeogenesis pathway. Since it is 
known that CAR regulates another enzyme of this pathway, PEPCK, it is possible that several enzymes 
involved in gluconeogenesis are regulated by CAR. In band 7, aldehyde dehydrogenase, an enzyme 
involved in phase II drug metabolism, was identified, whereas band 8 was recognize as alpha enolase, 
an enzyme of the glycolytic pathway. The significance of this last interaction is completely unknown. 
Although to date no differences in proteins interacting with CXR between control and PB samples 
could be observed due to the lower protein content of the PB-treated sample, our findings encourage 
future investigation of the CXR/CAR interacting proteins. 
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Protein Kinase C Zeta: Physiological Role 
In the present study, we established an involvement of atypical protein kinase C zeta (PKCζ), a 
protein kinase of the AGC family, in the LKB1-dependent activation of AMPK upon PB treatment. 
Inhibition of PKCζ with a pharmacological inhibitor reduced AMPK activation caused by PB. This AMPK 
activation was LKB1-dependent, involved LKB1 phosphorylation at Ser428, and led to an association of 
LKB1 with AMPK. In addition, overexpression of PKCζ in LMH or G2F cells increased PB induction. At 
the present time, the physiological relevance of the role of PKCζ in drug induction is unknown. 
There are at least 12 PKC isoforms classified into three subfamilies according to the structure of the 
N-terminal regulatory domain, the classical, the novel and the atypical isoforms, which are surprisingly 
non-redundant despite the high degree of homology [295]. PKCζ belongs to the last category, which 
controls cell proliferation, apoptosis and insulin-stimulated glucose transport [296-300]. Recently, 
overexpression of PKCζ in carcinomas of liver and urinary bladder [301, 302] and its involvement in 
the phosphorylation of the mTOR downstream target p70SK6 were reported [303]. Interestingly, PKCζ 
nuclear translocation in mouse was associated with hyperproliferation [304] and the AMPK activator 
metformin was reported to activate PKCζ in muscle of diabetic mice [305]. PKCζ overexpression 
increases PPARα activity in reporter gene assays with suggested increase in PPARα phosphorylation 
[306]. In addition, PKCζ  was shown to promote p300 interaction with the hypoxia-inducible factor 1α 
increasing its activity in transcriptional regulation [307]. If this applies also for CAR will be investigated 
in future studies aimed to unravel the link between PKCζ and drug induction mechanism. 
 Outlook 
 
Although our findings clearly demonstrate that AMPK is essential for hepatic PB induction of CYPs, 
they also raise many new questions, which must be addressed in the future. 
We showed that PB induction is abolished in AMPKα liver-specific knockout mice and their primary 
hepatocytes. Knowing that PB has pleiotropic effects, it would be interesting to investigate if AMPK 
mediates these effects, particularly the liver size increase, the tumor promoter and the antiapoptotic 
effect. In response to PB exposure, many CAR-independent mechanisms occur, which may be 
mediated by AMPK. Investigation of the mechanism, by which liver cells can alter gene expression in 
response to PB in a CAR-independent way, is important to understand the adaptation of liver cells to 
drugs. From microarray data in wildtype and CAR knockout mice it emerged that a large spectrum of 
genes are regulated by CAR upon PB treatment but many others resulted to be CAR-independent 
raising the question if and which of these genes are also AMPK-dependent. Studies aimed to 
investigate the role of AMPK on genes, such as transporters or phase II drug-metabolizing enzymes, 
would help to answer these questions. In addition, a PB time-course experiment in vivo should be 
performed to investigate the AMPK activity at several time-points acquiring insights about differences 
between short-term and long-term PB treatment. 
Furthermore, the role of the mTOR pathway on PB-mediated proliferation and tumorigenesis should 
be tested, since our preliminary experiment with rapamycin suggests mTOR involvement in CYP gene 
expression regulation in the short-term induction, but analysis of the long-term effect of PB on mTOR 
could elucidate if the tumor promoter effect of PB is linked to a mTOR dysregulation. 
Another important experiment is the investigation of PB induction of CYPs in LKB1 knockout mice. 
Since this kinase was shown to be the major AMPK upstream kinase in the liver [179], its genetic 
deletion should strongly impact PB-mediated CYP gene expression assuming that its role is essential.  
Obviously, a very interesting topic are the downstream AMPK targets. AMPK phosphorylates unknown 
proteins leading to increased CYP expression upon PB treatment. To definitively exclude the possibility 
of CAR as an AMPK target, experiments using the entire CAR protein, and not only peptides, should be 
performed. In fact, conformational features or the presence of other proteins may be necessary to 
allow or to prime phosphorylation. For these kinds of experiments, Shokat and collaborators 
developed a combined chemical/genetic method that consents to identify protein kinase substrates. 
This approach is based on a particular functionally silent point mutation in the ATP binding site of a 
kinase that allows the mutant kinase to use an ATP analogue, N6-(benzyl)-ATP, which is a poor 
substrate for all other protein kinases in the cell. By adding the radioactive labeled ATP analogue to a 
cell extract containing the mutated kinase, radiolabeling is detected exclusively in the mutant kinase 
direct targets. This elegant experiment allows to work in cell extract where all the proteins are 
present. However, since the radiolabeled ATP analogue cannot cross the cell membrane, it is not 
possible to perform experiments in intact cells [308]. Currently, modifications of ATP analogues that 
can cross the cell membrane are tested. 
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As already mentioned in the discussion, proteins like p300 and HNF4α, which were already identified 
as AMPK substrate, should also be considered as potential AMPK targets upon PB treatment 
potentiating CAR transcriptional regulation or CAR expression. 
In immunoprecipitation experiments, PP2A was shown to interact with mouse CAR [74] and with its 
chicken ortholog CXR (Results – Part VII), but the significance of this interaction is unknown. Low 
doses of okadaic acid, a potent PP2A inhibitor, completely block PB induction of CYP2Bs in mouse and 
rat hepatocytes by preventing CAR nuclear translocation, wherefore a role of this phosphatase in the 
nuclear CAR accumulation is suggested. Interestingly, Keen et al. showed that PP2A regulates mRNA 
stability of estrogen receptor (ER) via its 3’ UTR region. In fact, okadaic acid reduced ER mRNA to 
25% and activation of PP2A stabilized ER mRNA [309]. In preliminary experiments, hCAR mRNA level 
was strongly decreased by okadaic acid treatment down to 35% in primary cultures of human 
hepatocytes (FIGURE 1) suggesting that PP2A stabilizes CAR mRNA, possibly enhancing its translation 
and consequently its nuclear translocation. 
 
 
FIGURE 1 
Okadaic acid decreases CAR mRNA level in primary cultures of human hepatocytes. Human hepatocytes were 
treated with 100nM okadaic acid (OA) for 16h. CAR mRNA was measured by RT-PCR. p<0.01. 
 
 
CAR was colocalized with PGC1α in nuclear speckles [206], which are highly dynamic sites for storage 
and assembly of splicing factors and other proteins involved in regulation of transcription, which are 
then released upon gene activation targeting mRNAs to transcriptionally active sites. It is intriguing 
that okadaic acid was shown to affect the composition of these subnuclear regions [310] potentially 
leading to splicing and mRNA export regulation, which may be the reason for the decreased CAR 
mRNA level upon okadaic acid treatment.  Interestingly, according to our results in AMPK liver-specific 
knockout mice, CAR seems to be localized in these transcriptionally silent nuclear speckles upon PB 
treatment, whereas more diffuse localization was observed in wildtype mice ([181] in APPENDIX 3) 
explaining possibly the abolished PB induction in AMPK knockout mice. However, no difference was 
observed in CAR nuclear transfer in wildtype versus knockout mice. These results imply that AMPK is 
not involved in the PB-induced cytoplasmic-nuclear transfer of CAR, but possibly in its subnuclear 
localization.  
As mentioned in the discussion, the efficiency of importinα-mediated nuclear transport is increased by 
AMPK suggesting that nuclear translocation of proteins involved in gene expression regulation may be 
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enhanced affecting transcriptional and post-transcriptional events. Therefore, gene expression pattern 
are potentially affected by AMPK and proteins involved in drug-mediated CYP gene regulation could be 
importinα cargoes. Future studies should reveal whether or not CAR is a cargo for importins.  
CAR was found to localize at the plasma membrane in an approximately 160kDa complex and this 
association was increased by PB treatment in mouse liver suggesting that CAR may exert non-
genomic effects on signaling cascades that potentially indirectly affect gene expression [311]. 
Interestingly, CAR translocation to the nucleus and to the plasma membrane occurred simultaneously 
supporting the notion that CAR membrane localization is not a prerequisite for the nuclear transfer. 
The elucidation of potential CAR non-genomic effects in the liver may lead to important new insights 
into the regulation of drug metabolism by xenobiotics. Furthermore, AMPK is possibly involved in this 
pathway, thus the search for its targets may be directed in this direction. Such non-genomic effects 
were shown for estrogen receptor α, thyroid hormone receptor and vitamin D receptor, which were 
shown to affect G-protein coupled receptor, ion channels and Src, respectively [312, 313]. Interesting 
is the case of the non-genomic effects of estrogen on eNOS mediated by a subpopulation of estrogen 
receptor localized at caveolae in the plasma membrane (FIGURE 2): estrogen receptor and eNOS are 
coupled in a functional signaling module in caveolae. By binding of estrogen to the estrogen receptor 
on the caveolae, G-protein coupled receptors are activated, which mediates downstream events 
including activation of MAPK and Akt signaling, stimulation of Hsp90 binding to eNOS, and 
perturbation of the local calcium environment, leading to eNOS phosphorylation and calmodulin-
mediated eNOS stimulation. The potential generation of ROS is consequently increased. Other studies 
indicate that estrogen is transported into mitochondria by both passive diffusion and by receptor-
mediated endocytosis and that it enhances mitochondrial transcription. Estrogen inhibition of the 
electron transport chain were also observed possibly caused by a estrogen-mediated change in 
membrane fluidity, which as consequence enhances the rate of electron transfer (due to increased 
collision between respiratory chain complex and electron carriers) and ROS formation [314, 315]. 
Some of these events are reminiscent with some PB effects, wherefore it would be interesting to study 
the hypothesis of a membrane-mediated PB-CAR signaling. 
 
 
Form Chambliss et al. [315] 
 
FIGURE 2 
Non-genomic effect of estrogen. Activation of eNOS by estrogen at the plasma membrane via G-coupled receptors.  
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From the CXR immunoprecipitation studies, several proteins were identified with functions that could 
be related to CYP gene regulation. For example, the heterogeneous nuclear ribonucleoprotein U 
(hnRNP U) is known to associate with the histone acetylase (HAT) and transcription activator 
CBP/p300 affecting transcription regulation. Additionally, hnRNP U was shown to be associated with 
the phosphorylated C-terminal domain (CTD) of polymerase II (Pol II) promoting transcription [316]. 
These observations prompt studies to investigate whether this interaction between CXR and hnRNP U 
has functional relevance impacting CYP expression. The interaction between CXR and the proteins 
involved in miRNA gene regulation (Ago1/2 and TNRC6B) is also interesting in terms of function, 
leading possibly to a new strategy of nuclear receptors to fine tuning the transcription of drug-
metabolizing enzymes and other proteins involved in detoxification pathways. The interaction of CXR 
with these new partners should therefore be further investigated to unravel its physiological 
relevance.  
In addition, identification of the differential phosphorylated proteins detected by western blot of CXR 
immunoprecipitated lysates may reveal potential AMPK targets in the PB induction mechanism.
 Summary 
 
During the past several years, important advances have been made towards the understanding of the 
mechanisms regulating the expression of genes that determine drug clearance, including phase I and 
phase II drug-metabolizing enzymes and drug transporters. Orphan nuclear receptors have been 
recognized as key mediators of drug-induced changes in both metabolism and efflux mechanisms.  
Characteristically, xenobiotic-metabolizing members of the cytochrome P450 (CYP) superfamily are 
transcriptionally induced upon exposure to xenobiotics. This phenomenon increases the ability of the 
organism to adaptively defend itself against toxic foreign compounds. However, the induction of drug-
metabolizing CYPs has important clinical consequences, such as impacting drug treatment, causing 
drug-drug interactions and influencing endogenous regulatory pathways. Therefore, understanding 
how drugs lead to induction of drug-metabolizing enzymes is of huge importance for the human 
pharmacotherapy with a future aim to develop predictive tests for personalized medicine. 
In this thesis, we demonstrated that phenobarbital-type drug-mediated transcriptional regulation of 
CYP genes is achieved by a signaling cascade involving mitochondrial functions leading to reactive 
oxygen species generation, PKCζ and LKB1 phosphorylation and subsequent interaction between LKB1 
and AMPK, which is in turn phosphorylated and activated. The activation of PKCζ, LKB1 and AMPK 
adds new proximal targets to the so-far elusive sequence of events, by which phenobarbital-type 
drugs induce the transcription of multiple genes. In addition, our results propose mitochondria as a 
target for inducer drugs as a novel concept.  
Obviously, further studies are required to understand the mechanism more in detail. Especially the 
activation of AMPK by ROS production, the downstream targets of AMPK and the effect of 
phenobarbital on mitochondrial functions need further investigation.  
 
The molecular mechanism of hepatic drug induction is closely linked to endogenous regulatory 
pathways, raising the speculation that xenobiotic-sensing receptors evolved from nuclear receptors 
that handled toxic lipophilic metabolites, such as cholesterol metabolites. Since xenobiotic compounds 
have similar hydrophobic properties, these nuclear receptors may have extended their substrate 
specificity to include xenobiotics. Thus, organisms could sense like toxic endogenous metabolites, for 
example bile acids. 
The evolutionary origin of AMPK may also be similar to the one of the drug metabolism. In single-
celled eukaryotes, AMPK orchestrates the response to glucose starvation, which may have been its 
original “raison d’être”. However, during evolution of multicellular organisms AMPK became involved in 
the regulation of energy intake and expenditure at the whole body level, while hormones and 
cytokines have acquired the ability to regulate AMPK. Furthermore, AMPK may have turned from an 
energy-sensing kinase to a stress-sensing protein. Therefore, it is reasonable that this kinase is 
activated by compounds which upregulate CYPs. Drugs are probably sensed by AMPK as stress, 
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because drug metabolism is an energy consuming process. For this reason rapid initial AMPK 
activation by drugs could downregulate unnecessary pathways allowing the organism to concentrate 
on the disposal of these compounds. 
To survive environmental stress like phenobarbital exposure, cells activate a variety of adaptive 
mechanisms, including inhibition of the energy-costly mRNA translation and promotion of cell survival 
in the short-term, later liver size increase and cell proliferation in the long-term. These mechanisms 
produce a transient hepatomegalic response that promotes drug clearance, but clearly also creates a 
tumorigenic environment. The proliferative and antiapoptotic environment induced by CAR activators, 
such as phenobarbital and TCPOBOP, may be an important contributor to early stages of 
hepatocarcinogenesis, for example by promoting accumulation of cells carrying tumorigenic genetic 
changes.  
As a result of drug-mediated CAR activation, drug-metabolizing enzymes are induced, whether 
gluconeogenesis, energy metabolism and fatty acid oxidation are inhibited allowing liver cells to 
increase their drug metabolism potential and lower their energy metabolism, wherefore the cells have 
ultimately more capacity to metabolize drugs and xenobiotics.  
The question of how our body has adapted itself to deal with foreign compounds that it has never 
encountered before (reminiscent of the immnune system) is a fascinating challenge for the future. 
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Reagents 
Metyrapone (2-methyl-1,2-di-3-pyridyl-1-propanone), N-acetyl L-cysteine (NAC), metformin and 
protein G agarose beads were obtained from Sigma (Buchs, Switzerland) and AICAR (5’-
phosphoribosyl-5-aminoimidazol-4-carboxamide) from Toronto Research (North York, Canada). 
Phenobarbital sodium salt (5-ethyl-5-phenyl-barbituric acid sodium salt), dinitrophenol (DNP), 
rotenone, and sodium azide (NaN3) were purchased from Merck (Dietikon, Switzerland) and 
Compound C (6-[4-(2-Piperidin-1-yl-ethoxy)-phenyl)]-3-pyridin-4-yl-pyrrazolo[1,5-a]-pyrimidine) from 
Calbiochem (Laufelfingen, Switzerland). Antibodies against AMPKα1 and AMPKα2 were purchased 
from Upstate Biotechnology (Luzern, Switzerland) and antibodies against ACC-pSer79, AMPK-pThr172, 
HA-tag, MAPK, AMPKα, LKB1, LKB1-pSer428, PKCζ and PKCζ-pThr410 from Cell Signaling Technology 
(Allschwil, Switzerland). All other reagents and supplies were obtained from standard sources.  
 
 
Cell Culture Methods 
 
Culture and transient transfection of LMH cells 
LMH cells were obtained from ATCC (catalogue no. 2117-CRL, batch no. F12213). They were 
cultivated in William's E medium supplemented with 10% fetal calf serum, 1% glutamine (2mM), and 
1% penicillin/streptomycin (50IU/ml) on gelatin-coated dishes. Cells were seeded for 3 days and 
when they reached approximately 80% surface density, they were transfected for 48h using the 
NucleofectorTM Kit T (AMAXA Biosystems, Köln, Germany) with Solution T according to the AMAXA 
protocol. Alternatively, cells were transfected for 48h by Lipofectamine2000 (Invitrogen, Nivelles, 
Belgium) as described in the manufacturer’s protocol. 
 
Preparation of LMH ρ0 cells  
LMH cells were grown for 12 weeks in medium containing 50ng/ml ethidium bromide, 50mg/ml 
uridine, and 1mM pyruvate. The ρ0 status of the cells was confirmed by the decrease of mitochondrial 
marker genes via RT-PCR and by the incapacity of surviving without uridine and pyruvate. RT-PCR 
primer sequences are summarized in Table 1 in the supplemental data. 
 
Preparation of primary culture of mice hepatocytes 
Mouse hepatocytes were prepared from animals anaesthetized with Ketamin/Xylazine (Sigma, Buchs, 
Switzerland). The hepatic portal vein was canulated and perfused with HEPES-EGTA pH 7.4 at a flow 
rate of 8ml/min for 5min. The liver was then perfused for 6min with a collagenase solution (type 2 
Worthington, Lakewood NJ, USA) continuously gassed with carbogen. The livers were extracted and 
put in Leibowitz L-15 medium (Sigma, Buchs, Switzerland) supplemented with 10% newborn calf 
serum (Invitrogen, Basel, Switzerland). Hepatocytes were then filtered through a nylon mesh and 
centrifuged three times for 5min at 50xg and 4°C. After determination of viability, cells were allowed 
to attach at a density of 200’000 cell per well of 12-well dishes in Williams’E medium supplemented 
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with 10% fetal calf serum, 4µg/ml insulin, 200µM glutamine and 1% penicillin/streptomycin (50U/ml) 
on collagen-coated dishes. After overnight incubation, the medium was replaced with serum-free 
Williams’E medium for 24h and the cell were subsequently exposed to compounds. 
 
Preparation of primary cultures of human hepatocytes 
Liver tissue (50-200mg) was obtained from consented patients undergoing surgical resections in the 
clinic of visceral surgery in Bern (Switzerland). Tissue was perfused with two cannulea with buffers 
heated to 37°C at a rate of 100ml/min. Firstly, PBS containing 10mM HEPES for 5min followed by 
500ml of PBS/HEPES containing 2mM EGTA were used. EGTA was then removed by 500ml of the first 
buffer. The enzyme solution (0.05% collagenase, 0.02% dispase, 0.017% hyaluronidase and 
0.02%DNase in HBSS containing 5mM CaCl2) was recirculated through the liver piece for a period of 
7-12min until it was sufficiently softened. The tissue was mechanically disrupted in DMEM containing 
10% fetal calf serum, filtered through 50micron sterile gauze and washed twice in DMEM by keeping 
the suspension on ice. Hepatocytes were subsequently seeded on rat-tail collagen coated plastic 
dishes at a density of 100’000 cells per well of a 12-well dish in DMEM supplemented with 10% heat-
inactivated fetal bovine serum, 1mM dexamethasone and 50IU/ml penicillin/streptomycin. After 
overnight attachment, the medium was replaced by serum-free Williams’E medium supplemented with 
100nM hydrocortisone, 0.5x ITS solution (Sigma) and 50IU/ml penicillin/streptomycin. Cells were 
incubated under these conditions for 24h and subsequently exposed to the compounds of interest. 
 
AMPKα1 and AMPKα2 downregulation by diced siRNA (d-siRNA) duplexes  
RNAi analysis was performed by BLOCK-iT Dicer RNAi Kit (Invitrogen, Nivelles, Belgium). Primers used 
for the sense and antisense DNA templates amplification are summarized in Table 1 in the 
supplemental informations. RNA transcription was done by BLOCK-iT T7 Enzyme Mix and the double-
stranded RNA transcripts were cleaved by BLOCK-iT Dicer Enzyme into d-siRNA duplexes, which were 
transiently transfected into LMH cells by Lipofectamine2000 according to standard protocols. After 48h 
of transfection, LMH cells were treated with 500µM PB or metyrapone for 16h in order to perform RT-
PCR measurements, or 1h for AMPK activity measurements and western blots. 
 
 
Assays 
 
Western blots 
LMH lysates were prepared as described above, but lysis was performed in 200µl buffer. The lysates 
were centrifuged at 14000rpm and 4°C for 10min, the supernatant transferred to a fresh tube, snap-
frozen in liquid nitrogen, and stored at -80°C. Protein concentration was determined by BCA assay 
and 30µg of total proteins were loaded. Proteins were separated on 10% SDS-PAGE and blotted for 
1h onto a nitrocellulose membrane using a Biorad Minigel system with transfer buffer containing 
39mM glycine, 48mM Tris, 0.0375% SDS, and 20% methanol. The blots were incubated overnight at 
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4°C with a 1/1000 dilution of the primary antibody in Roche Blocking Reagent. Proteins were 
visualized according to the enhanced chemiluminescence protocol (Amersham Pharmacia Biotech, 
Zürich, Switzerland).  
 
Immunoprecipitation 
LMH cells were cultivated on 10cm dishes, transfected with HA-LKB1 or Myc_AMPKα1/2 by 
Lipofectamine2000 for 48h, and treated with PB or metyrapone for 20 or 40min. The cells were 
scraped in 150mM NaCl, 50mM Tris pH 8, 1% Triton X-100 and protease inhibitors (Complete Mini 
EDTA-free), left 15min on ice, sonicated two times for 5 seconds, and centrifuged 10min at 4°C and 
14000rpm. BCA assay was used to determine the protein content of the supernatant, which was then 
incubated for 30min at 4°C under rotation with protein G agarose beads for the preclearing. After 
removal of the beads, antibody was added to the lysates, which were incubated under rotation at 4°C 
for 2h. Finally, protein G agarose beads were rotated with lysates under the same conditions. The 
beads were washed three times with lysis buffer, two times with PBS before being resuspended in 
protein loading buffer. 
 
AMPK activity measurement 
AMPK activity was measured using the SAMS peptide (HMRSAMSGLHLVKRR) phosphorylation assay kit 
from Upstate Biotechnology (Luzern, Switzerland) according to the manufacturer’s protocol. Briefly, 
cells were grown in 6cm dishes until they reached about 80% confluence before being put in serum-
free medium for 24h. Treatments were added straight to the culture dishes and cells incubated for 1h 
at 37°C. Culture medium was quickly removed, the cells were washed once with ice-cold PBS and 
harvested in 400µl lysis buffer containing 50mM Tris pH 7.5, 50mM NaF, 1mM EDTA, 1mM EGTA, 
1mM sodium pyrophosphate, 250mM mannitol, 1% Triton X-100, protease inhibitors (Complete Mini 
EDTA-free, Roche Molecular Biochemicals, Rotkreuz, Switzerland), 5µg/ml soybean trypsin inhibitors, 
0.2mM sodium orthovanadate, and 1mM DTT. After PEG precipitation and BCA protein assay (Biorad, 
Reinach, Switzerland), 15µg of total proteins were used in a 40µl reaction in the presence of 75mM 
MgCl2, 0.5mM ATP, 0.3mM AMP, 0.2mM SAMS, 0.4mM DTT and 1mCi/100µl [γ-
32P]ATP for 10min at 
30°C. At the end of the incubation, 35µl of supernatant from the reaction mixture were spotted on 
Whatman filter papers (P81) which were then washed three times with 0.75% phosphoric acid, once 
with acetone and then allowed to dry before scintillation counting in 5ml scintillation cocktail. 
 
LKB1 activity measurement 
LKB1 activity was measured using the LKBtide peptide and LKB1 enzyme mix from Upstate 
Biotechnology (Luzern, Switzerland). Cells were grown in 6cm dishes until they reached about 80% 
confluence before being put in serum-free medium for 24h. Treatments were added straight to the 
culture dishes and cells incubated for 1h at 37°C. Culture medium was quickly removed, the cells were 
washed once with ice-cold PBS and harvested in 400µl lysis buffer containing 50mM Tris pH 7.5, 
50mM NaF, 1mM EDTA, 1mM EGTA, 1mM sodium pyrophosphate, 250mM mannitol, 1% Triton X-100, 
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protease inhibitors (Complete Mini EDTA-free, Roche Molecular Biochemicals, Rotkreuz, Switzerland), 
5µg/ml soybean trypsin inhibitors, 0.2mM sodium orthovanadate, and 1mM DTT. After PEG 
precipitation and BCA protein assay (Biorad, Reinach, Switzerland), 15µg of total proteins were used 
in a 40µl reaction in the presence of 75mM MgCl2, 0.5mM ATP, 0.3mM AMP, 0.2mM SAMS, 0.4mM 
DTT and 1mCi/100µl [γ-32P]ATP for 10min at 30°C. The reaction was stopped on ice water and 20µl of 
supernatant from the reaction mixture were spotted on Whatman filter papers (P81) which were then 
washed three times with 0.75% phosphoric acid, once with acetone and then allowed to dry before 
scintillation counting in 5ml scintillation cocktail. 
 
RNA isolation and real-time PCR analysis 
RNA from LMH cells was isolated by Trizol Reagent. 1µg of total RNA was reverse-transcribed with the 
Moloney Murine Leukemia Virus (MMLV) reverse transcriptase assay (Roche Molecular Biochemicals, 
Rotkreuz, Switzerland). PCR was performed using the real-time PCR core reagent kit (PE Applied 
Biosystems, Rotkreuz, Switzerland), and the mRNA levels were quantified with an ABI PRISM 
7700 sequence detection system according to the manufacturer’s protocol. Different genes were 
measured in separate tubes, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA levels 
were used for normalization of the results (APPENDIX TABLE 2 for primer sequences). The data are 
shown as relative expression to control sample. 
 
LMH reporter gene assays 
LMH cells were cultured onto 96-well dishes coated with gelatin at a density of 40’000 cell per well. 
Transfections were performed using 0.2µl/well FUGENE6 transfection reagent (Roche Molecular 
Biochemicals, Rotkreuz, Switzerland) in serum-free Williams’ E medium for 6h and then the medium 
was changed to serum-supplemented Williams’ E. The transfection mix contained 100ng reporter gene 
construct, 25ng β-gal vector and 16/32ng of AMPKα1, AMPKα2 or LKB1 vector. 
 
Transactivation assay 
Transactivation assay were carried out in monkey kidney CV-1 cells. Cells were maintained in DMEM-
F12 supplemented with 10% fetal bovine serum. Before experiments, cells were splitted 1:10 in 
DMEM-F12 without phenol red, supplemented with 10% charcoal-stripped fetal bovine serum. After 3 
days of growth, cells were plated onto 96-well dishes at a density of 25’000 cells per well and grown 
overnight. CV-1 cells were transiently transfected in OptiMEM medium with 1µl of Lipofectamine 
reagent per well. Transfection mixes containing 8ng receptor expression vector, 20ng reporter vector, 
60ng pRSV-βgal and 8-16ng of AMPKα1 or AMPKα2 vector were added to the cells. 24h after 
transfection, the medium was replaced by DMEM-F12 without phenol red, supplemented with 10% 
delipidated, charcoal-stripped fetal calf serum containing the inducer compounds of interest. Cells 
were then incubated for additional 24h, after which cell extracts were prepared with 200µl of passive 
lysis buffer (Promega). Luciferase expression was assayed by the Luciferase assay kit (Promega) with 
10µl of cell lysates. At the same time, β-galactosidase activities were determined by adding 180µl of 
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chlorophenol red-1β-D-galactopyra (CPRG) substrate solution (Roche Molecular Biochemicals) to 20µl 
of the cell lysates. After 10-30min of incubation at 37°C, absorption at 550nm wavelength was 
measured using a Labsystems Multiscan RC microplate reader (Labsystems, Frankfurt). Luciferase 
expression was then normalized against measured b-gal activities to compensate for variations in 
transfection efficiency. 
 
Immunofluorescence 
LMH cells were cultivated on LabTek dishes coated with gelatin. Cells were washed with PBS, fixed in 
4% paraformaldehyde (PFA) for 30min at RT, and permeabilized in 4% PFA/0.5% Triton X-100 for 
5min at RT. Cells were rinsed for 5min in 10mM Tris pH 7.5/10mM NaCl, subsequently twice in PBS 
and blocked in 2% BSA/10% serum/0.1% Tween20 for 30min at RT. Staining with primary and 
secondary antibody were done in blocking solution for 1h each at RT. After extensive washing with 
PBS, cells were stained with 0.5µg/ml DAPI and subsequently analyzed by fluorescence microscopy.  
 
Mitochondrial membrane potential measurement  
Cells were cultivated in serum-free medium for 24h were detached by trypsin and resuspended in 
serum-free Williams’E medium. Approximately 4x105 cells were transferred to an Eppendorf tube and 
incubated at 37°C for 20min with 1µl of a 5mg/ml JC-1 (Invitrogen, Nivelles, Belgium) stock in DMSO, 
and either with 500µM PB or 0.2mM DNP. After two washing steps with 1ml PBS and 5min 
centrifugation at 400g the cells were resuspended in 300µl PBS and the fluorescence was measured in 
triplicates with 100µl of cell suspension. The JC-1 dye can enter the mitochondrial membrane and 
form aggregates. If the potential drops, the dye is released into the cytoplasm as monomers. 
Aggregates and monomers emit fluorescence at two different wavelengths that can be monitored, 
590nm and 540nm, respectively (FIGURE 1A). The ratio of the fluorescence at 590nm and at 540nm 
was calculated and depicted on a graph. The results were also confirmed by FACS analysis, which 
clearly showed two different shifted populations (FIGURE 1B). 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 1 
Detection of mitochondrial membrane potential changes 
by JC-1 dye. (A) Fluorescence emission of the JC-1 dye. Cells 
were treated with different compounds. Mitochondrial 
membrane potential changes are represented by the 
appearance of a peak at 540nm. (B) FACS analysis of treated 
versus control cells. The population shift correspond to a shift in 
the emission wavelength linked to the appearance of the 540nm 
peak. 
 
A B 
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Reactive oxygen species formation measurement 
Human hepatocytes were cultivated for 24h in serum-free medium, detached with trypsin, washed 
with PBS, and incubated at 37°C with carboxydichlorodihydrofluorescein diacetate (carboxy-H2DCFDA, 
Molecular Probes, Nivelles, Belgium) for 30min. After treatment for 1h with 500µM PB or 5µM 
rotenone, cells were washed once with PBS and the fluorescence was measured at 535nm 
wavelenght.  
 
ATP level measurement 
ATP was measured by ATP Bioluminescence Assay Kit HS II (Roche Diagnostic, Penzberg, Germany) 
as described in the manufacturer’s protocol. Cells were cultivated on 96-well dishes, treated with the 
compounds of interest for different times and lysed with the kit cell lysis reagent. 50µl of luciferase 
reagent were added to the multiwell plate and luciferase activity was measured. 
 
Animals 
C57/Bl6 wild-type animals maintained on standard laboratory chow with food and water ad libitum 
were used for the experiments. Ten to twelve-week-old female mice (n=5) were injected i.p. with 
vehicle alone (sterile NaCl) or AICAR 50mg/kg. After different treatment time, animals were killed and 
the liver was extracted. Approximately 100mg of the liver were solubilized in 1ml Trizol Reagent 
(Invitrogen) and total RNA was extracted according to the manufacturer protocol. 
 
Statistics 
Significant differences between means were determined by the two-tailed Student’s t-test for paired 
samples. Error bars represent standard deviation of at least three experiments. 
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TABLE 1: REAL-TIME PCR PRIMER SEQUENCES 
 
chGAPDH   765F  GGTCACGCTCCTGGAAGATAGT 
838R  GGGCACTGTCAAGGCTGAGA 
788T  ATGGCGTGCCCATTGATCACAAGTTTC 
CYP2H1   1076F  AGGGTGGTGAGGGCAAATC 
1140R  ACAGGCATTGTGACCAGCAA 
1096T  TCGCAGTTGCCTCCAGGTCTCCC 
CYP3A37   1446F   GTCCCAAAGAAAGGCAATGGT 
1509R  GGCCATTTGGGTTGTTCAAG 
1468T  TTGGCCCAGGAATGCCCAGC 
chALAS1   1031F  GCAGGGTGCCAAAACACAT 
1108R  TCGATGGATCAGACTTCTTCAACA 
1051T  TTCCGCCATAACGACGTCAACCATCTT 
CXR   432F  GCAGAGCAGCAGGAGCTCAT 
521R  AGGCTGGTAGTGCTGGAACTG 
469T  CGCACAAACGCACCTTCGACTCC 
h18s   F  AGTCCCTGCCCTTTGTACACA 
   R  CGATCCGAGGGCCTCACTA 
   T  CGCCCGTCGCTACTACCGATTGG 
CYP2B6            1009F  ACATCGCCCTCCAGAGCTT 
                  1090R  GTCGGAAAATCTCTGAATCTCATAGA 
1032T  ACCGAGCCAAAATGCCATACACAGAGG 
CYP3A4     F  CATTCCTCATCCCAATTCTTGAAGT 
                    R  CCACTCGGTGCTTTTGTGTATCT 
   T  CGAGGCGACTTTCTTTCATCCTTTTTACAGATTTTC 
hALAS1   7F  ATGATGCCAGGCTGTGAGATTT 
   7R  GCTGTTTCGAATCCCTTGGA 
   7T  TCTGATTCTGGGAACCATGCCTCCA 
hCAR   F  CACATGGGCACCATGTTTGA 
   R  AAGGGCTGGTGATGGATGAA 
   T  TTTGTGCAGTTTAGGCCTCCAGCTCATCT 
mGAPDH  649F  CCAGAACATCATCCCTGCATC 
   878R  GGTCCTCAGTGTAGCCCAAGAT 
   781T  CCGCCTGGAGAAACCTGCCAAGTATG 
Cyp2b10  460F  CAATGTTTAGTGGAGGAACTGCG 
   527R  CACTGGAAGAGGAACGTGGG 
   488T  CCCAGGGAGCCCCCCTGGA 
Cyp3a11   1459F  AGAACTTCTCCTTCCAGCCTTGTA 
   1598R  GAGGGAGACTCATGCTCCAGTTA 
   1548T  CTAAAGGTTGTGCCACGGGATGCAGT 
mALAS1   1002F  GGCCTCCCGGTCATCC 
   1068R  TGTTCTTAGCAGCATCGGCA 
   1019T  CTGTCCGAGTCACATCATCCCTGTGC 
mCAR   440F  CATTGCGGCGAGCCA 
   502R  GCTGATTCAGTTGCAAAGATGC 
   456T  ACAGGCACAGCGGCGGGC 
mPXR   519F  GAGGAAGAAGAGGGAAAAGATTGAG 
   584R  TGCTGTTCTTCCGTCAGCC 
   545T  CTCCACCGCCTGGAGGGCAG 
mHNF4α  1159F  AGATGCTTCTCGGAGGGTCTG 
   1246R  TTGGTGCCCATGTGTTCTTG 
   1181T  CAGTGATGCACCCCACACCCACC 
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Abbreviations 
 
2-DG   2-deoxyglucose 
AhR   aromatic hydrocarbon receptor 
ACC    acetyl-CoA carboxylase 
AICAR    5’-phosphoribosyl-5-aminoimidazol-4-carboxamide 
ALAS1    δ-aminolevulinic acid synthase 1  
AMPK    AMP-activated protein kinase  
bp   basepair(s) 
CAR    constitutive androstane receptor 
CaMK     calcium/calmodulin-dependent protein kinase 
CCRP   cytoplasmic CAR retention protein 
CXR    chicken xenobiotic receptor  
CYP    cytochrome P450 
DBD   DNA-binding domain  
DN   dominant negative 
DNP    dinitrophenol 
DR   direct repeat 
eEF   eukariotic elongatio factor 
eIF   eukariotic initiation factor 
ER   everted reapeat 
FOXO1   forkhead box protein O1A 
FXR   farnesoid X receptor 
GAPDH   glyceraldehydes-3-phosphate dehydrogenase 
GLUT    glucose transporter 
GR   glucocorticoid receptor 
HNF4α   hepatocyte nuclear factor 4α 
HPLC   high pressure liquid chromatography 
Hsp90   heat shock protein 90 
IF   immunofluorescence 
IP   immunoprecipitation 
IR   inverted repeat 
kDa   kilodalton(s) 
LBD   ligand-binding domain  
LMH   leghorn male hepatoma 
LXR   liver X receptor  
MDR1   multidrug resistance gene 1 
miRNA   micro RNA 
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MRP2   multidrug resistance-associated protein 2 
mtDNA   mitochondrial DNA  
mTOR   mammalian target of rapamycin 
NAC    N-acetyl L-cysteine  
NOS   nitric oxide synthase 
NR   nuclear receptor 
OA   okadaic acid 
OATP2   organic anion transport protein 2 
PAGE    polyacrylamide gel electrophoresis 
PB    phenobarbital  
PBREM   phenobarbital-responsive enhancer module 
PBRU   phenobarbital-responsive enhancer unit 
PCN   5-pregnen-3β-ol-20-one-16α-carbonitrile 
PCR   polymerase chain reaction 
PEPCK   phosphoenolpyruvate carboxykinase 
PGC-1α   peroxisome proliferator-activated receptor γ coactivator α 
PKCζ   protein kinase C ζ 
PKA   cAMP-dependent protein kinase A 
PP2A   protein phosphatase 2A 
PPAR   peroxisome proliferator-activated receptor 
PXR    pregnane X receptor  
ROS    reactive oxygen species  
RT-PCR   real-time PCR  
RXR   9-cis-retinoic acid receptor 
siRNA   small interfering RNA 
SULT   sulfotransferase 
TCPOBOP  1,4-bis-[2-(3,5-dichloropyridyloxy)]benzene 
TSC2   tuberous sclerosis complex 2  
UCP-1   uncoupling protein 1 
UGT   UDP-glucuronosyltransferase 
5’ UTR   5’ untranslated region 
VDR   vitamin D receptor 
XLS   xenobiotic localization signal 
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